Cardiology — MCQs

Q: A 61-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis with valve area $0.5\mathrm{cm}^2$. He develops syncope during exercise testing. What is the most appropriate management?

Urgent aortic valve replacement. ***Urgent aortic valve replacement*** - The patient has **severe aortic stenosis** (valve area $0.5\mathrm{cm}^2$) and is highly symptomatic, indicated by **syncope during exercise**, which significantly increases the risk of sudden cardiac death. - **Aortic valve replacement (AVR)** or TAVR is the definitive and urgent treatment required for symptomatic severe AS to alleviate symptoms and improve survival. *Medical management* - Medical therapy does not treat the underlying **fixed mechanical obstruction** of the aortic valve, making it ineffective for severe symptomatic AS. - Relying solely on medical management in this scenario leads to a very poor prognosis due to the high risk of **sudden cardiac death**. *Balloon aortic valvuloplasty* - BAV is primarily a temporary measure, often used as a **bridge to AVR/TAVR** or in hemodynamically unstable patients, due to its high rate of restenosis. - Given the patient is likely a surgical candidate, BAV is not considered the **definitive long-term solution** for severe AS. *Heart transplantation* - Heart transplantation is reserved for **end-stage heart failure** that is refractory to other medical and surgical options. - The primary pathology (severe AS) is surgically addressable via AVR, making transplantation an **inappropriate** initial therapy. *ICD insertion* - Syncope in severe AS is typically due to **flow limitation** and **exertional hypotension** caused by the fixed obstruction, rather than primary ventricular tachyarrhythmias. - Treating the underlying mechanical pathology with AVR resolves the cause of the syncope and the high risk of sudden death; therefore, an **ICD is not indicated**.

Q: A 57-year-old diabetic man presents with a non-healing foot ulcer for 3 months. Ankle-brachial pressure index is 0.3. What does this indicate?

Severe arterial disease. ***Severe arterial disease*** - An **Ankle-Brachial Pressure Index (ABPI)** of **0.3** indicates severely reduced blood flow to the lower extremities. - This severe reduction in arterial supply is consistent with the patient's **non-healing foot ulcer** and diabetes, a major risk factor for peripheral arterial disease. *Normal arterial supply* - **Normal ABPI** values typically range from **0.90 to 1.30**, which is significantly higher than the given 0.3. - An ABPI of 0.3 suggests profound compromise, far from normal blood flow required for tissue healing. *Mild arterial disease* - **Mild arterial disease** is generally indicated by an **ABPI between 0.70 and 0.90**. - An ABPI of 0.3 is well below this range, signifying much more severe impairment of arterial flow. *Moderate arterial disease* - **Moderate arterial disease** corresponds to an **ABPI between 0.40 and 0.69**. - The patient's ABPI of 0.3 is lower than this range, indicating a more critical level of arterial obstruction. *Venous disease* - The **ABPI** is a diagnostic tool primarily used to assess **arterial insufficiency**, not venous disease. - While venous disease can cause ulcers, an ABPI of 0.3 specifically points to significant **peripheral arterial disease** as the underlying cause.

Q: A 53-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral regurgitation with flail posterior leaflet. LV function is normal but LV end-systolic dimension is 45mm. What is the most appropriate management?

Mitral valve repair. ***Mitral valve repair***- Repair is the preferred management for **severe primary mitral regurgitation (MR)**, especially when the mechanism is degenerative (like a **flail leaflet**), as it provides better long-term survival and preserves native annular-ventricular continuity.- Surgery is mandated because the patient is **symptomatic** (dyspnea and fatigue) and meets criteria for severe MR (along with an **LVESD of 45 mm**, which is an independent indication for surgery even in asymptomatic patients with preserved LVEF).*Medical management*- Medical management (e.g., ACE inhibitors/beta-blockers) is appropriate only for **asymptomatic patients** who do not meet surgical LV dimensional or functional thresholds.- It is **insufficient** to halt the progression or reduce mortality in symptomatic severe primary MR, which requires definitive surgical correction.*Mitral valve replacement*- Replacement is reserved for valves deemed **unrepairable** due to extensive destruction, calcification, or complex pathology.- Repair is favored because it avoids the risks associated with prosthetic valves, such as lifelong **anticoagulation** (for mechanical valves) and prosthetic valve dysfunction.*Heart transplantation*- This procedure is reserved for **end-stage heart failure** (NYHA Class III/IV symptoms) that is refractory to all other medical and surgical therapies.- The patient has **normal LV function** (preserved LVEF), making transplantation completely unnecessary and inappropriate.*Balloon valvuloplasty*- This intervention is the primary treatment for severe, pliable **mitral stenosis**, most commonly due to rheumatic disease.- It is **contraindicated** in severe MR, particularly MR secondary to leaflet prolapse or flail, as it would worsen the severity of the regurgitation.

Q: A 46-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral stenosis with valve area 0.7 cm². He is in atrial fibrillation with rapid ventricular response. What is the most appropriate initial management?

Rate control with digoxin. ***Rate control with digoxin***- Rapid ventricular rate in **atrial fibrillation** significantly reduces **diastolic filling time**, which is crucial for adequate **left ventricular filling** in severe **mitral stenosis (MS)**.- Rate control (e.g., with rate-limiting calcium channel blockers, beta-blockers, or **digoxin** in the setting of MS, especially if associated with heart failure) is the immediate priority to alleviate acute symptoms of heart failure.*Immediate cardioversion*- Cardioversion is generally postponed until the patient is properly **anticoagulated** (due to high risk of systemic **thromboembolism**) unless the patient is **hemodynamically unstable** (e.g., shock/hypotension).- In severe MS, AF often recurs due to chronic **left atrial enlargement** and high pressure, making rate control the preferred strategy over rhythm control initially.*Balloon mitral valvuloplasty*- This is the preferred definitive treatment for symptomatic severe MS but is an invasive procedure and is not appropriate as the *initial* acute management for **AF with RVR**.- A stable patient requires rate control and anticoagulation first before determining the timing of the **structural intervention** (BMV).*Mitral valve replacement*- **Mitral valve replacement (MVR)** is a major surgical procedure reserved for patients with MS who fail percutaneous **balloon mitral valvuloplasty (BMV)** or have unfavorable valve morphology.- This is not indicated as the *initial* non-invasive step to manage acute **rate complications** in a symptomatic patient.*Anticoagulation alone*- Anticoagulation is essential management for MS complicated by AF (high **thromboembolism** risk) but does not address the acute physiological cause of **dyspnea and fatigue** (the rapid heart rate).- Ignoring the **rapid ventricular response** would leave the patient vulnerable to acute circulatory deterioration and continued pulmonary congestion.

Q: A 62-year-old man presents with progressive dyspnea and orthopnea. Chest X-ray shows cardiomegaly and pulmonary edema. Echocardiogram shows EF 25%. What is the most appropriate first medication?

ACE inhibitor. ***ACE inhibitor*** - **ACE inhibitors** (or ARNI) are the foundational, first-line **Guideline-Directed Medical Therapy (GDMT)** for heart failure with reduced EF (**HFrEF**, EF $\le$ 40%) due to their proven mortality benefit. - They block the **Renin-Angiotensin-Aldosterone System (RAAS)**, preventing maladaptive cardiac remodeling and reducing **afterload** and **preload**. *Furosemide* - While necessary for managing current acute symptoms like **pulmonary edema** and volume overload, diuretics like furosemide only provide symptomatic relief. - They do not improve the long-term prognosis or mortality in **HFrEF** and are adjuncts to GDMT, not the first medication for foundational treatment. *Digoxin* - Digoxin is considered a palliative option for symptom relief in patients who remain severely symptomatic despite being on maximal doses of **ACEi/ARB/ARNI**, **beta-blocker**, and **MRA** (Spironolactone). - It is not a prognostic agent and is associated with a narrow therapeutic index, making it unsuitable as the initial therapy. *Beta-blocker* - **Beta-blockers** (e.g., carvedilol, metoprolol succinate) are crucial prognostic drugs but should be initiated *after* an **ACE inhibitor**. - They should only be started when the patient is stable and **euvolemic**, as initiating them during acute decompensation can worsen heart failure symptoms due to negative **inotropy**. *Spironolactone* - **Spironolactone** (a Mineralocorticoid Receptor Antagonist or **MRA**) is a prognostic medication used in HFrEF, but it is typically added as a second or third agent. - It is reserved for patients who remain symptomatic (**NYHA Class II-IV**) despite optimal titration of **ACE inhibitor** and **beta-blocker**.

Q: A 51-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis. He's high surgical risk due to comorbidities. What is the most appropriate treatment?

Transcatheter aortic valve replacement. ***Transcatheter aortic valve replacement*** - **TAVR** is the preferred intervention for patients with **symptomatic severe aortic stenosis** who are at **high or prohibitive surgical risk** for traditional **Surgical Aortic Valve Replacement (SAVR)**. - This minimally invasive approach avoids open-heart surgery and cardiopulmonary bypass, making it suitable for comorbid patients and improving symptoms and prognosis. *Medical management* - Medical therapy for **severe aortic stenosis** provides only limited **symptomatic relief** and does not alter the natural history or improve the poor prognosis once symptoms develop. - Once a patient with severe AS becomes **symptomatic** (dyspnea, fatigue), definitive intervention is required, as medical management alone offers little survival benefit. *Balloon aortic valvuloplasty* - **Balloon aortic valvuloplasty (BAV)** is typically a temporary measure or a **bridge-to-treatment** for decompensated patients due to its high short-term risk of **restenosis**. - It is not considered a definitive, long-term solution for severe AS in adults due to its lack of durable efficacy compared to valve replacement procedures. *Surgical aortic valve replacement* - **SAVR** is the traditional gold standard but requires **open-heart surgery**, carrying significant **morbidity and mortality**, especially in patients deemed **high surgical risk**. - Current guidelines recommend **TAVR** as the preferred option for high-risk patients with symptomatic severe AS due to its less invasive nature. *Heart transplantation* - **Heart transplantation** is a last-resort therapy primarily indicated for refractory **end-stage heart failure** when other surgical or interventional options are exhausted or not applicable. - For isolated, symptomatic severe aortic stenosis, replacing the valve (via TAVR or SAVR) directly addresses the primary pathology and is the appropriate first-line strategy.

Cardiology UK Medical PG Practice Questions and MCQs

Question 1: A 61-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis with valve area $0.5\mathrm{cm}^2$. He develops syncope during exercise testing. What is the most appropriate management?

A. Medical management
B. Balloon aortic valvuloplasty
C. Urgent aortic valve replacement (Correct Answer)
D. Heart transplantation
E. ICD insertion

Explanation: ***Urgent aortic valve replacement*** - The patient has **severe aortic stenosis** (valve area $0.5\mathrm{cm}^2$) and is highly symptomatic, indicated by **syncope during exercise**, which significantly increases the risk of sudden cardiac death. - **Aortic valve replacement (AVR)** or TAVR is the definitive and urgent treatment required for symptomatic severe AS to alleviate symptoms and improve survival. *Medical management* - Medical therapy does not treat the underlying **fixed mechanical obstruction** of the aortic valve, making it ineffective for severe symptomatic AS. - Relying solely on medical management in this scenario leads to a very poor prognosis due to the high risk of **sudden cardiac death**. *Balloon aortic valvuloplasty* - BAV is primarily a temporary measure, often used as a **bridge to AVR/TAVR** or in hemodynamically unstable patients, due to its high rate of restenosis. - Given the patient is likely a surgical candidate, BAV is not considered the **definitive long-term solution** for severe AS. *Heart transplantation* - Heart transplantation is reserved for **end-stage heart failure** that is refractory to other medical and surgical options. - The primary pathology (severe AS) is surgically addressable via AVR, making transplantation an **inappropriate** initial therapy. *ICD insertion* - Syncope in severe AS is typically due to **flow limitation** and **exertional hypotension** caused by the fixed obstruction, rather than primary ventricular tachyarrhythmias. - Treating the underlying mechanical pathology with AVR resolves the cause of the syncope and the high risk of sudden death; therefore, an **ICD is not indicated**.

Question 2: A 57-year-old diabetic man presents with a non-healing foot ulcer for 3 months. Ankle-brachial pressure index is 0.3. What does this indicate?

A. Normal arterial supply
B. Mild arterial disease
C. Moderate arterial disease
D. Severe arterial disease (Correct Answer)
E. Venous disease

Explanation: ***Severe arterial disease*** - An **Ankle-Brachial Pressure Index (ABPI)** of **0.3** indicates severely reduced blood flow to the lower extremities. - This severe reduction in arterial supply is consistent with the patient's **non-healing foot ulcer** and diabetes, a major risk factor for peripheral arterial disease. *Normal arterial supply* - **Normal ABPI** values typically range from **0.90 to 1.30**, which is significantly higher than the given 0.3. - An ABPI of 0.3 suggests profound compromise, far from normal blood flow required for tissue healing. *Mild arterial disease* - **Mild arterial disease** is generally indicated by an **ABPI between 0.70 and 0.90**. - An ABPI of 0.3 is well below this range, signifying much more severe impairment of arterial flow. *Moderate arterial disease* - **Moderate arterial disease** corresponds to an **ABPI between 0.40 and 0.69**. - The patient's ABPI of 0.3 is lower than this range, indicating a more critical level of arterial obstruction. *Venous disease* - The **ABPI** is a diagnostic tool primarily used to assess **arterial insufficiency**, not venous disease. - While venous disease can cause ulcers, an ABPI of 0.3 specifically points to significant **peripheral arterial disease** as the underlying cause.

Question 3: A 55-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic regurgitation with LV end-systolic dimension 58mm and EF 48%. She is asymptomatic at rest. What is the most appropriate management?

A. Medical management
B. Aortic valve replacement (Correct Answer)
C. ACE inhibitors and monitoring
D. Exercise stress testing
E. Cardiac catheterization

Explanation: ***Aortic valve replacement*** - The patient presents with **severe aortic regurgitation** and objective evidence of **left ventricular (LV) dysfunction** (EF 48% < 50%) and **LV dilatation** (end-systolic dimension 58mm > 50-55mm). These findings are Class I indications for **aortic valve replacement**, even in an asymptomatic patient. - Surgical intervention is crucial to prevent irreversible myocardial damage and improve long-term outcomes in chronic **severe aortic regurgitation** once these thresholds for LV impairment are met. *Medical management* - Medical management is typically reserved for patients with **mild to moderate aortic regurgitation** or those with severe AR but **preserved LV function** and no significant LV dilatation who are asymptomatic. - It does not address the underlying mechanical defect of the **aortic valve** and will not reverse the progressive LV remodeling and dysfunction. *ACE inhibitors and monitoring* - While ACE inhibitors can be considered for management of hypertension or symptomatic heart failure in some AR patients, they are not the definitive treatment for **severe aortic regurgitation** with established LV dysfunction. - **Monitoring alone** is inappropriate given the significant LV remodeling and dysfunction, which necessitate surgical intervention to prevent further irreversible damage. *Exercise stress testing* - Exercise stress testing is primarily used to unmask symptoms in **asymptomatic patients** with severe valve disease (e.g., aortic stenosis or regurgitation) and **preserved LV function** to assess their functional capacity and guide surgical timing. - In this case, the patient already has clear echocardiographic evidence of **LV dysfunction** (EF 48%) and significant **LV dilatation** (ESD 58mm), which are direct indications for surgery, rendering stress testing unnecessary for decision-making. *Cardiac catheterization* - **Cardiac catheterization** is primarily a diagnostic procedure performed to assess for **coronary artery disease** (CAD) in patients undergoing cardiac surgery, especially in older individuals or those with CAD risk factors. - It is not the definitive management for **aortic regurgitation** itself but may be a pre-operative step. The primary treatment remains valve replacement.

Question 4: A 53-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral regurgitation with flail posterior leaflet. LV function is normal but LV end-systolic dimension is 45mm. What is the most appropriate management?

A. Medical management
B. Mitral valve replacement
C. Mitral valve repair (Correct Answer)
D. Heart transplantation
E. Balloon valvuloplasty

Explanation: ***Mitral valve repair***- Repair is the preferred management for **severe primary mitral regurgitation (MR)**, especially when the mechanism is degenerative (like a **flail leaflet**), as it provides better long-term survival and preserves native annular-ventricular continuity.- Surgery is mandated because the patient is **symptomatic** (dyspnea and fatigue) and meets criteria for severe MR (along with an **LVESD of 45 mm**, which is an independent indication for surgery even in asymptomatic patients with preserved LVEF).*Medical management*- Medical management (e.g., ACE inhibitors/beta-blockers) is appropriate only for **asymptomatic patients** who do not meet surgical LV dimensional or functional thresholds.- It is **insufficient** to halt the progression or reduce mortality in symptomatic severe primary MR, which requires definitive surgical correction.*Mitral valve replacement*- Replacement is reserved for valves deemed **unrepairable** due to extensive destruction, calcification, or complex pathology.- Repair is favored because it avoids the risks associated with prosthetic valves, such as lifelong **anticoagulation** (for mechanical valves) and prosthetic valve dysfunction.*Heart transplantation*- This procedure is reserved for **end-stage heart failure** (NYHA Class III/IV symptoms) that is refractory to all other medical and surgical therapies.- The patient has **normal LV function** (preserved LVEF), making transplantation completely unnecessary and inappropriate.*Balloon valvuloplasty*- This intervention is the primary treatment for severe, pliable **mitral stenosis**, most commonly due to rheumatic disease.- It is **contraindicated** in severe MR, particularly MR secondary to leaflet prolapse or flail, as it would worsen the severity of the regurgitation.

Question 5: A 56-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe aortic stenosis with valve area $0.5\mathrm{cm}^2$ and mean gradient 60 mmHg. He has multiple comorbidities making him high surgical risk. What is the most appropriate treatment?

A. Medical management only
B. Balloon aortic valvuloplasty
C. Transcatheter aortic valve replacement (Correct Answer)
D. Surgical aortic valve replacement
E. Heart transplantation

Explanation: ***Transcatheter aortic valve replacement*** - The patient has **symptomatic severe aortic stenosis** (dyspnea, ankle swelling, valve area $0.5\mathrm{cm}^2$, mean gradient 60 mmHg) and is classified as **high surgical risk** due to multiple comorbidities. - **TAVR** is the definitive, less invasive treatment of choice for severe symptomatic aortic stenosis in patients judged to be at high or prohibitive risk for standard **surgical aortic valve replacement (SAVR)**. *Medical management only* - Medical therapy (e.g., diuretics) offers only temporary symptomatic relief and does not alter the poor prognosis of severe symptomatic AS, which has a mean survival of 2-3 years without intervention. - Attempting **medical management** alone in this critical setting is inappropriate given the high risk of sudden death and the availability of effective interventional options like TAVR. *Balloon aortic valvuloplasty* - **BAV** provides temporary symptomatic relief but is not a durable solution for degenerative severe AS, as rapid restenosis typically occurs. - It is primarily used as a **bridge to definitive therapy (TAVR/SAVR)** in hemodynamically unstable patients or before urgent non-cardiac surgery. *Surgical aortic valve replacement* - **SAVR** is the gold standard intervention for severe AS in low-to-intermediate risk patients but is explicitly contraindicated here due to the patient's **high surgical risk** profile. - Proceeding with SAVR in this patient population is associated with significantly higher rates of morbidity and mortality compared to TAVR. *Heart transplantation* - **Heart transplantation** is reserved for end-stage heart failure refractory to all other medical, surgical, and interventional therapies, not as a primary treatment for severe aortic valve disease. - Valve replacement (TAVR or SAVR) is necessary to address the valvular pathology and is expected to reverse or stabilize the consequences of the pressure overload.

Question 6: A 46-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral stenosis with valve area 0.7 cm². He is in atrial fibrillation with rapid ventricular response. What is the most appropriate initial management?

A. Rate control with digoxin (Correct Answer)
B. Immediate cardioversion
C. Balloon mitral valvuloplasty
D. Mitral valve replacement
E. Anticoagulation alone

Explanation: ***Rate control with digoxin***- Rapid ventricular rate in **atrial fibrillation** significantly reduces **diastolic filling time**, which is crucial for adequate **left ventricular filling** in severe **mitral stenosis (MS)**.- Rate control (e.g., with rate-limiting calcium channel blockers, beta-blockers, or **digoxin** in the setting of MS, especially if associated with heart failure) is the immediate priority to alleviate acute symptoms of heart failure.*Immediate cardioversion*- Cardioversion is generally postponed until the patient is properly **anticoagulated** (due to high risk of systemic **thromboembolism**) unless the patient is **hemodynamically unstable** (e.g., shock/hypotension).- In severe MS, AF often recurs due to chronic **left atrial enlargement** and high pressure, making rate control the preferred strategy over rhythm control initially.*Balloon mitral valvuloplasty*- This is the preferred definitive treatment for symptomatic severe MS but is an invasive procedure and is not appropriate as the *initial* acute management for **AF with RVR**.- A stable patient requires rate control and anticoagulation first before determining the timing of the **structural intervention** (BMV).*Mitral valve replacement*- **Mitral valve replacement (MVR)** is a major surgical procedure reserved for patients with MS who fail percutaneous **balloon mitral valvuloplasty (BMV)** or have unfavorable valve morphology.- This is not indicated as the *initial* non-invasive step to manage acute **rate complications** in a symptomatic patient.*Anticoagulation alone*- Anticoagulation is essential management for MS complicated by AF (high **thromboembolism** risk) but does not address the acute physiological cause of **dyspnea and fatigue** (the rapid heart rate).- Ignoring the **rapid ventricular response** would leave the patient vulnerable to acute circulatory deterioration and continued pulmonary congestion.

Question 7: A 62-year-old man presents with progressive dyspnea and orthopnea. Chest X-ray shows cardiomegaly and pulmonary edema. Echocardiogram shows EF 25%. What is the most appropriate first medication?

A. Furosemide
B. Digoxin
C. ACE inhibitor (Correct Answer)
D. Beta-blocker
E. Spironolactone

Explanation: ***ACE inhibitor*** - **ACE inhibitors** (or ARNI) are the foundational, first-line **Guideline-Directed Medical Therapy (GDMT)** for heart failure with reduced EF (**HFrEF**, EF $\le$ 40%) due to their proven mortality benefit. - They block the **Renin-Angiotensin-Aldosterone System (RAAS)**, preventing maladaptive cardiac remodeling and reducing **afterload** and **preload**. *Furosemide* - While necessary for managing current acute symptoms like **pulmonary edema** and volume overload, diuretics like furosemide only provide symptomatic relief. - They do not improve the long-term prognosis or mortality in **HFrEF** and are adjuncts to GDMT, not the first medication for foundational treatment. *Digoxin* - Digoxin is considered a palliative option for symptom relief in patients who remain severely symptomatic despite being on maximal doses of **ACEi/ARB/ARNI**, **beta-blocker**, and **MRA** (Spironolactone). - It is not a prognostic agent and is associated with a narrow therapeutic index, making it unsuitable as the initial therapy. *Beta-blocker* - **Beta-blockers** (e.g., carvedilol, metoprolol succinate) are crucial prognostic drugs but should be initiated *after* an **ACE inhibitor**. - They should only be started when the patient is stable and **euvolemic**, as initiating them during acute decompensation can worsen heart failure symptoms due to negative **inotropy**. *Spironolactone* - **Spironolactone** (a Mineralocorticoid Receptor Antagonist or **MRA**) is a prognostic medication used in HFrEF, but it is typically added as a second or third agent. - It is reserved for patients who remain symptomatic (**NYHA Class II-IV**) despite optimal titration of **ACE inhibitor** and **beta-blocker**.

Question 8: A 61-year-old woman presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe tricuspid regurgitation. Right heart catheterization shows mean PAP 50 mmHg. What is the most likely diagnosis?

A. Left heart failure
B. Pulmonary hypertension (Correct Answer)
C. COPD
D. Pulmonary embolism
E. Tricuspid valve disease

Explanation: ***Pulmonary hypertension*** - The **mean pulmonary artery pressure (PAP) of 50 mmHg** measured by right heart catheterization is the definitive diagnostic criterion for **pulmonary hypertension**, which is defined as a mean PAP > 20 mmHg at rest. - The **progressive dyspnea** and **bilateral ankle swelling** (signs of right heart failure) along with **severe tricuspid regurgitation** (a common consequence of right ventricular pressure overload due to PH) are direct clinical manifestations of elevated pulmonary pressures. *Left heart failure* - While **left heart failure (LHF)** is the most common cause of **Group 2 pulmonary hypertension**, the right heart catheterization explicitly confirms the *presence* of pulmonary hypertension, making it the most direct diagnosis based on the provided hemodynamic data. - LHF primarily causes elevated **pulmonary capillary wedge pressure (PCWP)** due to back pressure from the left side of the heart, which would be the more specific diagnostic finding for LHF as the *primary* problem. *COPD* - **COPD** can lead to **Group 3 pulmonary hypertension** due to chronic hypoxia and vasoconstriction, but the question primarily focuses on the hemodynamic findings of severe PH and its consequences rather than specific lung disease features like smoking history or spirometry results. - The clinical presentation emphasizes the cardiac manifestations of high pulmonary pressures (dyspnea, ankle swelling, severe tricuspid regurgitation) rather than primary respiratory symptoms typical of advanced COPD. *Pulmonary embolism* - An acute massive **pulmonary embolism** typically presents with sudden or subacute onset of dyspnea and often chest pain, which is less consistent with the patient's history of **progressive dyspnea**. - While **chronic thromboembolic pulmonary hypertension (CTEPH)** is a form of pulmonary hypertension, the question asks for the *most likely diagnosis* given the direct finding of elevated PAP, which is pulmonary hypertension itself. *Tricuspid valve disease* - The **severe tricuspid regurgitation (TR)** observed is most likely *secondary* or functional, resulting from the severe right ventricular dilation and remodeling caused by the chronic pressure overload from **pulmonary hypertension**. - Primary tricuspid valve disease would typically be the *cause* of the TR, but it would not directly explain the high **mean PAP of 50 mmHg** as the primary pathology unless it led to PH (which is less common as a primary mechanism).

Question 9: A 67-year-old man presents with progressive dyspnea and orthopnea. Chest X-ray shows cardiomegaly and Kerley B lines. BNP is 1800 pg/mL. What does BNP level indicate?

A. Mild heart failure
B. Moderate heart failure (Correct Answer)
C. Severe heart failure
D. Acute coronary syndrome
E. Pulmonary embolism

Explanation: ***Moderate heart failure***- A **BNP level of 1800 pg/mL** is highly elevated and confirms the diagnosis of acute decompensated heart failure; based on common clinical stratification, this level falls into the **moderate** severity range (often 900–1800 pg/mL).- This elevated level reflects significant **ventricular wall stress** and stretching due to volume overload, correlating strongly with the patient's clinical status (dyspnea, orthopnea, Kerley B lines).*Mild heart failure*- Mild heart failure is typically associated with BNP concentrations significantly lower than 1800 pg/mL, usually ranging between **100 to 500 pg/mL**.- Patients showing features of acute volume overload, such as **Kerley B lines** and pronounced orthopnea, rarely have BNP levels in the mild range.*Severe heart failure*- While 1800 pg/mL is very high, **severe heart failure** or decompensated end-stage disease is typically associated with BNP levels exceeding **2000 to 4000 pg/mL**, depending on the threshold used.- This threshold indicates profound biventricular dysfunction and is usually reserved for the most critical or shock states, which are higher than the patient's current measurement.*Acute coronary syndrome*- While acute myocardial infarction (a subset of ACS) can cause a secondary rise in BNP due to resulting acute heart failure, BNP's primary use is to aid in the diagnosis and staging of **heart failure**, not to diagnose ACS directly.- ACS findings are usually based on ECG changes or **troponin elevation**, whereas this clinical presentation is dominatingly characterized by signs of fluid overload.*Pulmonary embolism*- Large pulmonary embolisms can cause right heart strain and elevate BNP, but the levels are often **less predictable** and usually lower than 1800 pg/mL compared to severe biventricular failure.- The X-ray findings of **cardiomegaly** and **Kerley B lines** are highly specific indicators of pulmonary venous congestion due to left-sided heart failure, making PE an unlikely primary cause of this specific constellation of findings.

Question 10: A 51-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic stenosis. He's high surgical risk due to comorbidities. What is the most appropriate treatment?

A. Medical management
B. Balloon aortic valvuloplasty
C. Transcatheter aortic valve replacement (Correct Answer)
D. Surgical aortic valve replacement
E. Heart transplantation

Explanation: ***Transcatheter aortic valve replacement*** - **TAVR** is the preferred intervention for patients with **symptomatic severe aortic stenosis** who are at **high or prohibitive surgical risk** for traditional **Surgical Aortic Valve Replacement (SAVR)**. - This minimally invasive approach avoids open-heart surgery and cardiopulmonary bypass, making it suitable for comorbid patients and improving symptoms and prognosis. *Medical management* - Medical therapy for **severe aortic stenosis** provides only limited **symptomatic relief** and does not alter the natural history or improve the poor prognosis once symptoms develop. - Once a patient with severe AS becomes **symptomatic** (dyspnea, fatigue), definitive intervention is required, as medical management alone offers little survival benefit. *Balloon aortic valvuloplasty* - **Balloon aortic valvuloplasty (BAV)** is typically a temporary measure or a **bridge-to-treatment** for decompensated patients due to its high short-term risk of **restenosis**. - It is not considered a definitive, long-term solution for severe AS in adults due to its lack of durable efficacy compared to valve replacement procedures. *Surgical aortic valve replacement* - **SAVR** is the traditional gold standard but requires **open-heart surgery**, carrying significant **morbidity and mortality**, especially in patients deemed **high surgical risk**. - Current guidelines recommend **TAVR** as the preferred option for high-risk patients with symptomatic severe AS due to its less invasive nature. *Heart transplantation* - **Heart transplantation** is a last-resort therapy primarily indicated for refractory **end-stage heart failure** when other surgical or interventional options are exhausted or not applicable. - For isolated, symptomatic severe aortic stenosis, replacing the valve (via TAVR or SAVR) directly addresses the primary pathology and is the appropriate first-line strategy.

Question 11: A 56-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral regurgitation with flail leaflet. LV function is preserved. What is the preferred treatment?

A. Medical management
B. Mitral valve replacement
C. Mitral valve repair (Correct Answer)
D. Heart transplantation
E. Balloon valvuloplasty

Explanation: ***Mitral valve repair***- The standard of care for symptomatic patients with **severe primary mitral regurgitation (MR)** (due to flail leaflet) and preserved LV function is surgery (Class I indication).- **Mitral valve repair** is strongly preferred over replacement for degenerative MR (flail leaflet) as it is associated with better preservation of LV function and superior long-term survival outcomes.*Medical management*- Pharmacological treatment (e.g., diuretics, vasodilators) only provides symptomatic relief but does not address the underlying **structural lesion** (flail leaflet) or prevent progressive ventricular remodeling.- Surgical intervention is required because severe symptomatic MR, even with preserved LV function, significantly increases the risk of **heart failure complications** and death.*Mitral valve replacement*- While an option, **replacement** is generally reserved for failed repairs or valves too structurally damaged/calcified to repair, as repair avoids the need for chronic anticoagulation (with mechanical valves) and has better long-term survival figures.- Replacement carries risks such as **prosthetic valve endocarditis** and the need for lifelong **anticoagulation** (for mechanical valves).*Heart transplantation*- This is the treatment of last resort for **end-stage heart failure** refractory to all other medical and surgical therapies, typically associated with very severe and irreversible LV dysfunction.- The patient has preserved LV function and isolated valvular pathology, making this option **grossly excessive** and inappropriate.*Balloon valvuloplasty*- This procedure is utilized for the treatment of **mitral stenosis** (narrowing) due to rheumatic disease, not for severe **mitral regurgitation** (leakage).- It is contraindicated in MR caused by a flail leaflet and would not address the issue of the failing valve component.

Question 12: A 58-year-old man presents with progressive dyspnea and bilateral ankle swelling. JVP is elevated and there's a third heart sound. Chest X-ray shows pulmonary edema. What is the most likely cause of the third heart sound?

A. S3 gallop (Correct Answer)
B. S4 gallop
C. Opening snap
D. Ejection click
E. Pericardial knock

Explanation: ***S3 gallop*** - The presence of **dyspnea**, **bilateral ankle swelling**, **elevated JVP**, and **pulmonary edema** indicates severe **congestive heart failure (CHF)** and **volume overload**. - An **S3 gallop** is a low-frequency sound in early diastole, indicative of **ventricular volume overload** or **systolic heart failure**, resulting from rapid ventricular filling into a dilated, non-compliant ventricle. *S4 gallop* - An **S4 gallop** is a presystolic sound heard in late diastole, typically associated with **diastolic dysfunction** (e.g., in **hypertension**, **aortic stenosis**) due to atrial contraction into a stiff ventricle. - This patient's presentation with significant **pulmonary edema** and **volume overload** points more towards systolic dysfunction and an S3 rather than isolated diastolic dysfunction. *Opening snap* - An **opening snap** is a high-pitched diastolic sound characteristic of **mitral stenosis**, caused by the sudden opening of a stenotic mitral valve. - The clinical picture does not suggest primary valvular stenosis but rather global heart failure. *Ejection click* - An **ejection click** is a high-pitched systolic sound occurring shortly after S1, often related to the opening of a **stenotic semilunar valve** or a dilated great artery. - This is a systolic event, not the diastolic third heart sound described in the question. *Pericardial knock* - A **pericardial knock** is a loud, early diastolic sound heard shortly after S2, characteristic of **constrictive pericarditis**. - While associated with elevated JVP and edema, constrictive pericarditis often presents with less prominent **pulmonary edema** and may feature **Kussmaul sign**, which is not mentioned.

Question 13: A 57-year-old man presents with progressive dyspnea and chest pain. Echocardiogram shows severe aortic regurgitation with LV end-systolic dimension $55\mathrm{mm}$. What is the most appropriate management?

A. Medical management
B. Aortic valve replacement (Correct Answer)
C. ACE inhibitors
D. Diuretics
E. Observation

Explanation: ***Aortic valve replacement*** - The patient's **progressive dyspnea and chest pain** indicate symptomatic severe aortic regurgitation, and an **LV end-systolic dimension (LVESD) of 55mm** signifies significant left ventricular dilation and dysfunction. - Current guidelines recommend **aortic valve replacement** for symptomatic severe AR or asymptomatic severe AR with an LVESD exceeding 50mm (or 25 mm/m²), as this indicates a higher risk of adverse outcomes. *Medical management* - Medical management, primarily with vasodilators, is generally reserved for **asymptomatic patients with severe AR and preserved LV function** who do not meet surgical criteria. - It does **not correct the underlying valvular defect** and is insufficient for patients presenting with symptoms and objective evidence of significant LV dilation/dysfunction. *ACE inhibitors* - While **ACE inhibitors** can be used in patients with AR and concomitant hypertension or for symptomatic heart failure, they do not obviate the need for surgical intervention when surgical indications are met. - Their role is primarily in **afterload reduction** and managing heart failure symptoms, but they do not reverse the progression of severe valvular disease. *Diuretics* - **Diuretics** are used to manage symptoms of **volume overload** (e.g., dyspnea) in patients with heart failure secondary to AR. - However, they **do not address the underlying structural valve pathology** or prevent the progression of left ventricular remodeling and dysfunction, which requires definitive surgical correction. *Observation* - **Observation** is only appropriate for **asymptomatic patients with mild to moderate aortic regurgitation** or severe AR with stable, preserved LV function who do not meet surgical criteria. - Given the patient's **progressive symptoms** and an **LVESD of 55mm**, which is beyond the threshold for intervention, observation would be inappropriate and could lead to irreversible cardiac damage.

Question 14: A 41-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows dilated left ventricle with EF 25%. Coronary angiogram is normal. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Pericardial disease

Explanation: ***Dilated cardiomyopathy***- The presentation of heart failure symptoms (**dyspnea**, **edema**) with severe **systolic dysfunction** (**EF 25%**) and a **dilated left ventricle** is characteristic of Dilated Cardiomyopathy (DCM).- The diagnosis of DCM requires the exclusion of secondary causes like Coronary Artery Disease (CAD), which is satisfied by the **normal coronary angiogram**.*Ischemic cardiomyopathy*- This diagnosis requires the presence of significant **Coronary Artery Disease (CAD)**, which was explicitly ruled out by the **normal coronary angiogram**.- While it causes LV dilation and low EF, DCM is the appropriate term when ischemia is excluded as the underlying cause.*Hypertrophic cardiomyopathy*- Hypertrophic cardiomyopathy is characterized by marked **left ventricular wall thickening** (**hypertrophy**) with reduced cavity size, not the dilation observed in this patient.- Although it can cause heart failure, the primary defect is often severe **diastolic dysfunction**, contrasted with this patient's severe systolic failure.*Restrictive cardiomyopathy*- This condition is defined by impaired **diastolic filling** due to rigid ventricular walls, and typically presents with **normal or non-dilated** ventricular chambers.- Restrictive cardiomyopathy often maintains a near-normal **Ejection Fraction** (EF) initially, unlike the severely reduced EF (25%) seen here.*Pericardial disease*- Conditions such as **constrictive pericarditis** restrict cardiac filling but typically involve ventricles of **normal size** and usually good intrinsic systolic function (normal EF).- While chronic edema can occur, the primary pathology does not involve the severe **left ventricular dilation** and **systolic dysfunction** seen on echo.

Question 15: A 67-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows concentric LVH with EF 55% but impaired diastolic function. What is the most likely diagnosis?

A. Dilated cardiomyopathy
B. Heart failure with preserved ejection fraction (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Ischemic cardiomyopathy

Explanation: ***Heart failure with preserved ejection fraction*** - The combination of progressive dyspnea and fatigue, **concentric LVH** with a **preserved ejection fraction (EF 55%)**, and **impaired diastolic function** are the hallmark diagnostic criteria for **HFpEF**. - This condition is characterized by stiff, non-compliant ventricles that impair ventricular filling (diastolic function) rather than myocardial contractility (systolic function).*Dilated cardiomyopathy* - This condition is defined by ventricular chamber enlargement and globally reduced myocardial contractility, leading to a significantly **reduced ejection fraction (HFrEF)**, typically less than 40%. - The echocardiogram findings of **concentric LVH** and preserved EF contradict the features of DCM, which usually presents with thin ventricular walls.*Hypertrophic cardiomyopathy* - While HCM causes **diastolic dysfunction** and can have a preserved EF, it is primarily a genetic structural heart disease characterized by often **asymmetric hypertrophy** and sometimes dynamic left ventricular outflow tract obstruction. - The general presentation of HF with preserved EF due to concentric hypertrophy is more broadly classified as **HFpEF**, rather than a specific hypertrophic cardiomyopathy unless further diagnostic details (e.g., specific genetic mutation, severe asymmetric septal hypertrophy) are provided.*Restrictive cardiomyopathy* - This is a structural diagnosis primarily caused by infiltrative processes like **amyloidosis** or sarcoidosis, characterized by rigid ventricular walls leading to severe diastolic dysfunction and often **biatrial enlargement**. - Although a cause of HFpEF, restrictive cardiomyopathy typically presents with distinct restrictive filling patterns and often normal or slightly increased ventricular wall thicknesses, making HFpEF the broader and most direct diagnosis given the information.*Ischemic cardiomyopathy* - This condition results from myocardial damage due to coronary artery disease, typically leading to widespread **systolic dysfunction** and ventricular remodeling, causing **heart failure with reduced ejection fraction** (HFrEF). - The presence of a **preserved EF (55%)** in this patient directly contradicts the definition of ischemic cardiomyopathy, which is characterized by a reduced EF due to regional wall motion abnormalities.

Question 16: A 62-year-old woman presents with progressive dyspnea and bilateral ankle swelling. Chest X-ray shows cardiomegaly. BNP is 2800 pg/mL. Echocardiogram shows EF 30%. What is the most appropriate first-line medication?

A. Furosemide
B. ACE inhibitor (Correct Answer)
C. Beta-blocker
D. Spironolactone
E. Digoxin

Explanation: ***ACE inhibitor*** - **ACE inhibitors** (or ARBs/ARNIs) are the cornerstone of **Guideline-Directed Medical Therapy (GDMT)** for **Heart Failure with reduced Ejection Fraction (HFrEF)**, demonstrating significant reduction in morbidity and mortality. - They work by blocking the **Renin-Angiotensin-Aldosterone System (RAAS)**, leading to reduced afterload and preload, and reversing detrimental cardiac remodeling. *Furosemide* - Although vital for managing the patient's acute **volume overload** (dyspnea, ankle swelling) by inducing diuresis, it is a symptomatic treatment and is not considered the first-line medication to improve long-term survival in HFrEF. - Diuretics like Furosemide must be used in conjunction with foundational **GDMT** agents (ACEi/BB/MRA) but are not the initial mortality-reducing treatment. *Beta-blocker* - Beta-blockers are a mandatory class of first-line agents in HFrEF (along with RAAS inhibitors) that reduce mortality by blocking sympathetic overactivity. - However, they are often initiated or up-titrated *after* the patient is stabilized and on an ACE inhibitor because they can worsen symptoms during acute decompensation if not dosed carefully. *Spironolactone* - This agent is a **Mineralocorticoid Receptor Antagonist (MRA)**, which confers additional mortality benefit when added to a regimen of an ACE inhibitor (or ARB/ARNI) and a beta-blocker. - It is used as part of **triple therapy** and is not the appropriate *first* medication to initiate RAAS inhibition, especially due to risks like **hyperkalemia**. *Digoxin* - Digoxin is primarily used to control symptoms (reducing hospitalizations) in patients with severe HFrEF who remain symptomatic despite optimal **GDMT**, or for rate control in coexisting **atrial fibrillation**. - It does not improve overall survival and is therefore not a first-line choice for mortality benefit in HFrEF.

Question 17: A 53-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral stenosis with valve area 0.8 cm². She is in atrial fibrillation. What is the most appropriate treatment?

A. Medical management
B. Balloon mitral valvuloplasty (Correct Answer)
C. Mitral valve replacement
D. Heart transplantation
E. Cardioversion

Explanation: ***Balloon mitral valvuloplasty*** - This is the preferred initial treatment for symptomatic patients with **severe mitral stenosis** (valve area 0.8 cm²) if the valve anatomy is deemed favorable (e.g., non-calcified, minimal regurgitation). - It effectively reduces the **mitral gradient**, mitigating symptoms like dyspnea and fatigue, and is less invasive than surgical replacement. *Medical management* - Medical therapy (e.g., diuretics, beta-blockers) primarily helps with **symptom control** and managing the heart rate in atrial fibrillation but does not correct the underlying **hemodynamically significant obstruction**. - It is generally reserved for patients with mild or moderate MS, or those who are **asymptomatic**, which is not the case here (severe, symptomatic). *Mitral valve replacement* - Surgical replacement is indicated when the patient suffers severe symptoms but the mitral valve is **unsuitable for BMV** (e.g., severe **calcification**, significant **mitral regurgitation**, or failed prior valvuloplasty). - It is a significantly more invasive procedure with higher immediate risks compared to percutaneous balloon valvuloplasty. *Heart transplantation* - This measure is reserved only for patients with **end-stage heart failure** that remains refractory to maximal medical and surgical treatments. - It is inappropriate as a primary intervention when definitive treatment for the valvular disease (BMV or MVR) is feasible. *Cardioversion* - Cardioversion addresses the **atrial fibrillation** rhythm disturbance but does not resolve the underlying severe **mitral stenosis**, which is the primary cause of the patient's symptoms and AF. - While AF often requires rate control and anticoagulation, the *most appropriate* overall treatment must prioritize managing the severe valvular lesion.

Question 18: A 52-year-old man presents with progressive shortness of breath and fatigue. Echocardiogram shows severe aortic stenosis with valve area 0.6 cm². He is symptomatic in minimal exertion. What is the most appropriate management?

A. Medical management
B. Balloon aortic valvuloplasty
C. Aortic valve replacement (Correct Answer)
D. Heart transplantation
E. Observation

Explanation: ***Aortic valve replacement*** - This patient has **severe symptomatic aortic stenosis** (valve area 0.6 cm², symptoms with minimal exertion), for which **aortic valve replacement (AVR)** is the definitive treatment to improve survival and symptoms. - **Symptomatic severe aortic stenosis** is a Class I indication for AVR, as medical therapy alone does not alter the disease progression or improve prognosis.*Medical management* - Medical management (e.g., diuretics for symptoms) only provides **symptomatic relief** and does not address the underlying valve pathology or improve long-term survival in severe aortic stenosis. - It is generally reserved for **asymptomatic patients** or those who are not candidates for surgery due to prohibitive risk.*Balloon aortic valvuloplasty* - **Balloon aortic valvuloplasty (BAV)** provides only temporary symptomatic relief and has **limited long-term efficacy** in adults with severe aortic stenosis due to high rates of restenosis. - It is typically considered a **bridge to AVR** for critically ill patients or in specific situations like pregnancy, but not as a definitive treatment in this case.*Heart transplantation* - **Heart transplantation** is an extreme measure reserved for **end-stage heart failure** that is refractory to all other medical and surgical interventions. - While aortic stenosis can lead to heart failure, AVR is the appropriate first-line surgical intervention before considering transplantation.*Observation* - **Observation** is appropriate only for **asymptomatic patients** with severe aortic stenosis, with regular monitoring for symptom development or disease progression. - This patient is **symptomatic with minimal exertion**, indicating a need for intervention, not observation, to prevent adverse outcomes.

Question 19: A 59-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows EF 28% with global hypokinesis. Coronary angiogram is normal. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Pericardial disease

Explanation: ***Dilated cardiomyopathy*** - This diagnosis is strongly suggested by the presence of severe **systolic dysfunction** (EF 28%), **global hypokinesis**, and the exclusion of significant **ischemic etiology** by the **normal coronary angiogram**. - DCM leads to ventricular chamber enlargement and impaired contractility, clinically manifesting as **congestive heart failure** (dyspnea, ankle swelling). *Ischemic cardiomyopathy* - This diagnosis requires significant **coronary artery disease (CAD)** as the underlying cause, which is explicitly ruled out by the patient's **normal coronary angiogram**. - While it causes low EF and global hypokinesis, the etiology in this case must be non-ischemic (e.g., idiopathic, viral) to explain the negative angiogram. *Hypertrophic cardiomyopathy* - HCM is defined by significant **ventricular wall hypertrophy** and usually presents with a **preserved or hyperdynamic EF**, contradicting the EF of 28% (severe systolic dysfunction). - The primary issue is typically **diastolic dysfunction** due to impaired relaxation, making systolic failure with global hypokinesis an unlikely primary presentation. *Restrictive cardiomyopathy* - RCM is primarily a disorder of **diastolic dysfunction** (impaired filling due to stiff ventricles) and typically presents with a **preserved ejection fraction** (normal or near-normal). - This condition is usually associated with infiltrative diseases (e.g., **amyloidosis**) and does not typically cause severe primary **systolic failure** (EF 28%) and global hypokinesis. *Pericardial disease* - Conditions like **constrictive pericarditis** restrict cardiac filling but do not intrinsically reduce myocardial contractility, thereby maintaining a **normal or near-normal EF**. - This etiology cannot account for the observed severe **systolic dysfunction** and **global hypokinesis** (EF 28%), which indicates a primary myocardial problem.

Question 20: A 45-year-old man presents with progressive shortness of breath and fatigue. Echocardiogram shows severe aortic stenosis with valve area 0.8 cm² and mean gradient 50 mmHg. He is symptomatic with exertional dyspnea. What is the most appropriate management?

A. Medical management with diuretics
B. Balloon aortic valvuloplasty
C. Aortic valve replacement (Correct Answer)
D. ACE inhibitors
E. Observation

Explanation: ***Aortic valve replacement***- This patient has **severe aortic stenosis** (valve area 0.8 cm², mean gradient 50 mmHg) and is **symptomatic** with exertional dyspnea, which are clear indications for intervention.- For symptomatic severe aortic stenosis, **aortic valve replacement** (either surgical or transcatheter) is the definitive treatment to improve survival and alleviate symptoms, as per current guidelines (Class I recommendation).*Medical management with diuretics*- Medical therapy, such as diuretics, can provide **symptom relief** for heart failure in aortic stenosis but does not address the underlying mechanical obstruction or improve long-term survival.- Relying solely on medical management for severe, symptomatic AS leads to a very **poor prognosis**, with high mortality rates within a few years.*Balloon aortic valvuloplasty*- **Balloon aortic valvuloplasty (BAV)** offers only temporary hemodynamic improvement and is typically considered a **bridge to definitive AVR** in critically ill patients or for **congenital AS**.- It is not the preferred definitive treatment for calcific severe aortic stenosis in adults due to a high rate of **restenosis** and potential complications.*ACE inhibitors*- **ACE inhibitors** and other vasodilators are generally contraindicated or used with extreme caution in severe aortic stenosis due to the risk of precipitating **severe hypotension** by reducing preload and systemic vascular resistance.- These medications do not alleviate the fixed outflow obstruction and can worsen symptoms like **syncope** or lead to cardiogenic shock.*Observation*- **Observation** is appropriate only for patients with **asymptomatic severe aortic stenosis** or those with mild to moderate disease.- The presence of symptoms like exertional dyspnea indicates a high risk of adverse cardiovascular events, including sudden cardiac death, and necessitates prompt **aortic valve replacement**.

Question 21: A 55-year-old man presents with progressive shortness of breath and fatigue over 6 months. Echocardiogram shows concentric left ventricular hypertrophy with preserved ejection fraction. Cardiac catheterization shows normal coronary arteries. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy
C. Hypertrophic cardiomyopathy
D. Heart failure with preserved ejection fraction (Correct Answer)
E. Constrictive pericarditis

Explanation: ***Heart failure with preserved ejection fraction*** - The patient's symptoms of **shortness of breath** and **fatigue** combined with an echocardiogram showing **concentric left ventricular hypertrophy** and **preserved ejection fraction** (typically >50%) are diagnostic criteria for **HFpEF**. - **Normal coronary arteries** on cardiac catheterization further support a non-ischemic etiology, making HFpEF the most likely diagnosis, often secondary to chronic **hypertension**. *Ischemic cardiomyopathy* - This condition is characterized by **systolic dysfunction** (reduced ejection fraction) and ventricular remodeling due to **coronary artery disease**. - The patient has **preserved ejection fraction** and **normal coronary arteries**, which rules out ischemic cardiomyopathy as the primary cause. *Dilated cardiomyopathy* - This is defined by **ventricular chamber dilation** and impaired **systolic function** leading to a reduced ejection fraction. - The echocardiogram shows **concentric left ventricular hypertrophy** (thickened walls), not ventricular dilation, and a preserved ejection fraction. *Hypertrophic cardiomyopathy* - While it involves **left ventricular hypertrophy**, it is typically **asymmetric** (often septal) and often genetic in origin, sometimes leading to LV outflow tract obstruction. - The patient's presentation with acquired **concentric hypertrophy** and symptoms of heart failure is more consistent with HFpEF, often due to chronic pressure overload. *Constrictive pericarditis* - This condition results from a stiff or calcified **pericardium** that restricts diastolic filling, often with a normal myocardium and characteristic pericardial findings on imaging. - The presence of significant **concentric left ventricular hypertrophy** points to a primary myocardial pathology rather than an extrinsic pericardial restriction.

Question 22: A 25-year-old woman presents with a 2-week history of fever, weight loss, and a new heart murmur. Blood cultures grow Streptococcus viridans. Echocardiogram shows vegetation on the mitral valve. What is the most likely diagnosis?

A. Rheumatic fever
B. Infective endocarditis (Correct Answer)
C. Myocarditis
D. Pericarditis
E. Cardiomyopathy

Explanation: ***Infective endocarditis***- The constellation of fever, weight loss, a **new heart murmur**, **positive blood cultures** for ***Streptococcus viridans***, and **vegetation on the mitral valve** seen on echocardiogram are all classic diagnostic criteria for infective endocarditis.- ***Streptococcus viridans***, a common inhabitant of the oral flora, is a frequent cause of **subacute infective endocarditis**, particularly affecting previously damaged or sometimes normal heart valves. It directly explains the vegetations.*Rheumatic fever*- This condition is an immune-mediated sequela of a preceding **Group A Streptococcus (GAS)** pharyngitis, not directly caused by ***Streptococcus viridans*** bacteremia.- While it can cause **carditis** and valvular damage (often **mitral regurgitation**), the pathology is an inflammatory process, not direct bacterial colonization forming vegetations.*Myocarditis*- Myocarditis involves inflammation of the **myocardium** (heart muscle), typically presenting with symptoms such as chest pain, heart failure, or arrhythmias.- It does not primarily manifest with a **new heart murmur** due to valvular dysfunction, nor does it cause **valvular vegetations** directly.*Pericarditis*- Pericarditis is inflammation of the **pericardium**, often causing sharp, positional chest pain and sometimes a **pericardial friction rub**.- This condition does not cause **valvular vegetations** or a new heart murmur resulting from damage to the heart valves themselves.*Cardiomyopathy*- Cardiomyopathy is a primary disease of the **heart muscle**, leading to impaired pumping function (e.g., dilated, hypertrophic) and symptoms of **heart failure**.- It is a structural and functional abnormality of the heart muscle and does not explain the acute infectious process (fever, bacteremia) or the specific presence of **vegetations** on a heart valve.

Question 23: A 50-year-old man presents with progressive shortness of breath and ankle swelling. Chest X-ray shows cardiomegaly and pulmonary edema. ECG shows atrial fibrillation. Echocardiogram shows severe mitral regurgitation. What is the most likely cause of his symptoms?

A. Ischemic heart disease
B. Mitral valve disease (Correct Answer)
C. Hypertensive heart disease
D. Cardiomyopathy
E. Pericardial disease

Explanation: ***Mitral valve disease***- The echocardiogram directly reveals **severe mitral regurgitation (MR)**, which is the primary cause for the patient's symptoms of **shortness of breath**, **pulmonary edema**, and **ankle swelling**, indicating **heart failure** due to **volume overload** in the left atrium and pulmonary circulation.- Severe MR leads to significant **left atrial enlargement** and increased pressure, which are major factors contributing to the development of **atrial fibrillation (AF)** observed on the ECG.*Ischemic heart disease*- While **ischemic heart disease (IHD)** is a very common cause of heart failure and can lead to functional MR due to ventricular remodeling or papillary muscle dysfunction, the most prominent and *direct* finding in this case is the documented **severe mitral regurgitation** itself.- The question's focus on severe valvular pathology makes valvular disease a more specific explanation for the immediate symptoms than general IHD, without further evidence of acute coronary events.*Hypertensive heart disease*- **Hypertensive heart disease** typically causes **left ventricular hypertrophy** and can lead to heart failure with preserved or reduced ejection fraction.- While hypertension can contribute to cardiac remodeling, the explicit finding of **severe mitral regurgitation** as the primary echocardiographic abnormality points more directly to a valvular etiology as the immediate cause of the patient's acute decompensation.*Cardiomyopathy*- **Cardiomyopathy** results in primary myocardial dysfunction leading to ventricular dilation and heart failure symptoms, which can include secondary (functional) mitral regurgitation.- However, if the severe mitral regurgitation is *primary* (e.g., due to leaflet prolapse or chordal rupture), then **mitral valve disease** is the direct root cause; if it is secondary, the cardiomyopathy would be the *underlying* cause, but the symptoms are explicitly mediated by the severe MR.*Pericardial disease*- **Pericardial diseases** such as constrictive pericarditis or cardiac tamponade primarily affect **diastolic filling** and cause symptoms related to elevated systemic venous pressure and reduced cardiac output.- These conditions do not typically present with **severe mitral regurgitation** as the main pathology explaining the pulmonary edema and cardiomegaly.

Question 24: A 40-year-old man presents with progressive dyspnea on exertion and fatigue over 3 months. Echocardiogram shows dilated left ventricle with ejection fraction of 25%. He has no history of coronary artery disease or hypertension. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Pericardial disease

Explanation: ***Dilated cardiomyopathy***- The classic presentation involves progressive **heart failure symptoms** (dyspnea, fatigue) accompanied by **left ventricular dilation** and severe **systolic dysfunction (EF < 40%)** on echocardiogram.- Since the patient has no history of **coronary artery disease (CAD)** or hypertension, this presentation strongly suggests **idiopathic dilated cardiomyopathy**, the most common form of non-ischemic cardiomyopathy.*Ischemic cardiomyopathy*- This diagnosis requires evidence of significant **coronary artery disease** or prior **myocardial infarction** causing the systolic dysfunction, which is explicitly absent in this case.- The underlying pathology is due to myocardial scarring and stunning resulting from **myocardial ischemia**.*Hypertrophic cardiomyopathy*- This condition is primarily characterized by unexplained **left ventricular hypertrophy** leading to impaired **diastolic filling**, not typically a dilated chamber.- While end-stage hypertrophic cardiomyopathy can involve systolic failure, the initial defining feature is a thickened, **non-dilated LV**.*Restrictive cardiomyopathy*- Defined by abnormally rigid, non-compliant ventricles leading to severe impairment of **diastolic filling** (restrictive physiology), usually with **preserved systolic function**.- The echocardiogram findings typically show normal LV size, often with **biatrial enlargement**, not **LV dilation** and low ejection fraction.*Pericardial disease*- Conditions like constrictive pericarditis mainly impair cardiac filling and stroke output due to external compression, affecting **diastolic function**.- Pericardial disease does not typically cause the primary myocardial disease necessary to result in such severe **left ventricular systolic dysfunction** and remodeling.

Question 25: A 60-year-old man presents with crushing central chest pain lasting 45 minutes. His ECG shows ST depression in leads V4-V6. Troponin I is elevated at 0.8 ng/ml (normal <0.04). What is the most likely diagnosis?

A. Unstable angina
B. NSTEMI (Correct Answer)
C. STEMI
D. Pericarditis
E. Aortic dissection

Explanation: ***NSTEMI***- This diagnosis is defined by evidence of myocardial necrosis (elevated **Troponin I**) in the setting of clinical symptoms of ischemia (crushing chest pain) and ECG changes (ST **depression**).- ST depression indicates **subendocardial ischemia** and differentiates it from STEMI, where transmural ischemia causes ST elevation.*Unstable angina*- The definition of unstable angina requires cardiac biomarkers (**Troponin** and CK-MB) to be **normal**, ruling it out when Troponin is elevated.- While symptoms and ECG (ST depression) are consistent with ACS, the presence of myocardial injury confirms infarction, not just unstable angina.*STEMI*- This diagnosis requires persistent **ST segment elevation** (or new LBBB) on the ECG, reflecting transmural myocardial ischemia.- The patient's ECG showing only ST **depression** (V4-V6) definitively excludes a primary STEMI diagnosis.*Pericarditis*- The pain associated with pericarditis is typically sharp, **pleuritic**, and improves when leaning forward, unlike crushing ischemic pain.- ECG classically shows **diffuse ST elevation** and **PR segment depression**, findings absent in this presentation.*Aortic dissection*- Pain is usually described as **tearing or ripping** and often radiates to the back, which differs from crushing ischemic pain.- While it is a life-threatening cause of chest pain, it characteristically does not cause primary **Troponin** elevation or ischemic ST changes.

Question 26: A 65-year-old man presents with progressive shortness of breath on exertion and orthopnea. Chest X-ray shows cardiomegaly and upper lobe blood diversion. Echocardiogram shows ejection fraction of 35%. What is the most appropriate first-line medication?

A. Furosemide
B. ACE inhibitor (Correct Answer)
C. Beta-blocker
D. Spironolactone
E. Digoxin

Explanation: ***ACE inhibitor***- It is a cornerstone medication for **Heart Failure with Reduced Ejection Fraction (HFrEF)** (EF < 40%), offering significant reduction in morbidity and all-cause mortality.- It works by inhibiting the conversion of **Angiotensin I to Angiotensin II**, blocking the deleterious effects of the **Renin-Angiotensin-Aldosterone System (RAAS)**, which includes harmful cardiac remodeling.*Furosemide*- Furosemide is a **loop diuretic** primarily used to relieve symptoms of volume overload (e.g., **pulmonary congestion** and orthopnea) by increasing fluid excretion.- While crucial for symptom management, it is *not* considered a first-line drug for improving long-term **survival or prognosis** in HFrEF.*Beta-blocker*- Beta-blockers (e.g., Carvedilol) are also essential **mortality-reducing agents** in HFrEF by blocking detrimental sympathetic nervous system activation.- Although the second major pillar of HFrEF therapy, they are typically initiated after or concurrently with an ACE inhibitor (or ARNI), usually once the patient is **euvolemic**.*Spironolactone*- This is an **Aldosterone Antagonist** used primarily in patients with persistent severe symptoms (NYHA Class II-IV) and low EF who are already receiving an ACEi/ARNI and a Beta-blocker.- It provides further prognostic benefit and prevents **potassium loss**, but is added after the two foundational therapies are established.*Digoxin*- Digoxin is used primarily for **symptom control** and to reduce the risk of hospitalization, especially in patients with coexisting **atrial fibrillation**.- Unlike ACE inhibitors and Beta-blockers, it does *not* provide a primary **mortality benefit** and is generally reserved for refractory cases.

Question 27: A 70-year-old man presents with progressive shortness of breath and ankle swelling over 3 months. Examination reveals elevated IVP, bilateral crepitations, and pitting edema. His NT-proBNP is 2500 pg/ml. What is the most appropriate initial investigation?

A. Chest X-ray
B. Echocardiogram (Correct Answer)
C. CT pulmonary angiogram
D. Coronary angiography
E. Exercise stress test

Explanation: ***Echocardiogram*** - The patient's progressive shortness of breath, ankle swelling, elevated **JVP**, bilateral crepitations, pitting edema, and significantly elevated **NT-proBNP** (2500 pg/ml) are classic features highly indicative of **heart failure**. - An **echocardiogram** is the **gold standard** initial investigation to assess cardiac structure and function, evaluate **ejection fraction** (differentiating **HFrEF** from **HFpEF**), and identify underlying valvular or myocardial pathologies. *Chest X-ray* - While a **chest X-ray** can reveal signs of pulmonary congestion (e.g., **Kerley B lines**, **cardiomegaly**) consistent with heart failure, it offers limited information on specific cardiac chamber dimensions, **valvular function**, or **ejection fraction**. - It serves as a complementary investigation but is not as definitive as an echocardiogram for establishing the primary cardiac etiology. *CT pulmonary angiogram* - A **CT pulmonary angiogram (CTPA)** is the primary investigation for diagnosing **pulmonary embolism (PE)**, which typically presents with acute onset symptoms rather than the 3-month progressive course described here. - The constellation of findings, especially the high **NT-proBNP**, strongly points towards primary cardiac dysfunction and fluid overload, making PE a less likely initial diagnosis. *Coronary angiography* - **Coronary angiography** is an invasive procedure primarily used to assess the severity of **coronary artery disease (CAD)** and guide potential revascularization. - It is usually performed after non-invasive tests suggest an ischemic cause for heart failure or in specific clinical scenarios, not as the initial diagnostic test for new-onset heart failure. *Exercise stress test* - An **exercise stress test** is typically used to evaluate for **inducible ischemia** and functional capacity in stable patients with suspected coronary artery disease. - It is generally contraindicated or inappropriate as an initial diagnostic tool in patients presenting with clear signs and symptoms of **decompensated heart failure** and fluid overload.

Question 28: A 45-year-old man presents with central chest pain radiating to his left arm and jaw. The pain started 2 hours ago and is described as crushing. His ECG shows ST elevation in leads II, III, and aVF. What is the most likely diagnosis?

A. Anterior STEMI
B. Inferior STEMI (Correct Answer)
C. Lateral STEMI
D. Posterior STEMI
E. Unstable angina

Explanation: ***Inferior STEMI*** - **ST elevation** in leads **II, III, and aVF** localizes the infarct to the inferior wall of the left ventricle. This specific pattern is diagnostic of an **Inferior STEMI**. - The occlusion is most commonly in the proximal or mid **right coronary artery (RCA)**, but can sometimes involve a dominant left circumflex artery (LCX).*Anterior STEMI* - Anterior STEMI is defined by **ST elevation** in the precordial leads, specifically **V1 through V4**. - This type of infarction typically involves the occlusion of the **left anterior descending (LAD) artery**.*Lateral STEMI* - Lateral wall involvement is identified by **ST elevation** in leads **I, aVL, V5, and V6**. - This usually signifies occlusion of the **left circumflex artery (LCX)** or a diagonal branch of the LAD.*Posterior STEMI* - A true posterior infarct is suspected when there are reciprocal changes, such as **ST depression** and tall R waves in anterior leads (**V1-V3**). - Definitive diagnosis requires **ST elevation** in posterior leads, such as **V7, V8, and V9**.*Unstable angina* - Unstable angina is characterized by acute ischemic symptoms but *lacks* persistent **ST elevation** on the ECG. - This condition is defined as having no (or minimal, non-diagnostic) rise in **cardiac biomarkers** (troponins) and does not necessitate immediate primary percutaneous coronary intervention (PCI).

Question 29: A 67-year-old man presents with progressive shortness of breath and ankle swelling over 3 months. Examination reveals elevated JVP, bilateral crepitations, and pitting edema. His NT-proBNP is 2500 pg/ml. What is the most appropriate initial investigation?

A. Chest X-ray
B. Echocardiogram (Correct Answer)
C. CT pulmonary angiogram
D. Coronary angiography
E. Exercise stress test

Explanation: ***Echocardiogram*** - The patient's presentation with progressive **shortness of breath**, **ankle swelling**, elevated **JVP**, bilateral **crepitations**, and a significantly elevated **NT-proBNP (2500 pg/ml)** is highly suggestive of **heart failure**. - An echocardiogram is the **most appropriate initial investigation** as it directly visualizes cardiac structure, assesses **left ventricular function (ejection fraction)**, identifies **valvular disease**, and evaluates chamber sizes, providing crucial information for diagnosis and guiding treatment.*Chest X-ray* - While a chest X-ray can show signs of **pulmonary congestion** (e.g., **cardiomegaly**, **pulmonary edema**, **pleural effusions**) that are consistent with heart failure, it does not provide information on **cardiac function** or **valvular pathology**. - It is a useful adjunct but cannot quantify the severity of heart failure or pinpoint the underlying cause of cardiac dysfunction, which an echocardiogram can. *CT pulmonary angiogram* - This investigation is primarily indicated for diagnosing **pulmonary embolism (PE)**, a condition that can cause acute shortness of breath. - However, the patient's symptoms are progressive over 3 months, indicating a more chronic process, and the features of **fluid overload** (ankle swelling, elevated JVP) are more characteristic of heart failure than PE. *Coronary angiography* - Coronary angiography is an invasive procedure used to assess for **coronary artery disease (CAD)**, which is a common underlying cause of heart failure. - It is typically reserved for patients where CAD is strongly suspected as the etiology of heart failure and revascularization is being considered, usually after non-invasive assessments like an echocardiogram. *Exercise stress test* - An exercise stress test evaluates for **myocardial ischemia** in patients with suspected coronary artery disease who are stable and able to exert themselves. - Given the patient's symptoms of progressive shortness of breath and clear signs of **heart failure decompensation**, an exercise stress test is contraindicated and inappropriate as an initial investigation.

Question 30: A 53-year-old man presents with progressive dyspnea and ankle swelling. Chest X-ray shows Kerley B lines and cardiomegaly. BNP is 2500 pg/mL. Echocardiogram shows EF 25%. What is the most appropriate initial medication?

A. Furosemide
B. ACE inhibitor (Correct Answer)
C. Beta-blocker
D. Spironolactone
E. Digoxin

Explanation: ***ACE inhibitor***- **ACE inhibitors** are first-line therapy for **heart failure with reduced ejection fraction (HFrEF)**, significantly improving survival and reducing hospitalizations.- They work by blocking the **renin-angiotensin-aldosterone system**, reducing afterload, preload, and ventricular remodeling.*Furosemide*- **Furosemide** is a loop diuretic primarily used for **symptomatic relief** of volume overload (dyspnea, ankle swelling) in heart failure.- While crucial for symptom management, it does **not improve long-term mortality** in chronic heart failure and is often given alongside agents that do.*Beta-blocker*- **Beta-blockers** are cornerstone therapies for **HFrEF** that improve survival, but they are typically initiated *after* an ACE inhibitor.- They should be started cautiously and titrated slowly, *only once the patient is euvolemic* and stable, as they can acutely worsen symptoms in decompensated states.*Spironolactone*- **Spironolactone**, a mineralocorticoid receptor antagonist, improves mortality in **HFrEF** by blocking aldosterone's detrimental effects.- It is typically added as a second-line agent *after* ACE inhibitors and beta-blockers have been optimized, especially in patients with persistent symptoms.*Digoxin*- **Digoxin** is used in heart failure primarily for **symptomatic control** and to reduce hospitalizations, particularly in patients with **atrial fibrillation**.- It does **not improve mortality** in heart failure and is usually considered for patients who remain symptomatic despite optimal guideline-directed medical therapy.

Question 31: A 58-year-old man presents with progressive dyspnea and fatigue over 6 months. Echocardiogram shows severe mitral regurgitation with flail posterior leaflet. LV function normal. He is symptomatic on exertion. What is the most appropriate management?

A. Medical management
B. Mitral valve replacement
C. Mitral valve repair (Correct Answer)
D. Heart transplantation
E. Balloon mitral valvuloplasty

Explanation: ***Mitral valve repair***- Guidelines recommend surgical intervention for symptomatic patients with severe primary **mitral regurgitation** (MR) and preserved LV function (LVEF >60%).- **Repair is preferred** over replacement for degenerative MR (like a flail posterior leaflet) as it preserves the subvalvular apparatus, associated with superior long-term **left ventricular** function and survival.*Medical management*- Medical therapy (e.g., diuretics, vasodilators) is indicated only for patients deemed **not surgical candidates** or for asymptomatic patients with chronic MR being monitored.- In severe, primary MR that is symptomatic, delaying definitive surgical intervention increases the risk of irreversible **Left Ventricular (LV) dysfunction**.*Mitral valve replacement*- While a definitive surgical option, replacement is generally reserved for cases where **mitral repair** is technically unfeasible or has failed.- Replacement carries a higher perioperative risk and involves the long-term risks associated with a prosthetic valve, such as the need for lifetime **anticoagulation** with a mechanical valve.*Heart transplantation*- This option is reserved for patients with severe, **end-stage heart failure** refractory to optimal medical and surgical treatments.- It is not indicated in this patient, as the description clearly states they have **normal LV function**.*Balloon mitral valvuloplasty*- This procedure is strictly indicated for patients with severe **mitral stenosis**, particularly of **rheumatic etiology**.- It is contraindicated in patients with predominant severe **mitral regurgitation**, especially if caused by a structural defect like a **flail leaflet**.

Question 32: A 63-year-old man presents with progressive dyspnea and bilateral ankle swelling. Chest X-ray shows cardiomegaly and pulmonary edema. BNP is 2500 pg/mL. Echocardiogram shows EF 25%. What is the most appropriate initial medication?

A. Furosemide
B. ACE inhibitor (Correct Answer)
C. Beta-blocker
D. Spironolactone
E. Digoxin

Explanation: ***ACE inhibitor*** - **ACE inhibitors** are considered **first-line therapy** for patients with **Heart Failure with reduced Ejection Fraction (HFrEF)**, such as this patient with an EF of 25% and symptoms. - They work by blocking the **renin-angiotensin-aldosterone system (RAAS)**, leading to **vasodilation**, reduced cardiac remodeling, and significant improvements in **morbidity and mortality**. *Furosemide* - **Furosemide** is a loop diuretic primarily used for **symptomatic relief of congestion** (dyspnea, edema, pulmonary edema) in heart failure. - While often administered initially in acute decompensated heart failure, it does **not improve long-term mortality** or alter the disease progression; it addresses symptoms, not the underlying pathophysiology as the initial disease-modifying agent. *Beta-blocker* - **Beta-blockers** are also cornerstone therapy for HFrEF, improving **mortality and morbidity** by reducing sympathetic overactivity and remodeling. - However, they are typically initiated *after* ACE inhibitors (or ARNI/ARB) and only once the patient is **clinically stable and euvolemic**, as starting them in a congested patient can worsen heart failure symptoms. *Spironolactone* - **Spironolactone**, an **aldosterone antagonist**, is a **mortality-reducing agent** in HFrEF, particularly in patients with persistent symptoms or more severe disease. - It is usually added to an existing regimen of ACE inhibitors/ARBs and beta-blockers, not as the very first initial medication. *Digoxin* - **Digoxin** can improve symptoms and reduce hospitalizations in HFrEF by enhancing cardiac contractility and slowing heart rate in atrial fibrillation. - However, it does **not improve mortality** and is typically reserved for patients who remain symptomatic despite optimal guideline-directed medical therapy with ACE inhibitors, beta-blockers, and aldosterone antagonists.

Question 33: A 38-year-old man presents with sudden onset severe "tearing" chest pain radiating to his back. His blood pressure is 180/100 mmHg in the right arm and 120/80 mmHg in the left arm. What is the most likely diagnosis?

A. Myocardial infarction
B. Aortic dissection (Correct Answer)
C. Pulmonary embolism
D. Pericarditis
E. Pneumothorax

Explanation: ***Aortic dissection***- This presentation of sudden, severe, **'tearing' chest pain** radiating to the back, combined with a **significant inter-arm blood pressure differential** (180/100 mmHg in right arm vs. 120/80 mmHg in left arm), is the classic triad for **aortic dissection**.- The BP differential arises when the dissection flap extends into and obstructs the origin of a major branch vessel, such as the **subclavian artery**, reducing perfusion to that limb.*Myocardial infarction*- Pain associated with **myocardial infarction (MI)** is typically described as crushing, pressure-like, or squeezing, often radiating to the left arm or jaw, which differs from the *tearing* quality described here.- While an MI can cause hemodynamic instability, it does not typically cause the **inter-arm systolic blood pressure differential** characteristic of aortic dissection.*Pulmonary embolism*- **Pulmonary embolism (PE)** is characterized by sudden onset **dyspnea**, hypoxemia, and pleuritic chest pain (sharp pain worsened by breathing), and is rarely described as *tearing*.- A **blood pressure differential** between the arms is not a typical clinical feature of pulmonary embolism.*Pericarditis*- **Pericarditis** typically causes sharp, pleuritic pain that is characteristically relieved by *sitting up and leaning forward* and worsened by *lying supine*.- It is not associated with severe, tearing pain radiating to the back or a **pulse deficit** in the peripheral circulation.*Pneumothorax*- A **pneumothorax** causes sudden, sharp, pleuritic chest pain and shortness of breath due to lung collapse.- This condition does not cause the specific **severe tearing pain** or the highly diagnostic **blood pressure differential** between the arms observed in this case.

Question 34: A 56-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic regurgitation with LV end-systolic dimension 35mm and EF 50%. He is asymptomatic at rest. What is the most appropriate management?

A. Medical management
B. Aortic valve replacement (Correct Answer)
C. ACE inhibitors
D. Diuretics
E. Observation

Explanation: ***Aortic valve replacement*** - The presence of **severe aortic regurgitation** coupled with symptoms like **progressive dyspnea and fatigue** is a strong indication for **aortic valve replacement**, even if the patient reports being asymptomatic at rest, as these symptoms signify a need for intervention. - Current guidelines recommend surgical intervention for symptomatic patients with severe AR, regardless of LV function or dimensions, to prevent irreversible **left ventricular (LV) dysfunction** and improve prognosis. *Medical management* - While medical management can temporarily alleviate symptoms, it is **not definitive treatment** for severe, symptomatic aortic regurgitation and does not address the underlying valvular pathology. - Relying solely on medical management in this scenario would risk **progressive LV dysfunction** and potentially worse surgical outcomes if delayed. *ACE inhibitors* - **ACE inhibitors** are vasodilators that can reduce afterload and may be used in chronic AR to manage hypertension or as adjunctive therapy for heart failure symptoms. - However, they are **not a substitute for surgical correction** in severe, symptomatic AR, as they do not resolve the primary issue of valvular incompetence. *Diuretics* - **Diuretics** primarily manage symptoms of **fluid overload** and congestive heart failure by reducing preload, such as dyspnea and edema. - They provide **symptomatic relief** but do not treat the underlying severe aortic regurgitation or prevent its progression, making them inadequate as the primary management. *Observation* - **Observation** is generally reserved for patients with **asymptomatic severe aortic regurgitation** who have **preserved LV function (EF > 50%)** and normal LV dimensions (e.g., ESD < 50mm). - This patient, despite being asymptomatic at rest, presents with **progressive dyspnea and fatigue**, classifying him as symptomatic and thus requiring active intervention rather than observation.

Question 35: A 61-year-old man presents with progressive dyspnea and ankle swelling. Chest X-ray shows cardiomegaly. Echocardiogram shows concentric LVH with preserved EF but impaired diastolic function. What is the most likely diagnosis?

A. Dilated cardiomyopathy
B. Heart failure with preserved ejection fraction (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Ischemic cardiomyopathy

Explanation: ***Heart failure with preserved ejection fraction*** - The clinical presentation of **dyspnea** and **ankle swelling** (symptoms of heart failure) combined with echocardiographic findings of **preserved Ejection Fraction (EF)** and **impaired diastolic function** precisely defines **HFpEF**. - The presence of **concentric LVH** is a common structural finding in HFpEF, often due to long-standing hypertension, which impairs diastolic filling. *Dilated cardiomyopathy* - This condition is characterized by **ventricular dilation** and significantly **reduced Ejection Fraction** (systolic dysfunction), which contradicts the preserved EF in the patient. - It typically results in **heart failure with reduced ejection fraction (HFrEF)**, not HFpEF, and involves eccentric rather than concentric remodeling. *Hypertrophic cardiomyopathy* - While HCM involves LVH and impaired diastolic function, **HFpEF** is the broader clinical syndrome that encompasses these findings as a consequence, representing the patient's overall functional status. - HCM classically involves **asymmetric septal hypertrophy** and can have outflow tract obstruction, which are not explicitly described as defining features here. *Restrictive cardiomyopathy* - RCM is a type of cardiomyopathy leading to impaired diastolic function and often **HFpEF**, but it typically presents with distinct features like severely **dilated atria** and a rapid, restrictive filling pattern, often due to infiltrative diseases like **amyloidosis**. - While it aligns with preserved EF and impaired diastole, **HFpEF** is the most encompassing and likely diagnosis based on the provided minimal criteria. *Ischemic cardiomyopathy* - ICM is caused by extensive coronary artery disease leading to myocardial damage and typically manifests as **systolic dysfunction** with a significantly **reduced Ejection Fraction** (HFrEF). - The patient's **preserved EF** makes ischemic cardiomyopathy an unlikely primary diagnosis for this specific heart failure phenotype.

Question 36: A 56-year-old man presents with progressive shortness of breath and fatigue. Echocardiogram shows severe aortic stenosis with valve area 0.6 cm². He is high surgical risk. What is the most appropriate treatment?

A. Medical management
B. Balloon aortic valvuloplasty
C. Transcatheter aortic valve replacement (Correct Answer)
D. Surgical aortic valve replacement
E. Heart transplantation

Explanation: ***Transcatheter aortic valve replacement*** - This is the preferred definitive treatment for patients with **severe symptomatic aortic stenosis** who are deemed **high surgical risk** for traditional **Surgical Aortic Valve Replacement (SAVR)**. - TAVR is a less invasive procedure, improving outcomes and survival compared to medical therapy in this high-risk population. *Medical management* - Medical therapy (e.g., diuretics) is primarily aimed at managing symptoms of heart failure but does not resolve the underlying obstruction or improve the poor mortality risk associated with **severe aortic stenosis**. - Initiating medical management as the sole definitive treatment is associated with a poor prognosis once severe AS symptoms develop. *Balloon aortic valvuloplasty* - **Balloon aortic valvuloplasty (BAV)** offers temporary relief but is associated with high rates of restenosis and is generally reserved as a **bridge-to-surgery/TAVR** or for palliation. - It is not considered the appropriate long-term definitive treatment for a patient who is otherwise a suitable candidate for TAVR due to its limited durability. *Surgical aortic valve replacement* - **SAVR** remains the surgical gold standard, but it is contraindicated or non-preferred in patients identified as **high surgical risk** due to significantly elevated perioperative morbidity and mortality rates. - The patient’s high surgical risk status mandates the selection of the less invasive TAVR procedure over open heart surgery (SAVR). *Heart transplantation* - **Heart transplantation** is reserved for end-stage **refractory heart failure** where all other potential surgical and mechanical interventions have failed or are not feasible. - It is overtreatment for isolated, severe aortic stenosis that can be effectively managed with TAVR.

Question 37: A 62-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe tricuspid regurgitation with elevated right heart pressure. Right heart catheterization shows mean PAP 50 mmHg. What is the most likely diagnosis?

A. Left heart failure
B. Pulmonary hypertension (Correct Answer)
C. Pulmonary embolism
D. COPD
E. Tricuspid valve disease

Explanation: ***Pulmonary hypertension*** - A mean Pulmonary Artery Pressure (**PAP**) of 50 mmHg, which is significantly higher than the normal range (<25 mmHg), meets the defining hemodynamic criterion for **pulmonary hypertension**.- Severe right heart pressure elevation, leading to **severe tricuspid regurgitation** and systemic congestion (**bilateral ankle swelling**), are classic clinical consequences of established pulmonary hypertension (often resulting in **Cor Pulmonale**).*Left heart failure*- While **Left Heart Failure (LHF)** is the most common *cause* of pulmonary hypertension (Group 2 PH), the RHC finding of mean PAP 50 mmHg confirms PH is established.- If LHF were the immediate and only defining feature, a highly elevated **pulmonary capillary wedge pressure (PCWP)** would be expected, but the diagnosis confirmed by the 50 mmHg reading is PH itself.*Pulmonary embolism*- **Chronic thromboembolic pulmonary hypertension (CTEPH)** is a recognized cause (Group 4 PH), but this is a specific *etiology*, whereas the confirmed hemodynamic state is **pulmonary hypertension**.- An acute PE typically presents with sudden onset of dyspnea and is usually associated with symptoms like **tachypnea** or **pleuritic chest pain**, not the presented chronic course.*COPD*- **COPD** (Group 3 PH cause) typically results in milder PH, usually with mean PAP values below 35-40 mmHg, making 50 mmHg less typical for isolated COPD.- COPD is an underlying lung disease and potential *cause*, not the comprehensive hemodynamic diagnosis confirmed by the severely elevated **mean PAP**.*Tricuspid valve disease*- **Severe tricuspid regurgitation** is a *result* of the profound dilation of the right ventricle annulus due to chronic, severe **pulmonary hypertension** and high RV afterload.- Primary tricuspid valve disease (e.g., rheumatologic or carcinoid) would show severe TR but would not necessarily exhibit a mean PAP of 50 mmHg unless severe PH had developed secondarily.

Question 38: A 58-year-old man presents with progressive dyspnea and ankle swelling. Chest X-ray shows upper lobe blood diversion. Echocardiogram shows EF 35% with global hypokinesi. Coronary angiogram is normal. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Valvular heart disease

Explanation: ***Dilated cardiomyopathy*** - The patient's presentation with **progressive dyspnea** and **ankle swelling** (heart failure symptoms), along with an echocardiogram showing a severely reduced **ejection fraction (EF 35%)** and **global hypokinesis**, strongly indicates significant systolic dysfunction. - A **normal coronary angiogram** effectively rules out **ischemic cardiomyopathy**, making non-ischemic dilated cardiomyopathy the most probable diagnosis given the global impairment of ventricular contraction. *Ischemic cardiomyopathy* - This condition is defined by **systolic dysfunction** (heart failure with reduced ejection fraction, HFrEF) directly caused by underlying **coronary artery disease**. - The patient's **normal coronary angiogram** conclusively excludes significant obstructive coronary artery disease, thereby ruling out ischemic cardiomyopathy. *Hypertrophic cardiomyopathy* - Hypertrophic cardiomyopathy is characterized by inappropriate and often massive **ventricular hypertrophy**, typically leading to **diastolic dysfunction** and often a preserved ejection fraction. - The finding of severe **systolic dysfunction (EF 35%)** and **global hypokinesis** is inconsistent with the primary pathophysiology and typical echocardiographic findings of hypertrophic cardiomyopathy. *Restrictive cardiomyopathy* - Restrictive cardiomyopathy involves rigid ventricular walls that impair **diastolic filling**, leading to heart failure symptoms, often with a **preserved or near-normal ejection fraction**. - This condition is less likely to present with the severe **global hypokinesis** and significantly reduced ejection fraction (EF 35%) observed in this patient, which are hallmarks of systolic dysfunction. *Valvular heart disease* - While severe **valvular heart disease** can lead to heart failure, the primary focus of the echocardiogram on **global hypokinesis** and reduced EF, coupled with the exclusion of CAD, points to a primary myocardial problem. - A diagnosis of primary valvular heart disease would necessitate the identification of a specific, severe **valvular lesion** (e.g., severe aortic stenosis or mitral regurgitation) as the clear cause of the ventricular dysfunction, which is not indicated here.

Question 39: A 61-year-old man presents with sudden onset severe "tearing" chest pain radiating to his back. CT angiogram shows Stanford type B aortic dissection extending from the arch to the renal arteries. His BP is 165/95 mmHg. What is the most appropriate initial management?

A. Emergency surgical repair
B. Endovascular stent graft
C. Medical management with beta-blockers (Correct Answer)
D. Thrombolysis
E. Observation only

Explanation: ***Medical management with beta-blockers***- Stanford type B aortic dissection, which involves the aorta distal to the left subclavian artery, is typically managed medically in its uncomplicated form.- Initial management with **beta-blockers** aims to reduce **heart rate** and **blood pressure**, thereby decreasing shear stress on the aortic wall and preventing dissection propagation.*Emergency surgical repair*- **Emergency surgical repair** is the definitive treatment for **Stanford type A aortic dissection**, which involves the ascending aorta and is associated with a higher mortality risk requiring immediate intervention.- For **uncomplicated Stanford type B dissections**, surgery is generally reserved for complications such as rupture, organ malperfusion, or refractory pain, not as initial management.*Endovascular stent graft*- **Endovascular stent grafting (TEVAR)** is an important treatment option for **complicated Stanford type B dissections**, such as those with malperfusion, rupture, or expanding aneurysm, or in cases of failed medical management.- However, it is not the primary **initial management** for an uncomplicated acute type B dissection.*Thrombolysis*- **Thrombolysis** is indicated for conditions caused by acute thrombotic occlusion, such as **myocardial infarction** or **pulmonary embolism**.- It is **contraindicated** in acute aortic dissection as it can worsen the dissection, cause hemorrhage, and significantly increase mortality.*Observation only*- Aortic dissection is a **medical emergency** requiring prompt intervention, not mere observation.- Without active pharmacological management to control **blood pressure** and **heart rate**, the dissection can rapidly progress, rupture, or lead to end-organ ischemia.

Question 40: A 51-year-old man presents with progressive shortness of breath and fatigue. Echocardiogram shows severe aortic stenosis with valve area 0.6 cm² and mean gradient 55 mmHg. He is high surgical risk. What is the most appropriate treatment?

A. Medical management
B. Balloon aortic valvuloplasty
C. Transcatheter aortic valve replacement (Correct Answer)
D. Surgical aortic valve replacement
E. Heart transplantation

Explanation: ***Transcatheter aortic valve replacement*** - This is the standard intervention for symptomatic patients with **severe aortic stenosis** (AVA < 1.0 cm², Mean Gradient > 40 mmHg) who are determined to be at **high or prohibitive surgical risk**. - TAVR is less invasive than SAVR and provides significant improvement in symptoms and prognosis while avoiding the dangers associated with **open cardiac surgery** in a high-risk patient. *Medical management* - Medical therapy (e.g., diuretics) only manages symptoms of heart failure and does not treat the underlying **valve obstruction** in severe AS. - Intervention (SAVR or TAVR) is required for symptomatic severe AS to improve survival, as the condition carries a significantly **poor prognosis** without intervention. *Balloon aortic valvuloplasty* - **BAV** provides typically only temporary symptomatic relief and is associated with a high rate of **restenosis** within 6-12 months, making it unsuitable as a definitive long-term solution in adults. - It is generally reserved as a **bridge-to-TAVR/SAVR** intervention for unstable patients or for the treatment of **congenital AS** in pediatric patients. *Surgical aortic valve replacement* - SAVR is the traditional, definitive treatment for severe AS; however, it is contraindicated in this specific case because the patient has been classified as **high surgical risk**. - Due to the high risk of operative mortality or serious morbidity associated with open surgery, a less invasive option like **TAVR** is the preferred choice. *Heart transplantation* - Heart transplantation is reserved for patients with end-stage **refractory heart failure** who have exhausted all other treatment options. - Since the primary pathology is severe valvular disease, management involves replacing the abnormal valve, usually making heart transplantation **unnecessary** at this stage.

Question 41: A 64-year-old man presents with progressive dyspnea and ankle swelling. Chest X-ray shows cardiomegaly. Echocardiogram shows concentric LVH with preserved EF but impaired diastolic function. What is the most likely diagnosis?

A. Dilated cardiomyopathy
B. Heart failure with preserved ejection fraction (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Ischemic cardiomyopathy

Explanation: ***Heart failure with preserved ejection fraction***

Question 42: A 53-year-old woman presents with progressive dyspnea and fatigue. Echocardiogram shows severe tricuspid regurgitation with elevated right heart pressures. Right heart catheterization shows mean PAP 48 mmHg. What is the most likely diagnosis?

A. Left heart failure
B. Pulmonary hypertension (Correct Answer)
C. Pulmonary embolism
D. COPD
E. Tricuspid valve disease

Explanation: ***Pulmonary hypertension*** - The definitive diagnostic criterion for **pulmonary hypertension** is a mean pulmonary artery pressure (PAP) exceeding 20 mmHg on **right heart catheterization**; 48 mmHg clearly confirms this diagnosis. - Progressive dyspnea and fatigue, coupled with signs of severe right heart strain (elevated right heart pressures and severe **tricuspid regurgitation**), are classic clinical manifestations of established pulmonary hypertension. *Left heart failure* - While **left heart failure (LHF)** is the most common cause of pulmonary hypertension (Group 2 PH), the elevated mean PAP (48 mmHg) is the direct, most likely diagnosis confirmed by RHC, irrespective of the underlying etiology. - LHF typically causes **pulmonary venous congestion**, which leads to post-capillary PH, but the presence of PH is the overarching diagnosis based strictly on the hemodynamic measurements. *Pulmonary embolism* - **Acute pulmonary embolism (PE)** typically presents acutely with sudden onset of dyspnea, often accompanied by chest pain or syncope, which contrasts with the progressive symptoms described here. - If this were **Chronic Thromboembolic Pulmonary Hypertension (CTEPH)**, it would fall under Group 4 PH, but the confirmed elevated mean PAP remains the official diagnosis. *COPD* - **Chronic Obstructive Pulmonary Disease (COPD)** is a common cause of Group 3 PH, driven by chronic hypoxia and pulmonary capillary destruction. - This diagnosis requires demonstrating obstructive ventilatory defects on **spirometry** and typically involves a significant smoking history, neither of which are provided in the scenario. *Tricuspid valve disease* - The severe **tricuspid regurgitation (TR)** is almost certainly secondary (functional), resulting from severe dilation and increased pressure of the right ventricle overloaded by the **pulmonary hypertension**. - Primary TR (e.g., due to endocarditis or congenital defects) is less common and would not necessarily cause such a high mean PAP unless associated with severe right heart failure.

Question 43: A 54-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe mitral regurgitation with flail posterior leaflet. LV function is normal. He is symptomatic on exertion. What is the most appropriate management?

A. Medical management
B. Mitral valve replacement
C. Mitral valve repair (Correct Answer)
D. Heart transplantation
E. Balloon mitral valvuloplasty

Explanation: ***Mitral valve repair*** - The patient presents with **severe mitral regurgitation** due to a **flail posterior leaflet** and is **symptomatic** with preserved **left ventricular (LV) function**. This clinical picture, particularly the normal LV function, makes repair the optimal strategy. - **Mitral valve repair** is preferred over replacement in degenerative MR due to lower operative mortality, better preservation of **LV function**, and avoidance of lifelong anticoagulation associated with mechanical valves. *Medical management* - Medical therapy alone does not address the underlying **severe mechanical defect** causing the mitral regurgitation. - Given the patient's symptoms and severe MR with normal LV function, surgical intervention is indicated to prevent **progressive LV dysfunction** and improve long-term outcomes. *Mitral valve replacement* - While an option for severe MR, **mitral valve replacement** is generally reserved for for cases where repair is not anatomically feasible or has failed. - It is associated with higher operative risk and a need for lifelong anticoagulation with mechanical valves, or limited durability with bioprosthetic valves, compared to a successful repair. *Heart transplantation* - **Heart transplantation** is indicated for end-stage heart failure refractory to other treatments. - This patient has a treatable structural valve lesion and **normal LV function**, making transplantation an excessively aggressive and inappropriate initial intervention. *Balloon mitral valvuloplasty* - **Balloon mitral valvuloplasty** is a percutaneous intervention primarily used for **mitral stenosis**, not mitral regurgitation. - Applying this procedure to a flail mitral leaflet would likely worsen the **mitral regurgitation** and is therefore contraindicated.

Question 44: A 58-year-old man presents with progressive dyspnea and bilateral ankle swelling. Chest X-ray shows cardiomegaly and pulmonary edema. Echocardiogram shows EF 30% with global hypokinesis. Coronary angiogram is normal. What is the most likely diagnosis?

A. Ischemic cardiomyopathy
B. Dilated cardiomyopathy (Correct Answer)
C. Hypertrophic cardiomyopathy
D. Restrictive cardiomyopathy
E. Hypertensive heart disease

Explanation: ***Dilated cardiomyopathy*** - The presence of severe **systolic dysfunction** (EF 30%) and **global hypokinesis** indicates ventricular dilatation and failure, consistent with DCM. - The crucial finding is the **normal coronary angiogram**, which rules out ischemic heart disease, making non-ischemic dilated cardiomyopathy the most likely diagnosis. *Ischemic cardiomyopathy* - This diagnosis is ruled out because the **coronary angiogram is normal**, meaning the systolic dysfunction is not due to significant coronary artery disease. - Ischemic damage typically causes **regional wall motion abnormalities** corresponding to specific vascular territories, unlike the global hypokinesis reported here. *Hypertrophic cardiomyopathy* - HCM is characterized by unexplained **ventricular hypertrophy** (thickened walls) and primarily causes **diastolic dysfunction**, not global dilatation and severe systolic failure. - Although HCM can progress to systolic failure, the primary insult is hypertrophy, and the ventricle is typically non-dilated initially. *Restrictive cardiomyopathy* - Characterized by rigid, non-compliant ventricles, leading to severe **diastolic dysfunction** (impaired filling) but usually a **preserved Ejection Fraction (EF)**. - Imaging typically shows non-dilated ventricles and marked bi-atrial enlargement, which contrasts with the ventricular dilation implied by global hypokinesis and cardiomegaly. *Hypertensive heart disease* - Chronic hypertension initially leads to **concentric left ventricular hypertrophy** and **diastolic dysfunction** rather than primary global hypokinesis and severe systolic failure (DCM pattern). - While chronic hypertension can eventually cause secondary DCM, the primary structural diagnosis covering global systolic failure with dilation and normal coronaries is **dilated cardiomyopathy**.

Question 45: A 51-year-old man presents with progressive dyspnea and fatigue. Echocardiogram shows severe aortic regurgitation with LV end-systolic dimension 55mm and EF 50%. He is asymptomatic at rest. What is the most appropriate management?

A. Medical management
B. Aortic valve replacement (Correct Answer)
C. ACE inhibitors
D. Diuretics
E. Observation

Explanation: ***Aortic valve replacement*** - This patient meets surgical criteria for severe asymptomatic aortic regurgitation (AR) because the Left Ventricular End-Systolic Dimension (**LVESD** $\ge$ **50 mm**) and the Ejection Fraction (**LVEF** $\le$ **50%**) are compromised. - Early intervention is required regardless of symptoms to prevent irreversible **LV dysfunction** and adverse clinical outcomes, making Aortic Valve Replacement (AVR) the definitive management. *Medical management* - General medical management is typically reserved for asymptomatic patients who do **not** meet the criteria for surgical intervention (i.e., LVEF > 50% and LVESD < 50 mm). - Medical therapy attempts to reduce volume overload but does not address the structural lesion causing the progressive **LV chamber dilation**. *ACE inhibitors* - **ACE inhibitors** are useful for treating hypertension or symptomatic heart failure in patients with AR, but they are not the primary treatment for severe, progressive AR that has reached surgical thresholds. - They have not been shown to be effective in preventing the need for surgery or reversing **LV dilation** in asymptomatic severe AR, unlike the clear benefit of surgical correction. *Diuretics* - Diuretics primarily manage symptoms related to congestion, such as **pulmonary edema** or peripheral edema. - Since the patient is currently **asymptomatic** at rest, diuretics are not indicated as the primary treatment and do not address the underlying **severe hemodynamic abnormality**. *Observation* - Observation is appropriate only for asymptomatic patients with **preserved LVEF** ($> 50$\%) and normal LV dimensions (LVESD $< 50$ mm). - Given the patient's LVESD of 55 mm and LVEF of 50%, observation risks **irreversible deterioration** of the left ventricle and is contraindicated.

Question 46: A 63-year-old man presents with progressive dyspnea and ankle swelling. Chest X-ray shows Kerley B lines and cardiomegaly. BNP is 2500 pg/mL. Echocardiogram shows EF 25%. What is the most appropriate initial medication?

A. Furosemide
B. ACE inhibitor (Correct Answer)
C. Beta-blocker
D. Spironolactone
E. Digoxin

Explanation: ***ACE inhibitor***- Given the diagnosis of **heart failure with reduced ejection fraction (HFrEF)** (EF 25%) and symptoms, an ACE inhibitor is a cornerstone of **guideline-directed medical therapy (GDMT)**. - It significantly improves **mortality and morbidity** in HFrEF by preventing cardiac remodeling and reducing both preload and afterload. *Furosemide*- While crucial for managing **symptoms of fluid overload** (dyspnea, ankle swelling, Kerley B lines) by reducing preload, **furosemide** does not improve long-term mortality or modify the disease progression in HFrEF.- It provides symptomatic relief, but it is not the *initial* disease-modifying medication for improving outcomes in HFrEF. *Beta-blocker*- **Beta-blockers** are also GDMT for HFrEF, improving mortality and morbidity, but they are generally initiated *after* an ACE inhibitor, once the patient is euvolemic and hemodynamically stable.- Initiating a beta-blocker too early in a patient with significant fluid overload can worsen symptoms or lead to acute decompensation due to negative inotropic effects. *Spironolactone*- **Spironolactone**, a mineralocorticoid receptor antagonist, is a GDMT for HFrEF that improves mortality, but it is typically added *after* an ACE inhibitor and beta-blocker in patients with persistent symptoms or reduced EF.- It is not considered the *initial* medication due to potential side effects like **hyperkalemia** and its role as an add-on therapy. *Digoxin*- **Digoxin** can improve symptoms and reduce hospitalizations in HFrEF, but it does not improve overall mortality.- It is typically reserved for patients who remain symptomatic despite optimal doses of ACE inhibitors, beta-blockers, and MRAs, or for rate control in atrial fibrillation with HFrEF, and has a narrow therapeutic window.

Question 47: A 59-year-old woman presents with progressive shortness of breath and fatigue. Echocardiogram shows severe mitral stenosis with valve area 0.8 cm². She is in atrial fibrillation. What is the most appropriate treatment?

A. Medical management only
B. Balloon mitral valvuloplasty (Correct Answer)
C. Mitral valve replacement
D. Mitral valve repair
E. Heart transplantation

Explanation: ***Balloon mitral valvuloplasty*** - For symptomatic patients with **severe mitral stenosis (MVA 0.8 cm ²)** who have favorable valve morphology, **percutaneous balloon mitral valvuloplasty (PBMV)** is the treatment of choice, offering high success and low complication rates. - The presence of **atrial fibrillation** is a common consequence of left atrial enlargement due to chronic mitral stenosis, and PBMV can alleviate the pressure overload. *Medical management only* - Although medical management (rate control for AF, diuretics) is used to manage symptoms, it does not address the underlying **severe mechanical obstruction** (MVA 0.8 cm²) and is insufficient as definitive therapy for symptomatic severe MS. - Delaying definitive intervention in symptomatic severe MS increases the risk of complications such as **pulmonary hypertension**, right heart failure, and systemic embolism. *Mitral valve replacement* - **Mitral valve replacement (MVR)** is reserved for patients with severe MS who have **unfavorable valve anatomy** (heavy calcification, significant subvalvular disease) or who fail PBMV. - Surgical intervention carries higher operative risk compared to PBMV for suitable candidates. *Mitral valve repair* - **Mitral valve repair** is typically the preferred surgical approach for **mitral regurgitation**, not usually for severe, chronic, purely stenotic rheumatic valve disease. - Repair in severe MS often yields inadequate results due to the extensive scarring and fusion of the valve leaflets and commissures. *Heart transplantation* - **Heart transplantation** is the definitive treatment only for end-stage refractory heart failure (NYHA Class III/IV) that is not amenable to standard surgical or interventional therapies. - This patient's presentation of severe mitral stenosis, while serious, does not indicate end-stage heart failure requiring transplantation as a primary treatment.

Question 48: A 68-year-old man presents with progressive dyspnea and bilateral ankle swelling. Echocardiogram shows severe tricuspid regurgitation with elevated right heart pressure. Right heart catheterization shows mean pulmonary artery pressure of 45 mmHg. What is the most likely diagnosis?

A. Left heart failure
B. Pulmonary hypertension (Correct Answer)
C. Tricuspid valve disease
D. Right heart failure
E. Pulmonary embolism

Explanation: ***Pulmonary hypertension***- The right heart catheterization result of a **mean pulmonary artery pressure (mPAP) of 45 mmHg** definitively diagnoses **pulmonary hypertension**, which is defined as an mPAP greater than 20 mmHg at rest.- The progressive **dyspnea** and **bilateral ankle swelling**, along with **severe tricuspid regurgitation** and elevated right heart pressure, are all clinical manifestations of the right ventricular dysfunction caused by the elevated pulmonary pressures.*Left heart failure*- While **left heart failure (LHF)** is a common *cause* of pulmonary hypertension (Group 2 PH), the question asks for the most likely *diagnosis* confirmed by the direct hemodynamic measurement.- LHF typically presents with signs of **left ventricular dysfunction** and elevated **pulmonary capillary wedge pressure (PCWP)**, which are not the primary diagnostic finding emphasized here.*Tricuspid valve disease*- The **severe tricuspid regurgitation (TR)** observed is typically a *secondary* condition, resulting from progressive dilation and dysfunction of the right ventricle due to chronic, severe **pulmonary hypertension**.- Primary tricuspid valve disease is less common and would not inherently explain the underlying **mean pulmonary artery pressure of 45 mmHg** as the root cause.*Right heart failure*- **Right heart failure (RHF)** is a *consequence* or clinical syndrome that develops when the right ventricle fails to pump blood effectively against a high afterload, as is the case in **pulmonary hypertension**.- The symptoms of **dyspnea** and **bilateral ankle swelling** are clinical signs of RHF, but the underlying elevated pressure state is the primary diagnosis.*Pulmonary embolism*- While a **pulmonary embolism** (especially chronic thromboembolic pulmonary hypertension or CTEPH) can lead to **pulmonary hypertension**, the most direct and specific diagnosis confirmed by the mPAP measurement of 45 mmHg is simply pulmonary hypertension.- Acute pulmonary embolism usually presents with a more rapid onset and distinct clinical features, and CTEPH is a *type* of pulmonary hypertension rather than the overarching diagnosis itself.

Question 49: A 28-year-old woman presents with recurrent syncope during exercise. ECG shows deep Q waves in leads II, III, and aVF with T-wave inversion. Echocardiogram reveals asymmetric septal hypertrophy. What is the most appropriate management?

A. Beta-blockers
B. ACE inhibitors
C. Implantable cardioverter defibrillator (Correct Answer)
D. Septal myectomy
E. Heart transplantation

Explanation: ***Implantable cardioverter defibrillator*** - Recurrent syncope during exercise in a patient with **Hypertrophic Cardiomyopathy (HCM)**, evidenced by **asymmetric septal hypertrophy**, is a critical high-risk factor for **sudden cardiac death (SCD)** due to ventricular arrhythmias. - The presence of syncope (a major high-risk feature) mandates the placement of an **ICD** for primary prevention of fatal arrhythmias, as it directly addresses the life-threatening risk.*Beta-blockers* - These are standard first-line medical therapy for reducing symptoms (angina, dyspnea) in HCM by decreasing heart rate and contractility, thereby alleviating dynamic **left ventricular outflow tract (LVOT) obstruction**. - However, beta-blockers alone are not sufficient to prevent **SCD** in a high-risk patient presenting with documented syncope, making an ICD more appropriate for this specific presentation.*ACE inhibitors* - **ACE inhibitors** and other vasodilators generally reduce systemic vascular resistance and preload, which can decrease ventricular filling and worsen the dynamic **LVOT obstruction** in HCM. - Therefore, these medications are typically avoided or used with great caution in patients with obstructive HCM, as they can exacerbate symptoms like syncope.*Septal myectomy* - This is an invasive surgical procedure indicated for severe, persistent symptoms related to significant **LVOT obstruction** (>50 mmHg) that are refractory to maximum medical therapy (e.g., beta-blockers). - While it addresses the obstruction, it is not the immediate, lifesaving intervention required to mitigate the high risk of **SCD** signaled by the patient's syncope; an ICD directly protects against fatal arrhythmias.*Heart transplantation* - This is reserved for patients with end-stage HCM who develop refractory, debilitating **NYHA Class III/IV heart failure** or severe arrhythmias despite all other medical and device interventions. - Given the patient's age and primary presentation centering on SCD risk rather than end-stage failure, transplantation is too aggressive and not indicated for initial management.

Question 50: A 45-year-old man presents with central chest pain radiating to his left arm and jaw. The pain started 2 hours ago and is described as crushing. His ECG shows ST elevation in leads II, III, and aVF. What is the most likely diagnosis?

A. Anterior STEMI
B. Inferior STEMI (Correct Answer)
C. Lateral STEMI
D. Posterior STEMI
E. Unstable angina

Explanation: ***Inferior STEMI***- **ST elevation** in leads **II, III, and aVF** specifically indicates myocardial infarction of the **inferior wall** of the left ventricle. This finding, combined with classic chest pain, is diagnostic of an **Inferior STEMI**.- The occlusion responsible for an inferior STEMI most commonly involves the **right coronary artery (RCA)**, especially its proximal or mid segments, or less commonly, a dominant left circumflex artery (LCX).*Anterior STEMI*- **Anterior STEMI** is characterized by **ST elevation** in the precordial leads, typically **V1 through V4**.- This type of myocardial infarction is primarily caused by an occlusion of the **left anterior descending (LAD) artery**.*Lateral STEMI*- A **lateral STEMI** is identified by **ST elevation** in leads **I, aVL, V5, and V6**.- This usually signifies an occlusion of the **left circumflex artery (LCX)** or a diagonal branch of the LAD.*Posterior STEMI*- A **posterior STEMI** is suggested by **ST depression** and prominent R waves in leads **V1-V3** (reciprocal changes).- Definitive diagnosis often requires obtaining posterior ECG leads (**V7, V8, V9**) to visualize **ST elevation** directly.*Unstable angina*- **Unstable angina** presents with acute ischemic chest pain but *lacks* persistent **ST elevation** on the electrocardiogram.- While cardiac biomarkers may be elevated or normal, the absence of **ST elevation** on ECG differentiates it from a STEMI, which necessitates immediate reperfusion.

Question 51: A 66-year-old man attends cardiology clinic for cardiovascular risk assessment. He is asymptomatic with no history of cardiovascular disease. He has type 2 diabetes managed with metformin, hypertension treated with ramipril, and was diagnosed with chronic kidney disease stage 3a last year. He stopped smoking 5 years ago (30 pack-year history). His father died of myocardial infarction aged 58. Examination: BP 136/82 mmHg, BMI 29 kg/m². Blood tests show: total cholesterol 5.8 mmol/L, HDL 1.1 mmol/L, non-HDL 4.7 mmol/L, HbA1c 58 mmol/mol, eGFR 52 mL/min/1.73m². His QRISK3 score is calculated at 28%. What is the most appropriate management regarding cardiovascular risk reduction?

A. Commence atorvastatin 20 mg once daily and recheck lipids in 3 months (Correct Answer)
B. Commence atorvastatin 80 mg once daily without need for routine lipid monitoring
C. Advise lifestyle modifications only as QRISK3 is below treatment threshold
D. Commence atorvastatin 40 mg and aspirin 75 mg daily
E. Arrange CT coronary angiography before starting any medication

Explanation: ***Commence atorvastatin 20 mg once daily and recheck lipids in 3 months***- This patient has multiple significant cardiovascular risk factors (Type 2 diabetes, hypertension, CKD stage 3a, 30 pack-year smoking history, family history of early MI, and a calculated **QRISK3 score of 28%**). For **primary prevention**, **NICE guidelines** recommend starting a **high-intensity statin** such as **atorvastatin 20 mg** in patients with a QRISK3 score ≥ 10% or with type 2 diabetes. A **repeat lipid profile** is required after 3 months to ensure a **>40% reduction in non-HDL cholesterol** has been achieved and to guide dose adjustments.*Commence atorvastatin 80 mg once daily without need for routine lipid monitoring*- **Atorvastatin 80 mg** is typically reserved for **secondary prevention** in patients with established cardiovascular disease or if lower doses fail to achieve lipid targets, not usually as an initial dose for primary prevention.- **Routine lipid monitoring** at 3 months is **essential** after initiating statin therapy to assess treatment efficacy and guide potential dose titration.*Advise lifestyle modifications only as QRISK3 is below treatment threshold*- The threshold for pharmacological intervention for primary prevention is a **QRISK3 score of 10% or greater**; this patient's score of **28%** is significantly higher and also has type 2 diabetes.- While **lifestyle modifications** are important, they are **insufficient** as the sole management for a patient with such a high calculated risk and existing comorbidities, who clearly needs statin therapy.*Commence atorvastatin 40 mg and aspirin 75 mg daily*- **Aspirin** is generally **not recommended** for the **primary prevention** of cardiovascular disease due to the increased risk of bleeding (e.g., gastrointestinal hemorrhage) outweighing the benefits in asymptomatic individuals.- The standard initial dose for primary prevention with atorvastatin is **20 mg**, with 40 mg usually considered if the initial 20 mg fails to meet the target non-HDL reduction.*Arrange CT coronary angiography before starting any medication*- **CT coronary angiography** is typically indicated for investigating **new-onset chest pain** suspected to be angina, not for asymptomatic individuals with clear indications for statin therapy based on validated risk scores.- In this asymptomatic patient with a high **QRISK3 score of 28%** and significant risk factors, initiating statin therapy is the appropriate first step for risk reduction, without needing further imaging before commencing treatment.

Question 52: A 70-year-old man is admitted with acute pulmonary oedema. Echocardiography reveals severe aortic stenosis with aortic valve area 0.7 cm², mean gradient 48 mmHg, and LVEF 35%. He has severe symptoms (NYHA class III) with minimal exertion causing breathlessness. His past medical history includes previous stroke with full recovery, chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²), and chronic obstructive pulmonary disease with FEV1 45% predicted. He is 168 cm tall, weighs 58 kg, and has a calculated surgical risk (EuroSCORE II) of 18%. What is the most appropriate definitive management strategy?

A. Transcatheter aortic valve implantation (TAVI) (Correct Answer)
B. Balloon aortic valvuloplasty as definitive treatment
C. Medical management with diuretics and ACE inhibitors only
D. Urgent coronary artery bypass grafting with valve replacement
E. Surgical aortic valve replacement

Explanation: ***Transcatheter aortic valve implantation (TAVI)*** - This patient has **symptomatic severe aortic stenosis** (NYHA class III, AVA 0.7 cm², mean gradient 48 mmHg) and numerous comorbidities including **CKD stage 3b**, **COPD**, and reduced **LVEF (35%)**, resulting in a very high surgical risk (EuroSCORE II 18%). - **TAVI** is the recommended definitive treatment for high-risk or inoperable patients with severe, symptomatic aortic stenosis, significantly improving prognosis compared to medical management. *Balloon aortic valvuloplasty as definitive treatment* - This procedure offers only temporary symptomatic relief and is associated with very high rates of **restenosis** within 6-12 months. - It is typically used as a **bridge to TAVI/SAVR** in hemodynamically unstable patients or for palliative purposes, not as a definitive long-term solution. *Medical management with diuretics and ACE inhibitors only* - Medical management alone does not address the underlying **mechanical obstruction** of severe aortic stenosis and has been shown to have poor long-term outcomes, with a 50% mortality rate at 2 years for **symptomatic severe AS**. - While **diuretics** can alleviate acute pulmonary edema, they do not alter the progression of the valvular disease or improve survival in severe, symptomatic cases. *Urgent coronary artery bypass grafting with valve replacement* - There is no mention of significant **coronary artery disease** requiring **CABG** in the patient's presentation. - Adding **CABG** to valve replacement would significantly increase the complexity and **operative risk** for an already high-risk patient, without clear indication. *Surgical aortic valve replacement* - Although **surgical aortic valve replacement (SAVR)** is a definitive treatment, this patient's **high surgical risk profile** (EuroSCORE II 18%) and multiple comorbidities (age 70, previous stroke, CKD, COPD, low LVEF) make SAVR a less favorable option. - Current guidelines recommend **TAVI** over SAVR for patients with severe symptomatic AS who are at high surgical risk, especially those with a **EuroSCORE II > 8-10%**.

Question 53: A 53-year-old woman with exertional chest pain undergoes CT coronary angiography which shows 50% stenosis in the mid-left anterior descending artery. She has no other significant coronary disease. Her symptoms occur 2-3 times per week when walking uphill but resolve with rest after 3-4 minutes. She is a non-smoker with well-controlled hypertension on amlodipine. Her resting ECG is normal. What is the most appropriate initial anti-anginal medication to add for symptom control?

A. Bisoprolol 2.5 mg once daily (Correct Answer)
B. Isosorbide mononitrate 30 mg twice daily
C. Ivabradine 5 mg twice daily
D. Nicorandil 10 mg twice daily
E. Ranolazine 375 mg twice daily

Explanation: ***Bisoprolol 2.5 mg once daily*** - **NICE guidelines** recommend either a **beta-blocker** or a calcium channel blocker as first-line treatment for **stable angina**; since she is already on amlodipine (a calcium channel blocker), adding a beta-blocker is the correct next step. - Bisoprolol reduces **myocardial oxygen demand** by decreasing heart rate and contractility, making it highly effective for preventing **exertional symptoms**. *Isosorbide mononitrate 30 mg twice daily* - **Long-acting nitrates** are considered **second-line** therapies, typically used if first-line agents are contraindicated or insufficient for symptom control. - Potential issues such as **nitrate tolerance** and headaches often make them less preferable than starting a beta-blocker as initial add-on therapy. *Ivabradine 5 mg twice daily* - This medication is reserved for patients in **sinus rhythm** who cannot tolerate beta-blockers or remain symptomatic with a heart rate **>70 bpm** despite optimal beta-blocker therapy. - It specifically inhibits the **If current** in the SA node but does not offer the broader cardiovascular protection or first-line status of beta-blockers. *Nicorandil 10 mg twice daily* - Nicorandil acts as both a **potassium-channel activator** and a nitrate, but it is classified as a **second-line** add-on treatment. - It is generally used when patients remain symptomatic on **dual therapy** or have contraindications to standard first-line medications. *Ranolazine 375 mg twice daily* - Ranolazine inhibits the **late sodium current** and is used as an adjunctive treatment for angina that is not controlled by other agents. - Like nicorandil, it is an **alternative second-line** option and is not the appropriate initial step following a calcium channel blocker.

Question 54: A 62-year-old man presents to the Emergency Department with 45 minutes of severe central chest pain and nausea. His initial ECG shows sinus rhythm with 2 mm ST-segment elevation in leads V1-V4. He receives aspirin 300 mg, ticagrelor 180 mg, and is transferred for primary PCI. Angiography reveals total occlusion of the proximal left anterior descending artery, which is successfully stented. Two days post-procedure, he develops sudden onset severe breathlessness and hypotension. Examination reveals BP 88/56 mmHg, heart rate 110 bpm, elevated JVP, and a new pansystolic murmur loudest at the left sternal edge. What is the most likely complication?

A. Acute mitral regurgitation due to papillary muscle rupture
B. Ventricular septal defect (Correct Answer)
C. Left ventricular free wall rupture
D. Acute stent thrombosis
E. Right ventricular infarction

Explanation: ***Ventricular septal defect***- This patient's presentation of sudden hemodynamic collapse and a new **pansystolic murmur** loudest at the **left sternal edge** following an **anterior STEMI** is pathognomonic for a ventricular septal defect (VSD).- VSD typically occurs within 3-5 days of a large myocardial infarction due to **septal wall necrosis**, leading to a left-to-right shunt and **cardiogenic shock**.*Acute mitral regurgitation due to papillary muscle rupture*- While it presents with a pansystolic murmur and shock, the murmur is typically loudest at the **cardiac apex** and radiates to the **axilla**.- This complication is more commonly associated with **inferior wall MIs** due to the single blood supply (PDA) of the **posteromedial papillary muscle**.*Left ventricular free wall rupture*- This usually results in sudden cardiovascular collapse with **electromechanical dissociation (PEA)** and signs of **cardiac tamponade** (muffled heart sounds).- It is often rapidly fatal and does not typically present with a loud, distinct **pansystolic murmur**.*Acute stent thrombosis*- Typically presents with a recurrence of **crushing chest pain** and new **ST-segment elevation** in the originally affected leads.- While it can cause hypotension and heart failure, it would not explain the sudden development of a new **mechanical murmur**.*Right ventricular infarction*- Classically presents with the triad of **hypotension**, **elevated JVP**, and **clear lung fields**, but is almost exclusively seen in **inferior STEMIs** (RCA occlusion).- This condition does not produce a **pansystolic murmur**; such a murmur would only appear if a VSD or tricuspid regurgitation happened concurrently.

Question 55: A 81-year-old woman presents with progressive breathlessness over 8 months. She can no longer climb stairs without stopping. Examination reveals BP 168/92 mmHg, heart rate 76 bpm regular, elevated JVP, bilateral basal fine inspiratory crackles, and mild ankle oedema. Heart sounds reveal a fourth heart sound. Echocardiography shows: LVEF 58%, left ventricular hypertrophy with normal wall motion, left atrial dilatation, E/e' ratio 18, and no significant valvular disease. NT-proBNP is 580 ng/L. What is the most likely diagnosis?

A. Heart failure with preserved ejection fraction (Correct Answer)
B. Pulmonary fibrosis with cor pulmonale
C. Aortic stenosis with preserved LV function
D. Restrictive cardiomyopathy
E. Hypertensive crisis with pulmonary oedema

Explanation: ***Heart failure with preserved ejection fraction***- The patient presents with classic signs and symptoms of heart failure (breathlessness, elevated JVP, crackles, oedema) coupled with a **preserved left ventricular ejection fraction (LVEF 58%)** and elevated **NT-proBNP**.- Key echocardiographic findings, including **left ventricular hypertrophy**, **left atrial dilatation**, an elevated **E/e' ratio of 18** (indicating increased LV filling pressures), and a **fourth heart sound**, all strongly point to significant **diastolic dysfunction**, which is the hallmark of HFpEF.*Pulmonary fibrosis with cor pulmonale*- While basal crackles are present, these are usually **"velcro-like"** in pulmonary fibrosis, and there's no primary evidence of significant interstitial lung disease.- **Cor pulmonale** involves right ventricular dysfunction secondary to lung disease, whereas the echocardiogram clearly shows **left ventricular hypertrophy** and signs of **left-sided diastolic dysfunction**, not primarily right heart strain from lung pathology.*Aortic stenosis with preserved LV function*- The echocardiography report explicitly states **"no significant valvular disease"**, which directly excludes hemodynamically significant aortic stenosis as the cause.- Aortic stenosis typically presents with a characteristic **systolic ejection murmur** best heard at the right upper sternal border, often radiating to the carotids, which was not described.*Restrictive cardiomyopathy*- While it causes **diastolic dysfunction** and can mimic HFpEF, it is less common than HFpEF in an elderly patient with long-standing hypertension and LVH.- Restrictive cardiomyopathy often involves specific patterns (e.g., **myocardial amyloidosis**) and may present with more prominent or earlier **right-sided heart failure** symptoms.*Hypertensive crisis with pulmonary oedema*- A **hypertensive crisis** is defined by a significantly higher blood pressure (typically >180/120 mmHg) and is characterized by an **acute, sudden onset** of symptoms.- This patient's symptoms have been **progressive over 8 months**, which is a chronic presentation inconsistent with an acute hypertensive emergency.

Question 56: A 76-year-old man with permanent atrial fibrillation is taking apixaban 5 mg twice daily for stroke prevention. He presents to the Emergency Department following a fall with a large scalp laceration requiring suturing. His past medical history includes previous ischaemic stroke 3 years ago, hypertension, and type 2 diabetes. His current medications are apixaban, metformin, and amlodipine. He is haemodynamically stable. Blood tests show: haemoglobin 142 g/L, platelets 245 × 10⁹/L, creatinine 98 μmol/L (eGFR 64 mL/min/1.73m²). CT head shows no intracranial haemorrhage. The laceration is sutured successfully. What is the most appropriate management of his anticoagulation?

A. Stop apixaban permanently and switch to aspirin 75 mg daily
B. Omit next dose of apixaban, restart after 48 hours if no bleeding complications
C. Continue apixaban at current dose without interruption (Correct Answer)
D. Reduce apixaban to 2.5 mg twice daily permanently
E. Stop apixaban for 1 week then recommence at reduced dose

Explanation: ***Continue apixaban at current dose without interruption***- In patients with **minor bleeding** that is successfully controlled with local measures (like suturing), **anticoagulation** should generally be continued without interruption.- This patient has a high **CHA₂DS₂-VASc score** (age ≥75, history of stroke, hypertension, diabetes), meaning the risk of a **thromboembolic event** from stopping apixaban outweighs the risk of re-bleeding from a managed scalp wound.*Stop apixaban permanently and switch to aspirin 75 mg daily*- Aspirin is significantly less effective than **DOACs** for stroke prevention in **atrial fibrillation** and offers no substantial reduction in major bleeding risk compared to apixaban.- Stopping therapy entirely after a minor trauma would leave this high-risk patient unprotected against a **recurrent ischaemic stroke**.*Omit next dose of apixaban, restart after 48 hours if no bleeding complications*- Brief interruption is typically reserved for **major surgery** or uncontrolled clinically significant bleeding; it is unnecessary for a successfully sutured **scalp laceration**.- Unnecessary omission of doses creates a **pro-thrombotic window** in a patient who has already suffered a previous stroke.*Reduce apixaban to 2.5 mg twice daily permanently*- Dose reduction criteria for **apixaban** require at least two of the following: age ≥80 years, weight ≤60 kg, or **creatinine ≥133 μmol/L**; this patient meets none of these.- Under-dosing anticoagulation in a high-risk patient is dangerous and results in inadequate **stroke prophylaxis**.*Stop apixaban for 1 week then recommence at reduced dose*- A one-week interruption is far too long for a minor trauma and significantly increases the risk of **cardioembolic stroke**.- There is no clinical indication for a **reduced dose** as his renal function (eGFR 64) and age do not meet the prescribing criteria for 2.5 mg twice daily.

Question 57: A 45-year-old woman of African-Caribbean origin presents to her GP with elevated blood pressure. She has had three clinic readings over 4 months averaging 154/96 mmHg. Ambulatory blood pressure monitoring confirms an average of 152/94 mmHg. She has no other medical history, takes no regular medications, and does not smoke. Her BMI is 24 kg/m². Blood tests show: sodium 139 mmol/L, potassium 4.1 mmol/L, creatinine 76 μmol/L (eGFR >90 mL/min/1.73m²), HbA1c 36 mmol/mol, total cholesterol 4.8 mmol/L. Urinalysis shows no protein. ECG and fundoscopy are normal. What is the most appropriate first-line antihypertensive medication?

A. Ramipril 2.5 mg once daily
B. Amlodipine 5 mg once daily (Correct Answer)
C. Bendroflumethiazide 2.5 mg once daily
D. Atenolol 50 mg once daily
E. Losartan 25 mg once daily

Explanation: ***Amlodipine 5 mg once daily*** - According to **NICE guidelines**, patients of **African or Caribbean family origin** of any age should be started on a **calcium channel blocker (CCB)** as first-line treatment. - **Amlodipine** is a preferred CCB that effectively lowers blood pressure in this demographic by reducing peripheral vascular resistance. *Ramipril 2.5 mg once daily* - This **ACE inhibitor** is typically first-line for patients **under 55 years** who are not of African or Caribbean origin. - ACE inhibitors are known to be **less effective as monotherapy** in black patients due to lower plasma **renin levels**. *Bendroflumethiazide 2.5 mg once daily* - While a **thiazide-like diuretic** is an acceptable first-line alternative for this demographic, it is usually reserved for cases where CCBs are **not tolerated** or if there is evidence of heart failure. - **Indapamide or chlortalidone** are now preferred over bendroflumethiazide when a diuretic is initiated for primary hypertension. *Atenolol 50 mg once daily* - **Beta-blockers** are not recommended as first-line therapy for hypertension unless the patient has specific indications like **atrial fibrillation** or heart failure. - They are generally less effective at preventing stroke than other antihypertensive classes and can adversely affect **glucose metabolism**. *Losartan 25 mg once daily* - Like ACE inhibitors, **Angiotensin II Receptor Blockers (ARBs)** are less effective in patients of **African-Caribbean origin** as monotherapy. - Losartan would typically be introduced at **Step 2** of the treatment algorithm in combination with a CCB for this specific patient group.

Question 58: A 58-year-old man with stable angina is commenced on sublingual glyceryl trinitrate (GTN) spray for symptom relief. He experiences exertional chest tightness approximately 3 times per week, which resolves after 2-3 minutes of rest. He asks how the GTN spray works to relieve his symptoms. Which of the following best describes the primary mechanism of action of GTN in relieving anginal chest pain?

A. Increases myocardial oxygen supply by coronary vasodilation
B. Reduces myocardial oxygen demand through venodilation and reduced preload (Correct Answer)
C. Improves coronary blood flow by reducing blood viscosity
D. Reduces myocardial oxygen demand through negative chronotropic effect
E. Inhibits platelet aggregation preventing acute thrombosis

Explanation: ***Reduces myocardial oxygen demand through venodilation and reduced preload***- Glyceryl trinitrate (GTN) primarily acts as a **nitric oxide donor**, leading to significant **venodilation**, which increases venous capacitance.- This **venodilation** effectively reduces **venous return** to the heart, decreasing **preload** and subsequently lowering **myocardial wall tension** and **myocardial oxygen demand**, thereby relieving angina.*Increases myocardial oxygen supply by coronary vasodilation*- While GTN can cause some **coronary vasodilation**, especially in larger epicardial vessels, its ability to significantly increase blood flow to ischemic areas with fixed **atherosclerotic stenoses** is limited.- The primary benefit in stable angina comes from reducing the heart's workload (demand), not from a major increase in **oxygen supply**.*Improves coronary blood flow by reducing blood viscosity*- GTN does not have any known effect on **blood viscosity** or its components, such as hematocrit or plasma proteins.- Modifying **blood viscosity** is not a mechanism employed by nitrates to relieve anginal symptoms.*Reduces myocardial oxygen demand through negative chronotropic effect*- GTN does not possess **negative chronotropic properties**; it does not directly slow the heart rate.- In fact, the systemic vasodilation and subsequent drop in blood pressure can sometimes induce a **reflex tachycardia**, which would increase, not decrease, oxygen demand.*Inhibits platelet aggregation preventing acute thrombosis*- GTN is not an **antiplatelet agent** and does not inhibit platelet aggregation or play a direct role in preventing **thrombosis**.- Medications like **aspirin** or **clopidogrel** are used for antiplatelet effects, which differ from the acute symptomatic relief provided by GTN.

Question 59: A 68-year-old woman presents to the Emergency Department with 2 hours of central chest pain. Her ECG shows widespread T-wave inversion in the anterior leads (V2-V6) and troponin I is elevated at 2,850 ng/L (normal <14 ng/L). She has a history of hypertension and hyperlipidaemia. Her observations are: BP 142/86 mmHg, heart rate 88 bpm, oxygen saturation 97% on room air. She is pain-free after sublingual GTN and morphine. What is the GRACE score used to predict in this clinical context?

A. 6-month mortality and risk of myocardial infarction or death (Correct Answer)
B. Risk of stroke following acute coronary syndrome
C. Likelihood of benefit from coronary revascularisation
D. Risk of major bleeding on antiplatelet therapy
E. Long-term cardiovascular mortality over 10 years

Explanation: ***6-month mortality and risk of myocardial infarction or death*** - The **GRACE score** (Global Registry of Acute Coronary Events) is a validated tool for risk stratification in **Acute Coronary Syndrome (ACS)**, predicting in-hospital and **6-month mortality**. - It incorporates variables such as **age**, **heart rate**, **systolic BP**, **creatinine**, and **ST-segment changes** to guide the timing of invasive management. *Risk of stroke following acute coronary syndrome* - Stroke risk in the context of atrial fibrillation is typically assessed using the **CHA₂DS₂-VASc** score, not the GRACE score. - While ACS increases general cardiovascular risk, GRACE specifically focuses on **ischemic events** and **death** rather than neurological complications. *Likelihood of benefit from coronary revascularisation* - GRACE determines the **prognostic risk** and urgency of intervention, but it does not specifically measure the physiological benefit of revascularisation itself. - Decisions on revascularisation benefit are often guided by **angiographic findings**, **fractional flow reserve (FFR)**, or symptoms. *Risk of major bleeding on antiplatelet therapy* - Bleeding risk in patients undergoing treatment for ACS is more accurately predicted using the **CRUSADE** or **ACUITY** scores. - Patients on long-term anticoagulation for other reasons utilize the **HAS-BLED** score to monitor bleeding potential. *Long-term cardiovascular mortality over 10 years* - Long-term (10-year) primary prevention risk is assessed using tools like **QRISK3** or the **Framingham Risk Score**. - The GRACE score is designed for **acute settings** to predict short-to-medium term outcomes (up to 6 months) following an ACS event.

Question 60: A 72-year-old man is reviewed in the heart failure clinic 6 months after diagnosis. He has heart failure with reduced ejection fraction (LVEF 29%) and is currently taking bisoprolol 10 mg once daily, ramipril 10 mg once daily, spironolactone 25 mg once daily, and furosemide 40 mg once daily. He remains breathless on minimal exertion (NYHA class III). His BP is 108/64 mmHg, heart rate 72 bpm in sinus rhythm. Blood tests show: sodium 136 mmol/L, potassium 4.8 mmol/L, creatinine 118 μmol/L (eGFR 52 mL/min/1.73m²), NT-proBNP 1650 ng/L. What is the most appropriate medication change to improve his prognosis?

A. Add digoxin 62.5 mcg once daily
B. Replace ramipril with sacubitril-valsartan (Correct Answer)
C. Increase furosemide to 80 mg once daily
D. Add ivabradine 5 mg twice daily
E. Increase spironolactone to 50 mg once daily

Explanation: ***Replace ramipril with sacubitril-valsartan*** - In patients with **HFrEF (LVEF ≤35%)** who remain symptomatic (NYHA class II-IV) despite optimal therapy with an **ACE inhibitor**, beta-blocker, and MRA, an **ARNI** (Sacubitril-valsartan) is indicated to reduce mortality and hospitalizations. - This patient meets the criteria with an **LVEF of 29%**, persistent symptoms (NYHA class III), and elevated **NT-proBNP levels**, making this the most evidence-based step for prognostic benefit. *Add digoxin 62.5 mcg once daily* - **Digoxin** is primarily used for **symptom control** and to reduce heart failure hospitalizations, but it does not improve long-term survival or **prognosis** in heart failure. - It is usually reserved for patients who remain symptomatic despite all other **prognostic-altering medications** having been optimized. *Increase furosemide to 80 mg once daily* - **Loop diuretics** like furosemide are essential for managing **fluid overload** and congestive symptoms (like breathlessness), but they do not improve long-term **survival** in heart failure. - While increasing the dose might alleviate current symptoms, it does not address the underlying **pathophysiological progression** or improve the patient's prognosis. *Add ivabradine 5 mg twice daily* - **Ivabradine** is indicated for patients in **sinus rhythm** with an LVEF ≤35% and a heart rate **≥70 bpm** (ESC guidelines) or **≥75 bpm** (NICE guidelines) despite maximum tolerated beta-blockade. - Although this patient is in sinus rhythm with a heart rate of 72 bpm, switching to an **ARNI** takes clinical precedence due to its superior **mortality benefit** profile as a foundational treatment in GDMT. *Increase spironolactone to 50 mg once daily* - This patient is already on a maintenance dose of **spironolactone**, and while the dose could theoretically be increased, it carries a significant risk of **hyperkalemia** and worsening renal function. - Substituting the ACE inhibitor for an **ARNI** provides a more robust, evidenced-based survival benefit compared to solely up-titrating the **MRA** at this stage of therapy.

Question 61: A 64-year-old woman with type 2 diabetes presents with 30 minutes of severe central chest pain. Her ECG shows 3 mm ST-segment elevation in leads II, III, and aVF with reciprocal depression in leads I and aVL. She is haemodynamically stable with BP 135/82 mmHg, heart rate 78 bpm, oxygen saturation 96% on room air. The nearest primary PCI centre is 90 minutes away by ambulance. She received aspirin 300 mg and ticagrelor 180 mg 15 minutes ago. What is the most appropriate immediate management?

A. Arrange immediate transfer for primary PCI (Correct Answer)
B. Administer thrombolysis immediately then transfer for angiography
C. Administer morphine, arrange urgent CT coronary angiography
D. Commence intravenous heparin infusion and observe for 2 hours
E. Arrange urgent echocardiography to assess ventricular function

Explanation: ***Arrange immediate transfer for primary PCI*** - Primary **Percutaneous Coronary Intervention (PCI)** is the preferred reperfusion strategy for **ST-elevation myocardial infarction (STEMI)**, especially if it can be performed within **120 minutes** of first medical contact. - In this case, the **90-minute transfer time** to the PCI center is within the therapeutic window, offering superior outcomes in terms of **mortality, reinfarction, and stroke** compared to fibrinolysis. *Administer thrombolysis immediately then transfer for angiography* - **Fibrinolysis** is generally recommended only when **primary PCI** cannot be delivered within **120 minutes** from diagnosis or if there are delays to reaching a PCI facility. - Administering thrombolysis when a PCI center is accessible within the time limit unnecessarily increases the risk of **major bleeding** and intracranial hemorrhage without providing superior clinical benefit. *Administer morphine, arrange urgent CT coronary angiography* - While **morphine** may be used for pain control, **CT coronary angiography** is typically used for investigating stable chest pain or non-STEMI, not for acute **STEMI** where the diagnosis is already established by **ECG changes**. - Delaying definitive reperfusion therapy to perform a CT scan leads to increased **myocardial necrosis** and a poorer patient prognosis, as time is muscle. *Commence intravenous heparin infusion and observe for 2 hours* - Observing a patient with an active STEMI for **2 hours** is critically inappropriate as it causes significant delay to necessary **reperfusion therapy**, leading to irreversible heart muscle damage. - While anticoagulation (like heparin) is part of the adjunct therapy for STEMI, it does not replace the urgent need for immediate mechanical or chemical **revascularization** to open the occluded artery. *Arrange urgent echocardiography to assess ventricular function* - **Echocardiography** should not delay immediate transfer to a cardiac catheterization lab during an acute STEMI with diagnostic **ST-segment elevation**. - While useful for assessing complications like **ventricular septal rupture** or wall motion later, the immediate priority in STEMI is restoring **coronary artery patency** through reperfusion.

Question 62: A 50-year-old man presents to his GP with intermittent palpitations. He describes episodes of rapid regular heartbeat lasting up to 2 hours, occurring approximately twice per month. He is otherwise well with no chest pain or breathlessness. Examination reveals BP 128/76 mmHg, heart rate 74 bpm regular, BMI 28 kg/m². ECG shows sinus rhythm. He has no past medical history of note. A 24-hour Holter monitor confirms paroxysmal atrial fibrillation with episodes totalling 3 hours. What is his CHA₂DS₂-VASc score?

A. 0
B. 4
C. 1 (Correct Answer)
D. 2
E. 3

Explanation: ***1*** - The CHA₂DS₂-VASc score assesses **stroke risk** in patients with **atrial fibrillation**. While this 50-year-old male has no history of **CHF**, **hypertension**, **diabetes**, **stroke/TIA**, or **vascular disease**, and is not aged 65-74 or ≥75. - However, for male patients with **atrial fibrillation**, a score of **1** is often considered a threshold for discussing **oral anticoagulation** in clinical practice, even with a calculated score of 0, especially for those aged **50-64**, reflecting a low but non-zero risk. *0* - This score would imply a very low risk of **thromboembolism** in a patient without atrial fibrillation, or one where anticoagulation is generally not warranted. - For a male patient with confirmed **atrial fibrillation**, even in the absence of other comorbidities, a score of **0** is generally considered too low for an accurate assessment of **stroke risk** in most guidelines guiding anticoagulation decisions. *4* - A score of **4** would indicate a very high risk, typically requiring a history of **stroke/TIA** (2 points) along with two or more additional risk factors like **hypertension** or **diabetes**. - The patient's history shows no such significant **comorbidities** or prior thromboembolic events. *2* - A score of **2** is usually assigned to patients with a history of **stroke/TIA** (2 points) or those **aged ≥75 years** (2 points). - The patient is only **50 years old** and has no past medical history of **thromboembolism**, making a score of 2 inapplicable. *3* - This score would typically be seen in patients with multiple risk factors, for instance, **age 65-74** (1 point) combined with two other risk factors such as **hypertension** (1 point) and **diabetes** (1 point). - Given the patient's young age and absence of any listed **comorbidities**, a score of 3 is not supported.

Question 63: A 55-year-old woman with newly diagnosed heart failure and reduced ejection fraction (LVEF 32%) has been started on ramipril and bisoprolol. She remains NYHA class II with mild exertional breathlessness. Her blood pressure is 118/72 mmHg and heart rate 68 bpm. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, creatinine 95 μmol/L (eGFR 62 mL/min/1.73m²), NT-proBNP 850 ng/L. Echocardiography confirms LVEF 32% in sinus rhythm. She tolerates her current medications well. What is the most appropriate next step to improve her long-term prognosis?

A. Add spironolactone 25 mg once daily (Correct Answer)
B. Add digoxin 125 mcg once daily
C. Replace ramipril with sacubitril-valsartan
D. Add ivabradine 5 mg twice daily
E. Add furosemide 40 mg once daily

Explanation: ***Add spironolactone 25 mg once daily*** - In patients with **HFrEF** (LVEF ≤ 35%) who remain symptomatic (NYHA class II) despite an **ACE inhibitor** (ramipril) and a **beta-blocker** (bisoprolol), a **Mineralocorticoid Receptor Antagonist (MRA)** such as spironolactone is the next cornerstone therapy to improve long-term prognosis and survival. - This patient meets the safety criteria for MRA initiation, with a **potassium of 4.2 mmol/L (< 5.0 mmol/L)** and an **eGFR of 62 mL/min/1.73m² (> 30 mL/min/1.73m²),** and is tolerating current medications well. *Add digoxin 125 mcg once daily* - **Digoxin** is primarily used for **symptom control** (reducing hospitalizations) in patients with heart failure who remain symptomatic despite optimal therapy, or for rate control in atrial fibrillation. - Unlike MRAs, it has **no proven mortality benefit** in heart failure with reduced ejection fraction, making it less suitable as the *next step to improve long-term prognosis*. *Replace ramipril with sacubitril-valsartan* - While **sacubitril-valsartan (ARNI)** is a cornerstone therapy for HFrEF that replaces an ACE inhibitor or ARB, current guidelines typically recommend initiating **four-pillar therapy** sequentially. - For a patient stable on an ACEi and beta-blocker and still symptomatic, the standard progression often involves adding an **MRA** and an **SGLT2 inhibitor** before switching the ACEi, especially if the ACEi is well-tolerated. *Add ivabradine 5 mg twice daily* - **Ivabradine** is indicated in symptomatic HFrEF patients who are in **sinus rhythm** with a **heart rate ≥ 70 bpm** (or ≥ 75 bpm depending on specific guidelines) despite optimal beta-blocker therapy. - This patient's current heart rate is **68 bpm**, which is below the threshold for initiating ivabradine therapy for heart failure. *Add furosemide 40 mg once daily* - **Furosemide** is a loop diuretic primarily used for **symptomatic relief** of fluid overload and congestion, such as significant dyspnea or edema; the patient currently only has mild exertional breathlessness. - While important for managing fluid balance and symptoms, diuretics like furosemide have **not been shown to reduce mortality** or improve long-term prognosis in HFrEF; they are not considered a

Question 64: A 60-year-old man attends for his annual review. He was diagnosed with hypertension 2 years ago and has been taking amlodipine 10 mg once daily. His clinic blood pressure today is 142/88 mmHg. He reports good adherence to medication and has no symptoms. He does not smoke and has a BMI of 26 kg/m². His 24-hour ambulatory blood pressure monitoring shows an average of 138/84 mmHg. Blood tests show eGFR 68 mL/min/1.73m², HbA1c 38 mmol/mol, total cholesterol 5.2 mmol/L. What is the most appropriate next step in his management?

A. Add ramipril and arrange review in 4 weeks
B. Add indapamide and review in 4 weeks
C. Increase amlodipine to 15 mg once daily
D. Continue current therapy and review in 12 months (Correct Answer)
E. Switch amlodipine to doxazosin

Explanation: ***Continue current therapy and review in 12 months*** - For patients under **80 years of age**, the target **ambulatory blood pressure monitoring (ABPM)** average is **<135/85 mmHg**; this patient's reading of 138/84 mmHg is borderline and does NOT strictly require treatment escalation. - Given he has no **target organ damage** (eGFR and HbA1c are normal) and his **clinic blood pressure** is close to the <140/90 mmHg target, maintenance of current therapy is the most appropriate conservative step. *Add ramipril and arrange review in 4 weeks* - Adding an **ACE inhibitor** is considered Step 2 of the **NICE hypertension guidelines**, but it is unnecessary if the patient is already near his personal target without evidence of complications. - This intervention would be more appropriate if the blood pressure remained significantly elevated or if there were signs of **albuminuria** or **chronic kidney disease**. *Add indapamide and review in 4 weeks* - **Thiazide-like diuretics** are generally considered as part of Step 3 therapy (combined with an ACEi/ARB and CCB) or Step 2 for specific patient profiles. - It is inappropriate to add a third-line class of medication when the patient's blood pressure is already well-controlled on a **calcium channel blocker** alone. *Increase amlodipine to 15 mg once daily* - The **maximum licensed dose** of **amlodipine** for hypertension is **10 mg** once daily; exceeding this dose is not standard clinical practice. - Increasing the dose beyond 10 mg significantly increases the risk of side effects like **pedal edema** without providing a proportional benefit in blood pressure reduction. *Switch amlodipine to doxazosin* - **Doxazosin**, an alpha-blocker, is typically reserved as Step 4 therapy for **resistant hypertension** and is not a first-line alternative to a calcium channel blocker. - Switching medications in a patient who is achieving near-target results and tolerating his current **monotherapy** well would be clinically counterproductive.

Question 65: What is the mechanism of action of sacubitril-valsartan in the treatment of heart failure with reduced ejection fraction?

A. Inhibits neprilysin enzyme and blocks angiotensin II receptors (Correct Answer)
B. Inhibits ACE enzyme and blocks aldosterone receptors
C. Enhances natriuretic peptide activity and inhibits renin release
D. Blocks angiotensin II receptors and inhibits aldosterone synthesis
E. Inhibits neprilysin enzyme and ACE enzyme simultaneously

Explanation: ***Inhibits neprilysin enzyme and blocks angiotensin II receptors*** - **Sacubitril** is a prodrug that inhibits **neprilysin**, an enzyme responsible for degrading **natriuretic peptides** (ANP/BNP), thereby enhancing vasodilation and natriuresis. - **Valsartan** is an **angiotensin II receptor blocker (ARB)** that counteracts the RAAS activation and potential increase in angiotensin II caused by neprilysin inhibition.*Inhibits ACE enzyme and blocks aldosterone receptors* - This describes the mechanism of an **ACE inhibitor** combined with a **Mineralocorticoid Receptor Antagonist (MRA)** like spironolactone. - **Sacubitril-valsartan** does not inhibit the **Angiotensin-Converting Enzyme (ACE)** and is actually contraindicated for use with it due to **angioedema** risk.*Enhances natriuretic peptide activity and inhibits renin release* - While it enhances **natriuretic peptides**, the drug does not directly inhibit **renin release**; renin levels may actually increase due to feedback loops. - **Direct Renin Inhibitors** like **Aliskiren** are the primary agents used to block renin production directly.*Blocks angiotensin II receptors and inhibits aldosterone synthesis* - Though it blocks **AT1 receptors**, it does not specifically target the **aldosterone synthase** enzyme to inhibit synthesis. - Reductions in **aldosterone** are a secondary downstream effect of RAAS blockade rather than the primary dual-mechanism of this specific combination.*Inhibits neprilysin enzyme and ACE enzyme simultaneously* - Inhibiting both enzymes simultaneously was the mechanism of **Omapatrilat**, which was never approved due to severe risks of **life-threatening angioedema**. - To avoid this risk, **Sacubitril** must be paired with an **ARB (Valsartan)** rather than an ACE inhibitor, requiring a 36-hour washout period between treatments.

Question 66: A 68-year-old woman presents to the Emergency Department with 90 minutes of central chest pain. ECG shows 3 mm ST-elevation in leads II, III, and aVF with reciprocal ST-depression in leads I and aVL. She is given aspirin 300 mg, ticagrelor 180 mg, and morphine. The nearest primary PCI centre is 90 minutes away by ambulance. She presented 45 minutes after symptom onset. What is the most appropriate management?

A. Arrange immediate transfer for primary PCI (Correct Answer)
B. Administer thrombolysis and transfer for angiography
C. Administer thrombolysis and arrange transfer only if failed reperfusion
D. Observe with serial ECGs and troponins
E. Arrange urgent but non-emergency transfer for angiography within 24 hours

Explanation: ***Arrange immediate transfer for primary PCI*** - This patient presents with a **ST-elevation myocardial infarction (STEMI)**, characterized by chest pain and **ST-elevation in leads II, III, and aVF** (inferior STEMI) with reciprocal changes. - Primary PCI is the preferred reperfusion strategy if it can be performed within **120 minutes** of the patient presenting to a facility that could offer fibrinolysis. Given the 90-minute transfer time, this falls within the recommended window. *Administer thrombolysis and transfer for angiography* - **Thrombolysis** (fibrinolysis) is typically reserved for situations where primary PCI cannot be performed within the **120-minute target**, or within the first 12 hours of symptom onset if PCI is not available. - While a transfer for angiography post-thrombolysis (pharmacoinvasive strategy) is recommended, the initial choice of thrombolysis over a feasible primary PCI is not optimal due to higher bleeding risks. *Administer thrombolysis and arrange transfer only if failed reperfusion* - Current guidelines recommend a **pharmacoinvasive strategy** for all patients who undergo thrombolysis, meaning transfer for angiography should occur regardless of perceived reperfusion success, typically within 2-24 hours. - Administering thrombolysis when **primary PCI is logistically achievable** within the recommended timeframe is suboptimal and exposes the patient to unnecessary risks of bleeding and stroke. *Observe with serial ECGs and troponins* - **Observation** with serial ECGs and troponins is appropriate for patients with suspected acute coronary syndrome but without persistent ST-elevation (e.g., NSTEMI or unstable angina). - For **STEMI**, immediate reperfusion (PCI or thrombolysis) is crucial to minimize **myocardial damage** and improve patient outcomes, as time is muscle. *Arrange urgent but non-emergency transfer for angiography within 24 hours* - A non-emergency transfer for angiography within 24 hours is typically indicated for patients with **NSTEMI** and high-risk features, or after successful thrombolysis for STEMI. - For an acute STEMI, delaying definitive reperfusion beyond the acute phase significantly increases the risk of **myocardial necrosis**, **heart failure**, and other complications.

Question 67: A 76-year-old man presents with increasing breathlessness over the past year. He describes a crescendo-decrescendo systolic murmur heard best at the right upper sternal edge radiating to the carotids. He has had three episodes of exertional syncope in the last 6 months. Echocardiography confirms severe aortic stenosis with aortic valve area 0.6 cm², mean gradient 55 mmHg, and LVEF 48%. He has chronic kidney disease stage 3b and previous stroke 4 years ago with good recovery. What is the most appropriate management?

A. Medical management with diuretics and ACE inhibitor
B. Surgical aortic valve replacement
C. Refer for transcatheter aortic valve implantation (TAVI) assessment (Correct Answer)
D. Balloon aortic valvuloplasty
E. Conservative management with symptom monitoring

Explanation: ***Refer for transcatheter aortic valve implantation (TAVI) assessment*** - The patient has **symptomatic severe aortic stenosis** (AVA 0.6 cm², mean gradient 55 mmHg) with symptoms like **exertional syncope**, which indicates a dire prognosis and requires intervention to improve survival. - Given the patient's age (76), significant **co-morbidities** like **CKD stage 3b** and a history of **stroke**, he is considered high-risk for surgical aortic valve replacement (SAVR), making **TAVI** the preferred or highly considered option after a **Heart Team** assessment. *Medical management with diuretics and ACE inhibitor* - Medical therapy, including diuretics, primarily provides **symptomatic relief** but does not address the mechanical obstruction of the aortic valve or improve the **overall prognosis** of severe symptomatic AS. - **ACE inhibitors** should be used with extreme caution or avoided in severe aortic stenosis due to the risk of precipitating **hypotension** given the fixed cardiac output and preload dependence. *Surgical aortic valve replacement* - While **SAVR** is a definitive treatment, the patient's advanced age and multiple **co-morbidities** (CKD stage 3b, prior stroke) place him at a higher **surgical risk** for open-heart surgery. - Current guidelines recommend a **Heart Team** evaluation to weigh the risks and benefits of SAVR versus TAVI, with TAVI often favored for elderly, high-risk patients. *Balloon aortic valvuloplasty* - **Balloon aortic valvuloplasty (BAV)** offers only **temporary symptomatic relief** and is associated with a high rate of **restenosis** within months, making it unsuitable as a definitive long-term treatment. - BAV is typically reserved as a **bridge to definitive TAVI or SAVR** in hemodynamically unstable patients, or for palliation in patients who are not candidates for valve replacement. *Conservative management with symptom monitoring* - **Conservative management** is inappropriate for symptomatic severe AS, as symptoms like **syncope** signify a critical stage with a very poor prognosis (e.g., 50% 2-year mortality) if left untreated. - Delaying intervention increases the risk of **sudden cardiac death** and irreversible myocardial damage, thereby missing the opportunity to improve survival and quality of life.

Question 68: A 54-year-old man with ischaemic cardiomyopathy (LVEF 26%) is reviewed in the heart failure clinic. He is on optimal medical therapy including ramipril, bisoprolol, spironolactone, and furosemide. Despite this, he has persistent symptoms (NYHA class II-III). His ECG shows sinus rhythm with heart rate of 88 bpm and QRS duration of 118 ms. Blood pressure is 112/70 mmHg. An implantable cardioverter-defibrillator (ICD) was fitted 18 months ago for primary prevention. What additional therapy should be considered?

A. Add ivabradine 5 mg twice daily (Correct Answer)
B. Add digoxin 62.5 mcg once daily
C. Upgrade ICD to cardiac resynchronisation therapy defibrillator (CRT-D)
D. Add hydralazine and isosorbide dinitrate
E. Increase bisoprolol dose

Explanation: ***Add ivabradine 5 mg twice daily***- **Ivabradine** is indicated for patients with HFrEF (LVEF ≤35%) in **sinus rhythm** with a resting heart rate **≥70 bpm** who remain symptomatic (NYHA class II-IV) despite optimal, maximally tolerated beta-blocker therapy.- This patient perfectly fits these criteria, having a **LVEF of 26%**, being in **sinus rhythm** with a heart rate of **88 bpm**, and remaining **symptomatic** (NYHA class II-III) on optimal medical therapy including bisoprolol.*Add digoxin 62.5 mcg once daily*- **Digoxin** is generally considered for symptomatic relief in patients with persistent heart failure, particularly those with concomitant **atrial fibrillation** and a rapid ventricular response, or those who remain symptomatic despite optimal guideline-directed medical therapy.- While it may reduce heart failure hospitalizations, it has not shown a **mortality benefit** in patients with HFrEF in sinus rhythm, unlike ivabradine in the specific subgroup.*Upgrade ICD to cardiac resynchronisation therapy defibrillator (CRT-D)*- **Cardiac resynchronisation therapy (CRT)** is indicated for patients with symptomatic HFrEF (LVEF ≤35%) and a significantly widened **QRS duration**, typically **≥130 ms** with LBBB morphology, or **≥150 ms** for non-LBBB.- The patient's **QRS duration of 118 ms** is below the generally accepted threshold for initiating CRT, making this option currently unsuitable.*Add hydralazine and isosorbide dinitrate*- This combination is primarily recommended for **African-American/Caribbean patients** with moderate-to-severe HFrEF who remain symptomatic despite optimal medical therapy, or for patients of any ethnicity who are **intolerant to ACE inhibitors or ARBs**.- There is no mention of the patient's ethnicity, and he is currently tolerating **ramipril** (an ACE inhibitor), so this combination is not the first-line additional therapy.*Increase bisoprolol dose*- The patient is stated to be on **optimal medical therapy**, which implies that his **bisoprolol** dose has been titrated to the maximum tolerated dose or target dose.- Despite this, his heart rate is still **88 bpm**, suggesting that further increasing the bisoprolol dose might be limited by side effects like hypotension (current BP 112/70 mmHg) or bradycardia, or it has already reached its maximal tolerated therapeutic effect; ivabradine offers a different mechanism for heart rate reduction.

Question 69: A 59-year-old man with newly diagnosed paroxysmal atrial fibrillation attends for discussion about anticoagulation. He has no other medical history and takes no regular medications. His CHA2DS2-VASc score is 1 (male, age 59) and HAS-BLED score is 0. He is concerned about bleeding risk and asks whether he needs anticoagulation. What is the most appropriate advice?

A. Anticoagulation is not indicated; aspirin 75 mg daily is sufficient
B. Anticoagulation is not indicated; no antithrombotic therapy needed
C. Anticoagulation with a DOAC should be offered as it reduces stroke risk (Correct Answer)
D. Anticoagulation should be deferred until CHA2DS2-VASc score reaches 2
E. Aspirin and clopidogrel dual therapy is the preferred option

Explanation: ***Anticoagulation with a DOAC should be offered as it reduces stroke risk***- For **males with a CHA2DS2-VASc score of 1**, guidelines (e.g., ESC/ACC/AHA) recommend considering or offering oral anticoagulation to reduce the risk of **thromboembolic stroke**.- **Direct Oral Anticoagulants (DOACs)** are generally preferred over warfarin for most patients due to their efficacy, ease of use, and favorable safety profile, particularly a lower risk of **intracranial hemorrhage**.*Anticoagulation is not indicated; aspirin 75 mg daily is sufficient*- **Aspirin** monotherapy is **not recommended** for stroke prevention in atrial fibrillation as it has been shown to be significantly less effective than oral anticoagulants.- The **bleeding risk** of aspirin in this context is similar to that of oral anticoagulants, but without the comparable benefit in **stroke reduction**.*Anticoagulation is not indicated; no antithrombotic therapy needed*- While a CHA2DS2-VASc score of 0 for males generally means no antithrombotic therapy, a score of **1 indicates an increased stroke risk** where the benefits of anticoagulation typically outweigh the risks.- Current guidelines differentiate a score of 0 (truly low risk) from a score of 1, where **anticoagulation should be discussed** and often initiated.*Anticoagulation should be deferred until CHA2DS2-VASc score reaches 2*- Delaying anticoagulation for a patient with a CHA2DS2-VASc score of 1 (male) means missing an opportunity for **early stroke prevention**, as their risk is already elevated.- Though anticoagulation is "recommended" at a score of 2 or more, it is "considered" or **offered** at a score of 1, making immediate discussion and offering appropriate.*Aspirin and clopidogrel dual therapy is the preferred option*- **Dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel is **ineffective** for stroke prevention in non-valvular atrial fibrillation compared to oral anticoagulation.- DAPT also significantly **increases the risk of major bleeding** compared to oral anticoagulants, without offering superior protection against **cardioembolic strokes**.

Question 70: A 71-year-old woman is admitted with acute decompensated heart failure. She has known heart failure with LVEF 34% and is usually managed on ramipril 10 mg, bisoprolol 7.5 mg, spironolactone 25 mg, and furosemide 80 mg daily. On admission: BP 96/58 mmHg, HR 68 bpm, oxygen saturation 90% on air. She has pulmonary crepitations and peripheral oedema. Bloods show: Na+ 128 mmol/L, K+ 5.3 mmol/L, urea 18.2 mmol/L, creatinine 168 μmol/L (baseline 110 μmol/L). What is the most appropriate immediate management?

A. Increase furosemide to 160 mg daily and withhold ACE inhibitor and spironolactone (Correct Answer)
B. Start intravenous dobutamine infusion
C. Give intravenous furosemide bolus and continue all regular medications
D. Start intravenous furosemide and withhold ACE inhibitor, continue other medications
E. Start ultrafiltration therapy

Explanation: ***Increase furosemide to 160 mg daily and withhold ACE inhibitor and spironolactone*** - The patient presents with **acute decompensated heart failure** complicated by **volume overload**, **acute kidney injury (AKI)**, and **hyperkalaemia** (K+ 5.3 mmol/L), indicating cardiorenal syndrome. - Increasing **furosemide** helps alleviate fluid overload, while temporarily stopping **ramipril** (ACE inhibitor) and **spironolactone** (MRA) is crucial to prevent further worsening of AKI and hyperkalaemia, which are critical in this acute setting. *Start intravenous dobutamine infusion* - **Dobutamine**, an inotrope, is typically reserved for patients with severe **cardiogenic shock** or profound hypoperfusion, which is not clearly evident despite borderline hypotension (BP 96/58 mmHg). - Administering an inotrope without clear indications of shock can increase myocardial oxygen demand and risk of **arrhythmias** in a stable, although decompensated, patient. *Give intravenous furosemide bolus and continue all regular medications* - Continuing **ramipril** and **spironolactone** is contraindicated given the patient's **acute kidney injury** (creatinine 168 μmol/L) and **hyperkalaemia** (K+ 5.3 mmol/L). - This approach would exacerbate renal dysfunction and potentially lead to life-threatening hyperkalaemia. *Start intravenous furosemide and withhold ACE inhibitor, continue other medications* - While withholding the **ACE inhibitor** is appropriate, continuing **spironolactone** (a potassium-sparing diuretic) is inappropriate in the presence of **hyperkalaemia** (K+ 5.3 mmol/L) and rising **creatinine**. - Both the ACE inhibitor and the mineralocorticoid receptor antagonist contribute to hyperkalaemia and can worsen renal function, thus both should be withheld. *Start ultrafiltration therapy* - **Ultrafiltration** is an advanced therapy typically considered for patients with **refractory volume overload** or severe **diuretic resistance** despite high-dose loop diuretics. - It is not an initial management step before maximizing and assessing the response to aggressive pharmacological diuresis.

Question 71: A 65-year-old man presents to the Emergency Department with sudden onset severe central chest pain radiating to the back, which started 3 hours ago. He has a history of hypertension and Marfan syndrome. On examination, blood pressure is 168/92 mmHg in the right arm and 142/86 mmHg in the left arm. Heart rate is 98 bpm. There is an early diastolic murmur at the left sternal edge. ECG shows sinus rhythm with left ventricular hypertrophy but no acute ischaemic changes. What is the most appropriate immediate investigation?

A. Transthoracic echocardiography
B. High-sensitivity troponin
C. CT aortic angiography (Correct Answer)
D. Chest X-ray
E. Coronary angiography

Explanation: ***CT aortic angiography***- This is the **gold standard** for diagnosing **acute aortic dissection** due to its high sensitivity and specificity, allowing for rapid assessment of the dissection flap and its extent.- In this patient, risk factors like **Marfan syndrome**, hypertension, and clinical signs such as a **blood pressure differential** and **aortic regurgitation** (early diastolic murmur) make this the definitive first-line test.*Transthoracic echocardiography*- While useful at the bedside for screening **pericardial effusion** or measuring the aortic root, it lacks the sensitivity to reliably exclude aortic dissection.- **Transoesophageal echocardiography** is much more accurate but is more invasive and often less readily available than CT.*High-sensitivity troponin*- While commonly performed for chest pain, it is **non-specific** and may be elevated in aortic dissection if the dissection affects the coronary arteries.- Relying on this marker can cause a **dangerous delay** in diagnosing a life-threatening dissection when the history strongly suggests a vascular catastrophe.*Chest X-ray*- It may demonstrate a **widened mediastinum** or an abnormal aortic contour, but up to 20% of patients with dissection have a normal X-ray.- This investigation lacks enough **sensitivity and specificity** to be used as a standalone tool for ruling out dissection.*Coronary angiography*- This is primarily used for **myocardial infarction** and is generally **contraindicated** if aortic dissection is suspected because the catheter could enter the false lumen and worsen the tear.- The ECG here shows **left ventricular hypertrophy** but no ST-segment changes, making a primary coronary event less likely than a dissection.

Question 72: A 43-year-old woman attends for cardiovascular risk assessment. She is asymptomatic. Her father had a myocardial infarction at age 48. She is a non-smoker. Blood pressure is 128/78 mmHg, BMI 24 kg/m². Lipid profile shows: total cholesterol 8.2 mmol/L, LDL cholesterol 5.8 mmol/L, HDL cholesterol 1.3 mmol/L, triglycerides 2.1 mmol/L. Her QRISK3 score is calculated as 12%. Physical examination reveals bilateral Achilles tendon xanthomata. What is the most appropriate next step?

A. Start atorvastatin 20 mg once daily
B. Provide lifestyle advice and reassess in 12 months
C. Start atorvastatin 80 mg once daily
D. Arrange CT coronary angiography
E. Refer to lipid clinic for assessment of familial hypercholesterolaemia (Correct Answer)

Explanation: ***Refer to lipid clinic for assessment of familial hypercholesterolaemia*** - This patient presents with classical features of **Familial Hypercholesterolaemia (FH)**, including a very high **LDL cholesterol (5.8 mmol/L)**, a strong **family history of premature coronary artery disease**, and the pathognomonic finding of **bilateral Achilles tendon xanthomata**. - **FH** is a genetic condition requiring urgent specialist assessment, genetic confirmation, and **cascade screening** of family members, as standard risk calculators like QRISK3 underestimate the true risk. *Start atorvastatin 20 mg once daily* - While statins are indicated, **atorvastatin 20 mg** is a low-intensity dose, which is generally insufficient for managing the severe hypercholesterolaemia seen in **Familial Hypercholesterolaemia (FH)**. - The initial management of suspected FH involves **specialist referral** for diagnosis and genetic testing, rather than immediate initiation of a potentially inadequate dose of statin. *Provide lifestyle advice and reassess in 12 months* - **Lifestyle modifications** alone are inadequate for achieving significant reductions in cholesterol levels in **Familial Hypercholesterolaemia (FH)**, which is a genetic disorder. - Delaying treatment for 12 months in a patient with a very high **LDL cholesterol**, strong family history, and **tendon xanthomata** would expose her to continued high risk of **premature cardiovascular events**. *Start atorvastatin 80 mg once daily* - **Atorvastatin 80 mg** is a high-intensity statin appropriate for the aggressive management of **Familial Hypercholesterolaemia (FH)**. - However, the most appropriate *next step* is to confirm the diagnosis of FH via a **lipid clinic referral** to ensure comprehensive management, genetic testing, and family screening, which precedes or is done in conjunction with initiating high-dose therapy. *Arrange CT coronary angiography* - **CT coronary angiography** is typically used to assess for **coronary artery disease** in symptomatic patients or for reclassification of risk in certain high-risk asymptomatic individuals. - For this asymptomatic patient, the immediate priority is to diagnose and manage her probable **Familial Hypercholesterolaemia**, not to screen for existing anatomical lesions.

Question 73: A 69-year-old man presents with progressive breathlessness over 6 months. He can now only walk 50 meters on the flat before stopping due to dyspnoea. He has paroxysmal atrial fibrillation and hypertension. Echocardiography shows left ventricular ejection fraction of 58%, left ventricular hypertrophy, left atrial dilatation, and E/e' ratio of 16. NT-proBNP is 580 pg/mL. What is the most appropriate initial pharmacological management?

A. Start ramipril and bisoprolol (Correct Answer)
B. Start spironolactone and furosemide
C. Start furosemide alone
D. Start sacubitril-valsartan
E. Start digoxin and furosemide

Explanation: ***Start ramipril and bisoprolol***- This patient presents with clear signs of **Heart Failure with preserved Ejection Fraction (HFpEF)**, characterized by **normal LVEF (58%)**, **LV hypertrophy**, **LA dilatation**, and **elevated E/e' ratio**, in the context of **dyspnoea** and elevated **NT-proBNP**.- **Ramipril (an ACE inhibitor)** is crucial for managing his **hypertension** and mitigating **LV remodeling**, which is central to HFpEF management. **Bisoprolol (a beta-blocker)** is essential for **rate control** in his **paroxysmal atrial fibrillation** and also helps manage hypertension, improving diastolic filling.*Start spironolactone and furosemide*- While **spironolactone (an MRA)** can be beneficial in HFpEF by reducing fibrosis and improving diastolic function, it's typically considered after optimizing blood pressure and heart rate, and often used to reduce hospitalizations rather than as *initial* management for all aspects.- **Furosemide (a loop diuretic)** will alleviate **symptomatic congestion** and breathlessness, but it does not address the underlying **hypertension** or the need for **rate control** in atrial fibrillation, which are critical initial steps.*Start furosemide alone*- **Furosemide** provides effective **symptomatic relief** from congestion and dyspnoea by reducing fluid overload.- However, monotherapy with a diuretic does not manage the patient's **hypertension**, control his **atrial fibrillation rate**, or offer **prognostic benefits** in HFpEF, making it an incomplete initial management strategy.*Start sacubitril-valsartan*- **Sacubitril-valsartan (an ARNI)** is primarily indicated for patients with **Heart Failure with reduced Ejection Fraction (HFrEF)** to improve mortality and reduce hospitalizations.- Although there is some emerging evidence for its use in HFpEF, particularly in a subset, it is generally not considered the **initial pharmacological management** for a newly diagnosed HFpEF patient with uncontrolled hypertension and AF.*Start digoxin and furosemide*- **Digoxin** is used for **rate control** in atrial fibrillation, especially if other agents like beta-blockers are contraindicated or ineffective, but it has a narrow therapeutic index and does not address **hypertension** or **LV hypertrophy**.- This combination lacks the comprehensive approach to manage the patient's **hypertension**, which is a key driver of his HFpEF, and does not provide the robust benefits of ACE inhibitors or beta-blockers in this context.

Question 74: A 52-year-old woman presents with 3 months of exertional chest tightness that occurs predictably when walking uphill and is relieved by rest within 5 minutes. She has a family history of ischaemic heart disease (father had myocardial infarction aged 54). She is a non-smoker with well-controlled hypertension. CT coronary angiography shows 60% stenosis of the proximal left anterior descending artery with no other significant disease. Fractional flow reserve (FFR) is 0.84. She is already taking aspirin, atorvastatin, and amlodipine. What is the most appropriate management of her angina?

A. Add ivabradine and continue medical management
B. Add bisoprolol and continue medical management (Correct Answer)
C. Refer for percutaneous coronary intervention to LAD
D. Add isosorbide mononitrate and continue medical management
E. Refer for coronary artery bypass grafting

Explanation: ***Add bisoprolol and continue medical management*** - **Beta-blockers** like **bisoprolol** are first-line pharmacological agents for managing symptoms of stable angina, especially when a patient is already on a calcium channel blocker like amlodipine. - The **Fractional Flow Reserve (FFR) of 0.84** indicates that the 60% LAD stenosis is not hemodynamically significant (threshold for significance is generally <0.80), thus favoring **optimal medical therapy** over revascularization. *Add ivabradine and continue medical management* - **Ivabradine** is a second-line anti-anginal agent, typically used if **beta-blockers** are contraindicated, not tolerated, or if angina is uncontrolled despite optimal doses of first-line agents, in patients in sinus rhythm with a heart rate ≥70 bpm. - Since beta-blockers haven't been tried in this patient, they should be prioritized before considering **ivabradine**. *Refer for percutaneous coronary intervention to LAD* - **Percutaneous coronary intervention (PCI)** is not indicated in this case because the **FFR of 0.84** confirms that the 60% stenosis is not causing **myocardial ischemia** and is not hemodynamically significant. - Revascularization of lesions with an FFR >0.80 has not shown benefit over **optimal medical therapy** in improving clinical outcomes for stable angina. *Add isosorbide mononitrate and continue medical management* - **Long-acting nitrates** like **isosorbide mononitrate** are generally considered second-line agents for angina symptom relief. - They are typically added if symptoms persist despite **beta-blockers** and/or calcium channel blockers, or if these first-line agents are contraindicated or not tolerated. *Refer for coronary artery bypass grafting* - **Coronary artery bypass grafting (CABG)** is a major surgical procedure reserved for patients with extensive coronary artery disease, such as **left main stem disease** or **multi-vessel disease**, or complex lesions not suitable for PCI. - This patient has single-vessel disease (LAD) that is not physiologically significant (FFR >0.80), making CABG an inappropriate and overly invasive option.

Question 75: A 78-year-old woman with permanent atrial fibrillation is reviewed in the anticoagulation clinic. She has a history of hypertension, type 2 diabetes, and previous ischaemic stroke 2 years ago. She is currently taking warfarin but has had multiple INR measurements outside therapeutic range despite good compliance. Her most recent INR results over 8 weeks show values of 1.8, 3.6, 2.1, 3.8, and 1.9 (target 2.0-3.0). She has normal renal function (eGFR 68 mL/min/1.73m²) and no history of bleeding. What is the most appropriate management?

A. Switch to apixaban 5 mg twice daily (Correct Answer)
B. Continue warfarin and add aspirin 75 mg once daily
C. Continue warfarin and review INR weekly
D. Switch to aspirin 75 mg once daily and clopidogrel 75 mg once daily
E. Switch to dabigatran 110 mg twice daily

Explanation: ***Switch to apixaban 5 mg twice daily***- In patients with **atrial fibrillation** and poor **INR control** (time in therapeutic range < 65%), NICE guidelines recommend switching to a **direct oral anticoagulant (DOAC)**.- A dose of 5 mg twice daily is correct as she does not meet the criteria for **dose reduction** (age ≥ 80, weight ≤ 60 kg, or creatinine ≥ 133 μmol/L).*Continue warfarin and add aspirin 75 mg once daily*- Adding **aspirin** to warfarin does not improve stroke prevention in AF and significantly increases the **risk of major bleeding**.- This patient already demonstrates **labile INRs**, making the addition of antiplatelets even more dangerous without addressing the underlying anticoagulation instability.*Continue warfarin and review INR weekly*- The patient has had multiple measurements outside the **therapeutic range (2.0-3.0)** despite good compliance, indicating that warfarin is unsuitable for her long-term management.- Continuing current therapy fails to address the high **thromboembolic risk** (CHA2DS2-VASc score of 7) associated with sub-therapeutic INR levels.*Switch to aspirin 75 mg once daily and clopidogrel 75 mg once daily*- **Dual antiplatelet therapy (DAPT)** is significantly less effective than anticoagulation for stroke prevention in AF.- Given the patient's high risk profile (age, diabetes, stroke history), DAPT offers **suboptimal protection** against ischaemic events.*Switch to dabigatran 110 mg twice daily*- While switching to a DOAC is correct, the 110 mg dose of **dabigatran** is typically reserved for patients aged **80 or older** or those at high risk of bleeding.- As this patient is 78 years old and has a normal **eGFR of 68**, the standard dose (150 mg) or an alternative DOAC like **apixaban** is more appropriate.

Question 76: A 49-year-old man presents to the Emergency Department with 2 hours of central crushing chest pain at rest. He has a history of hypertension and is a current smoker. Initial ECG shows sinus rhythm with 1 mm ST-segment depression in leads V4-V6. His high-sensitivity troponin I at presentation is 8 ng/L (normal <16 ng/L). Observations: BP 152/88 mmHg, heart rate 78 bpm, oxygen saturation 97% on air. He is given aspirin 300 mg, ticagrelor 180 mg, and sublingual GTN. What is the most appropriate next step in management?

A. Discharge with outpatient cardiology follow-up
B. Arrange immediate coronary angiography
C. Start fondaparinux and arrange angiography within 72 hours
D. Repeat high-sensitivity troponin at 3 hours from symptom onset (Correct Answer)
E. Observe for 6 hours and repeat troponin before discharge

Explanation: ***Repeat high-sensitivity troponin at 3 hours from symptom onset*** - The patient presents with classic symptoms of **Acute Coronary Syndrome (ACS)** and ischemic **ECG changes (ST-depression)**. However, the initial **high-sensitivity troponin (hs-cTn)** was taken only 2 hours after pain onset, which may be too early to detect a significant rise. - Guidelines (e.g., ESC 0/1h or 0/3h protocols) recommend serial troponin testing to detect a dynamic **rise or fall** in levels, which is crucial for differentiating **NSTEMI** from unstable angina or non-cardiac chest pain. *Discharge with outpatient cardiology follow-up* - This option is unsafe as the patient has **active chest pain** and **ischemic ECG changes (ST-segment depression)**, indicating a high probability of ACS. - Discharge is only appropriate if serial troponin measurements are definitively negative and the patient is deemed **low-risk** after comprehensive assessment. *Arrange immediate coronary angiography* - Immediate angiography (within 2 hours) is reserved for **ST-elevation myocardial infarction (STEMI)** or **very high-risk NSTE-ACS** (e.g., hemodynamic instability, refractory angina, life-threatening arrhythmias, mechanical complications). - This patient is currently hemodynamically stable, making immediate angiography premature before confirming myocardial injury with serial troponins. *Start fondaparinux and arrange angiography within 72 hours* - While **fondaparinux** and inpatient angiography are standard for confirmed intermediate-to-high-risk **NSTE-ACS**, the diagnosis must first be established with serial troponins. - Initiating full anticoagulation without confirming myocardial infarction via a dynamic troponin change or a high-risk score is premature at this diagnostic stage. *Observe for 6 hours and repeat troponin before discharge* - With the advent of **high-sensitivity troponin assays**, the diagnostic window for rule-in/rule-out of MI has significantly shortened. - Waiting 6 hours for a repeat troponin is an outdated practice for hs-cTn, as current guidelines recommend much shorter intervals (e.g., 0/1h or 0/3h) for more rapid and efficient diagnosis.

Question 77: A 57-year-old man with chronic heart failure due to dilated cardiomyopathy (LVEF 32%) is reviewed in the heart failure clinic. He is currently taking ramipril 10 mg once daily, bisoprolol 10 mg once daily, spironolactone 25 mg once daily, and furosemide 40 mg once daily. He remains breathless on minimal exertion (NYHA class III). His ECG shows sinus rhythm with QRS duration of 156 ms and left bundle branch block morphology. Blood pressure is 118/76 mmHg. Renal function and electrolytes are normal. What is the most appropriate next step in management?

A. Increase furosemide to 80 mg once daily
B. Increase spironolactone to 50 mg once daily
C. Refer for cardiac resynchronisation therapy assessment (Correct Answer)
D. Add ivabradine 5 mg twice daily
E. Add digoxin 125 mcg once daily

Explanation: ***Refer for cardiac resynchronisation therapy assessment*** - This patient meets the criteria for **Cardiac Resynchronisation Therapy (CRT)** due to **symptomatic heart failure (NYHA Class III)** with **reduced ejection fraction (LVEF 32%)**, **optimal medical therapy**, and a **wide QRS duration (156 ms)** with **Left Bundle Branch Block (LBBB)** morphology. - CRT improves **ventricular synchrony**, leading to enhanced cardiac output and significant reductions in **morbidity and mortality** in appropriately selected patients. *Increase furosemide to 80 mg once daily* - **Furosemide**, a loop diuretic, provides **symptomatic relief** from congestion but does not offer prognostic benefits or address the underlying **cardiac dyssynchrony**. - There are no specific signs of worsening **fluid overload** (e.g., increased weight, peripheral edema, pulmonary crackles) presented in the vignette to prioritize an increased diuretic dose as the next step. *Increase spironolactone to 50 mg once daily* - The patient is already on a **guideline-recommended dose of spironolactone (25 mg)**, which provides most of the mortality benefit from **mineralocorticoid receptor antagonism**. - Increasing the dose would not address the **electrical dyssynchrony** indicated by the wide QRS and LBBB, and could increase the risk of **hyperkalemia**. *Add ivabradine 5 mg twice daily* - **Ivabradine** is indicated for symptomatic **HFrEF patients** in **sinus rhythm** with a resting **heart rate ≥70-75 bpm** despite maximal beta-blocker therapy. - The patient's heart rate is not provided, and even if elevated, addressing the **QRS widening and LBBB** with CRT takes precedence given the strong evidence for its benefit. *Add digoxin 125 mcg once daily* - **Digoxin** is typically used for **rate control in atrial fibrillation** or as an adjunctive therapy for **symptomatic HFrEF** that remains refractory to other guideline-directed medical and device therapies, without a mortality benefit. - It does not address the **electromechanical dyssynchrony** present and is not the first-line intervention when clear indications for **CRT** exist.

Question 78: A 61-year-old woman attends her GP surgery for a routine health check. She has no symptoms and no significant past medical history. Clinic blood pressure measurement is 148/94 mmHg. On repeat measurement 5 minutes later, it is 146/92 mmHg. Physical examination is unremarkable. She is a non-smoker with BMI 26 kg/m². What is the most appropriate next step in management?

A. Start amlodipine 5 mg once daily
B. Arrange 24-hour urine collection for metanephrines
C. Arrange ambulatory blood pressure monitoring (Correct Answer)
D. Start ramipril 2.5 mg once daily
E. Repeat clinic blood pressure measurement in 1 month

Explanation: ***Arrange ambulatory blood pressure monitoring*** - For a patient with a clinic blood pressure between **140/90 mmHg and 179/120 mmHg**, the next step under **NICE guidelines** is to offer **Ambulatory Blood Pressure Monitoring (ABPM)** or Home Blood Pressure Monitoring (HBPM) to confirm the diagnosis. - This step is essential to rule out **white coat hypertension** and accurately categorize the patient's blood pressure stage before initiating long-term therapy. *Start amlodipine 5 mg once daily* - Initiating **antihypertensive medication** such as a Calcium Channel Blocker is premature without a confirmed diagnosis through ABPM or HBPM. - Pharmacotherapy is generally only started immediately for **Stage 2 hypertension** (clinic BP >160/100) with end-organ damage or **Stage 3 hypertension** (>180/120). *Arrange 24-hour urine collection for metanephrines* - Screening for **secondary causes** like **pheochromocytoma** is not indicated as the patient is asymptomatic and does not have resistant or paroxysmal hypertension. - Initial focus must remain on confirming **essential hypertension** through standardized monitoring protocols. *Start ramipril 2.5 mg once daily* - Starting an **ACE inhibitor** without diagnostic confirmation is incorrect and bypasses necessary risk assessment and staging protocols. - Even if diagnosed, the choice of first-line agent depends on **age** and **ethnicity**, which follows confirmation of persistent high blood pressure. *Repeat clinic blood pressure measurement in 1 month* - Simply repeating **clinic measurements** is insufficient for diagnosis and lacks the accuracy of out-of-office monitoring required by modern guidelines. - Waiting one month may delay necessary intervention if the patient truly has **hypertension**, whereas ABPM provides a definitive average over a 24-hour period.

Question 79: A 66-year-old woman with permanent atrial fibrillation presents with progressive fatigue and dyspnoea over 6 months. She takes apixaban 5 mg twice daily and no rate-control medication. Her heart rate is irregularly irregular at 115-130 bpm at rest, blood pressure 118/76 mmHg. Echocardiography shows normal left ventricular systolic function (LVEF 58%), mild left atrial dilatement, and no significant valvular disease. NT-proBNP is 420 ng/L (mildly elevated). She has failed previous trials of bisoprolol due to fatigue and diltiazem due to peripheral oedema. What is the most appropriate next pharmacological management for rate control?

A. Commence amiodarone 200 mg once daily for rhythm control
B. Commence digoxin 125 mcg once daily (Correct Answer)
C. Arrange urgent DC cardioversion
D. Commence verapamil 80 mg three times daily
E. Refer for AV node ablation and permanent pacemaker insertion

Explanation: ***Commence digoxin 125 mcg once daily*** - **Digoxin** is the most appropriate next step for **rate control** in permanent AF when first-line agents like **beta-blockers** and **calcium channel blockers** are contraindicated or not tolerated, as is the case for this patient. - It primarily works by increasing **vagal tone** on the **AV node** to reduce the ventricular rate, especially at rest, and does not have the fatigue or peripheral oedema side effects observed with the previously failed medications. *Commence amiodarone 200 mg once daily for rhythm control* - This patient has **permanent atrial fibrillation**, meaning the goal of management is **rate control**, not rhythm control. - **Amiodarone** is an antiarrhythmic typically used for **rhythm control**, and its long-term use is associated with significant **extracardiac toxicities** (e.g., pulmonary, thyroid, hepatic), making it unsuitable for routine rate control. *Arrange urgent DC cardioversion* - **DC cardioversion** is a procedure for **rhythm control**, typically indicated for hemodynamically unstable AF or for restoring sinus rhythm in symptomatic, non-permanent AF. - Given that the patient has **permanent AF** and is **hemodynamically stable**, cardioversion is not an appropriate intervention for her chronic symptoms. *Commence verapamil 80 mg three times daily* - **Verapamil** is a **non-dihydropyridine calcium channel blocker**, pharmacologically similar to **diltiazem**, which the patient previously failed due to **peripheral oedema**. - There is a high probability of **cross-intolerance** and recurrence of similar adverse effects, making it an unsuitable alternative in this clinical scenario. *Refer for AV node ablation and permanent pacemaker insertion* - **AV node ablation with pacemaker implantation** is an invasive, **last-resort strategy** for rate control in AF, considered only when all optimal pharmacological options have been exhausted and symptoms remain refractory. - This option is premature, as the patient has not yet tried **digoxin**, which is a viable pharmacological alternative for rate control.

Question 80: A 53-year-old man presents to his GP with 8 weeks of exertional chest tightness. He describes a pressure sensation across his chest occurring predictably during brisk walking uphill, relieved within 3-4 minutes of rest. He has type 2 diabetes, hypertension, and is an ex-smoker (quit 5 years ago, 20 pack-year history). Examination is unremarkable. Resting 12-lead ECG is normal. His blood pressure is 142/86 mmHg. What is the most appropriate initial investigation to establish the diagnosis?

A. Exercise tolerance test (ETT)
B. CT coronary angiography (CTCA) (Correct Answer)
C. Invasive coronary angiography
D. Stress echocardiography
E. Myocardial perfusion scintigraphy (MPS)

Explanation: ***CT coronary angiography (CTCA)***- According to **NICE guidelines (CG95)**, CTCA is the first-line investigation for patients with suspected **stable angina** who present with typical or atypical chest pain.- It provides high **negative predictive value** and can non-invasively identify **coronary artery disease (CAD)** or significant plaque burden in patients with metabolic risk factors like **diabetes**.*Exercise tolerance test (ETT)*- Current clinical guidelines no longer recommend ETT as the first-line test due to its **low sensitivity** and high rate of **false results**.- It is less reliable than imaging modalities for diagnosing obstructive **ischemic heart disease**.*Invasive coronary angiography*- This is an **invasive procedure** reserved for patients with high-risk features or those being considered for **revascularization**.- It is not indicated as an initial diagnostic tool when **non-invasive imaging** like CTCA can provide the diagnosis.*Stress echocardiography*- This is a **functional imaging** test used primarily if CTCA is technically difficult, contraindicated, or if imaging results are **inconclusive**.- It is not preferred over CTCA for the initial anatomical assessment of **coronary artery patency**.*Myocardial perfusion scintigraphy (MPS)*- Like stress echo, MPS is a **second-line functional test** used when anatomical imaging is not feasible or to assess the **significance of known stenoses**.- It involves **ionizing radiation** and is generally more resource-intensive than the primary recommendation of CTCA.

Question 81: A 69-year-old man with heart failure and reduced ejection fraction (LVEF 28%) on optimal medical therapy including ramipril, bisoprolol, spironolactone, and sacubitril-valsartan presents for device consideration. His ECG shows sinus rhythm with heart rate 68 bpm, QRS duration 158 ms with left bundle branch block morphology, and he remains NYHA class III despite maximal tolerated medical therapy. His blood pressure is 112/68 mmHg and eGFR 52 mL/min/1.73m². Which device therapy is most appropriate?

A. Implantable cardioverter-defibrillator (ICD) only
B. Cardiac resynchronisation therapy with defibrillator (CRT-D) (Correct Answer)
C. Cardiac resynchronisation therapy pacemaker (CRT-P) only
D. Permanent pacemaker with rate-response function
E. Continue medical therapy and reassess after 3 months

Explanation: ***Cardiac resynchronisation therapy with defibrillator (CRT-D)*** - The patient meets clear criteria for **CRT** due to an **LVEF ≤35%** (28%), **NYHA class III** symptoms, and a **QRS duration ≥150 ms** (158 ms) with **LBBB morphology** while in sinus rhythm, despite optimal medical therapy. - A **defibrillator (CRT-D)** is essential because he is at high risk of sudden cardiac death and meets **primary prevention ICD** criteria with an LVEF ≤35%. *Implantable cardioverter-defibrillator (ICD) only* - An ICD alone provides protection against **ventricular arrhythmias** but does not address the underlying **mechanical dyssynchrony** caused by the wide QRS complex and LBBB. - Without the **biventricular pacing** of CRT, the patient would likely remain highly symptomatic in NYHA class III, as the pump function remains inefficient. *Cardiac resynchronisation therapy pacemaker (CRT-P) only* - While CRT-P provides the necessary **biventricular pacing** to improve cardiac output and symptoms, it lacks the ability to terminate life-threatening ventricular arrhythmias with a **defibrillator**. - CRT-P is typically reserved for patients who have contraindications to ICD implantation or those with an **anticipated short life expectancy** where the ICD benefit is less clear. *Permanent pacemaker with rate-response function* - A standard **single or dual-chamber pacemaker** is indicated for bradyarrhythmias, not for the treatment of systolic heart failure with significant dyssynchrony. - Conventional right ventricular pacing can actually **worsen heart failure** by increasing ventricular dyssynchrony, which is already a problem in this patient. *Continue medical therapy and reassess after 3 months* - Guidelines recommend device consideration after **3 months of optimal medical therapy (OMT)**; this patient is already on maximal guideline-directed medical therapy including **sacubitril-valsartan** and remains symptomatic. - Delaying intervention in a patient already on **quadruple therapy** with persistent severe dysfunction (LVEF 28%) and marked dyssynchrony would be inappropriate as he has met indications for advanced therapy.

Question 82: A 47-year-old woman from Pakistan presents with progressive dyspnoea over 2 years. Echocardiography shows thickened mitral valve leaflets with doming, restricted leaflet motion, commissural fusion, and a mitral valve area of 1.2 cm². There is moderate mitral regurgitation and mild subvalvular thickening. The left atrium is dilated at 5.2 cm. She is in atrial fibrillation with good rate control on bisoprolol. Her CHA₂DS₂-VASc score is 3. What is the most appropriate management strategy?

A. Percutaneous mitral balloon valvuloplasty
B. Surgical mitral valve replacement (Correct Answer)
C. Medical management with diuretics and anticoagulation only
D. Surgical mitral valve repair
E. MitraClip percutaneous mitral valve repair

Explanation: ***Surgical mitral valve replacement***- The patient has severe **mitral stenosis** (MVA 1.2 cm²) and **moderate mitral regurgitation** with significant rheumatic changes (subvalvular thickening, commissural fusion), necessitating intervention.- In such complex **rheumatic mitral valve disease** with significant regurgitation and subvalvular involvement, **surgical mitral valve replacement** offers the most durable and effective hemodynamic outcome.*Percutaneous mitral balloon valvuloplasty*- This procedure is contraindicated in patients with **moderate to severe mitral regurgitation** or significant **subvalvular disease**, both of which are present here.- A high **Wilkins score** (suggested by subvalvular thickening and leaflet changes) predicts poor outcomes and a high risk of procedural failure for balloon dilation.*Medical management with diuretics and anticoagulation only*- While diuretics and anticoagulation manage symptoms and prevent **thromboembolism** in atrial fibrillation, they do not address the **mechanical obstruction** of the mitral valve.- Conservative management alone is insufficient for a symptomatic patient with a **mitral valve area** of 1.2 cm² (moderate/severe stenosis) and progressive dyspnea.*Surgical mitral valve repair*- Surgical repair is technically difficult in **rheumatic mitral disease** because the valve tissue is often scarred, thickened, and prone to further calcification.- Repair is less durable than **replacement** in the setting of rheumatic fever, frequently leading to recurrent stenosis or regurgitation.*MitraClip percutaneous mitral valve repair*- **MitraClip** is specifically indicated for primary or secondary **mitral regurgitation**, not for treating **mitral stenosis** or commissural fusion.- Applying a clip to a stenotic valve would further reduce the **mitral valve area**, severely worsening the patient's condition.

Question 83: A 82-year-old woman is admitted with acute decompensated heart failure. She has severe symptomatic aortic stenosis with an aortic valve area of 0.7 cm², mean gradient 48 mmHg, and LVEF 32%. She has multiple comorbidities including COPD, previous stroke with residual left-sided weakness, and frailty. Her EuroSCORE II is 18%. After multidisciplinary team discussion, she is considered too high risk for surgical aortic valve replacement. What is the most appropriate management option?

A. Medical management with diuretics and afterload reduction
B. Transcatheter aortic valve implantation (TAVI) (Correct Answer)
C. Balloon aortic valvuloplasty as definitive treatment
D. Palliative care without further intervention
E. Ross procedure (pulmonary autograft)

Explanation: ***Transcatheter aortic valve implantation (TAVI)*** - **TAVI** is the preferred treatment for patients with **severe symptomatic aortic stenosis** who are deemed **high or prohibitive surgical risk** (EuroSCORE II 18%, frailty, and comorbidities). - Clinical trials have proven that TAVI significantly improves **survival outcomes** and quality of life compared to medical management in patients unsuitable for surgery. *Medical management with diuretics and afterload reduction* - Medical therapy provides only symptomatic relief and does not address the mechanical obstruction, resulting in a **50% 2-year mortality** rate for severe AS. - **Vasodilators** used for afterload reduction must be used with extreme caution in severe AS as they can cause severe **hypotension** and syncope. *Balloon aortic valvuloplasty as definitive treatment* - This procedure is typically used only as a **bridge to TAVI** or surgery because it has a very **high rate of restenosis** within 6-12 months. - It is not considered a **definitive treatment** due to its lack of long-term mortality benefit compared to valve replacement. *Palliative care without further intervention* - While the patient is frail, palliative care is only suggested if the patient’s **quality of life** is not expected to improve or if life expectancy is **less than one year** despite TAVI. - Given the acute decompensation, TAVI offers a potentially life-saving intervention that addresses the primary cause of her **heart failure**. *Ross procedure (pulmonary autograft)* - This is a complex surgery involving the transplantation of the patient's own **pulmonary valve** to the aortic position, which is far too invasive for a high-risk 82-year-old. - It is primarily reserved for **younger patients** or children to avoid the long-term complications of prosthetic valves and allow for growth.

Question 84: A 74-year-old man with paroxysmal atrial fibrillation presents for anticoagulation review. He has hypertension treated with amlodipine, and had a transient ischaemic attack 18 months ago with full recovery. His CHA₂DS₂-VASc score is 5. He has no history of bleeding. Blood tests show: Hb 142 g/L, platelets 245 × 10⁹/L, creatinine 168 μmol/L, eGFR 34 mL/min/1.73m². Which anticoagulation option is most appropriate?

A. Warfarin with target INR 2.0-3.0
B. Apixaban 5 mg twice daily
C. Apixaban 2.5 mg twice daily (Correct Answer)
D. Rivaroxaban 20 mg once daily
E. Edoxaban 60 mg once daily

Explanation: ***Apixaban 2.5 mg twice daily*** - Apixaban requires a dose reduction to 2.5 mg twice daily if a patient meets two of three criteria: **age ≥80**, **weight ≤60 kg**, or **serum creatinine ≥133 μmol/L**. - While this patient only strictly meets the **creatinine criterion** (168 μmol/L) based on the data provided, clinical guidelines often favor the **2.5 mg dose** in patients with significant **renal impairment** (eGFR 34 mL/min) to balance **stroke prevention** and **bleeding risk**. *Warfarin with target INR 2.0-3.0* - While effective, **Direct Oral Anticoagulants (DOACs)** are now generally preferred over **Warfarin** for non-valvular atrial fibrillation because they require less monitoring and have a better safety profile regarding **intracranial hemorrhage**. - Warfarin remains a valid option in **severe renal failure** (eGFR <15 mL/min), but since this patient's **eGFR is 34 mL/min**, a DOAC is usually the first-choice recommendation. *Apixaban 5 mg twice daily* - The standard **5 mg dose** may increase the risk of bleeding in this patient due to his **elevated creatinine** (168 μmol/L) and reduced **eGFR (34 mL/min)**. - Prescribing decisions for apixaban must carefully account for guidelines regarding **renal function** and metabolic clearance to avoid **drug accumulation** and adverse events. *Rivaroxaban 20 mg once daily* - The standard dose of **20 mg** is inappropriate for patients with a **CrCl between 15-49 mL/min**. - For a patient with an **eGFR of 34 mL/min**, a reduced dose of **15 mg once daily** would be required if Rivaroxaban were the chosen agent. *Edoxaban 60 mg once daily* - Similar to other DOACs, the standard **60 mg dose** must be reduced to **30 mg once daily** if the **CrCl is between 15-50 mL/min**. - Using the full dose in the context of an **eGFR of 34 mL/min** significantly increases the **bioavailability** of the drug and the subsequent risk of **major bleeding**.

Question 85: A 58-year-old woman with newly diagnosed heart failure and LVEF 35% has been established on ramipril 10 mg daily, bisoprolol 10 mg daily, and furosemide 40 mg daily. She remains symptomatic with NYHA class II-III symptoms. Her blood pressure is 118/68 mmHg, heart rate 64 bpm. Blood tests show sodium 138 mmol/L, potassium 4.4 mmol/L, creatinine 104 μmol/L, eGFR 56 mL/min/1.73m². She is in sinus rhythm. Which additional therapy would provide the greatest mortality benefit?

A. Add spironolactone 25 mg once daily (Correct Answer)
B. Add ivabradine 5 mg twice daily
C. Add digoxin 125 mcg once daily
D. Replace ramipril with sacubitril-valsartan 24/26 mg twice daily
E. Add hydralazine 25 mg three times daily and isosorbide dinitrate 20 mg three times daily

Explanation: ***Add spironolactone 25 mg once daily*** - In patients with **HFrEF** (LVEF ≤ 35%) who remain symptomatic despite optimal doses of an **ACE inhibitor** and **beta-blocker**, adding a **Mineralocorticoid Receptor Antagonist (MRA)** like spironolactone provides a significant **mortality benefit**. - This patient satisfies the initiation criteria as her **potassium** is < 5.0 mmol/L and **eGFR** is > 30 mL/min/1.73m². *Add ivabradine 5 mg twice daily* - **Ivabradine** is indicated for symptomatic HFrEF only if the patient is in **sinus rhythm** with a resting heart rate **≥ 70 bpm** (or ≥ 75 bpm per some guidelines) despite maximum tolerated beta-blockers. - Since this patient's heart rate is already well-controlled at **64 bpm**, ivabradine would not be appropriate or beneficial. *Add digoxin 125 mcg once daily* - **Digoxin** can be used to improve symptoms and reduce the rate of **hospitalization** in patients with worsening heart failure. - However, it has not been shown to provide a **mortality benefit** in clinical trials like the DIG trial. *Replace ramipril with sacubitril-valsartan 24/26 mg twice daily* - **Sacubitril-valsartan (ARNI)** is a potent therapy, but clinical guidelines traditionally recommend adding an **MRA** first if the patient is still on a stable dose of ACEi/ARB. - Initiating an ARNI requires a mandatory **36-hour washout period** from ramipril to avoid the risk of **angioedema**. *Add hydralazine 25 mg three times daily and isosorbide dinitrate 20 mg three times daily* - The combination of **hydralazine and isosorbide dinitrate** is specifically recommended for **Black patients** with NYHA class III-IV symptoms as an adjunct therapy. - For other patients, it is typically reserved as an alternative when **ACE inhibitors or ARBs** are not tolerated due to renal impairment or hyperkalemia.

Question 86: A 64-year-old man with ischaemic cardiomyopathy and LVEF of 30% is reviewed in the heart failure clinic. He was commenced on ramipril 2.5 mg daily 6 weeks ago, which was increased to 5 mg daily 3 weeks ago. His current blood pressure is 126/74 mmHg and heart rate 88 bpm. Blood tests show sodium 139 mmol/L, potassium 4.6 mmol/L, creatinine 98 μmol/L (baseline 92 μmol/L), eGFR 68 mL/min/1.73m². He remains mildly breathless on moderate exertion (NYHA class II). What is the most appropriate next step in his management?

A. Continue ramipril 5 mg and review in 3 months
B. Increase ramipril to 10 mg daily
C. Add bisoprolol starting at 1.25 mg once daily (Correct Answer)
D. Add spironolactone 25 mg once daily
E. Add sacubitril-valsartan 24/26 mg twice daily

Explanation: ***Add bisoprolol starting at 1.25 mg once daily*** - For patients with **HFrEF** (LVEF < 40%), clinical guidelines recommend initiating both an **ACE inhibitor** and a **beta-blocker** as first-line foundational therapy. - Since the patient is stable on ramipril and has an elevated heart rate of **88 bpm**, adding a low-dose beta-blocker is the most important next step to reduce **mortality** and **hospitalization** risk. *Continue ramipril 5 mg and review in 3 months* - This approach is inappropriate as the patient remains symptomatic (**NYHA class II**) and is currently missing a life-prolonging **beta-blocker**. - Heart failure management requires active **up-titration** and addition of core medications rather than passive monitoring when the patient is not on optimal therapy. *Increase ramipril to 10 mg daily* - While increasing the ACE inhibitor to the **target dose** is eventually necessary, guidelines prioritize initiating both an ACE inhibitor and a **beta-blocker** first over maximum titration of one agent alone. - Introducing the beta-blocker now will better address the patient's **resting tachycardia** and provide additional sympathetic blockade benefit. *Add spironolactone 25 mg once daily* - **Mineralocorticoid receptor antagonists (MRAs)** like spironolactone are typically added as the third-line step for patients who remain symptomatic despite optimal doses of **ACE inhibitors** and **beta-blockers**. - The patient must first be established on the foundational **beta-blocker** therapy before advancing to MRA treatment. *Add sacubitril-valsartan 24/26 mg twice daily* - **ARNI** therapy (sacubitril-valsartan) is indicated as a **replacement** for an ACE inhibitor or ARB in patients who remain symptomatic despite an optimal dose of ACEI/ARB **and** a beta-blocker. - It is not indicated at this stage because the patient has not yet been started on a **beta-blocker**, which is a prerequisite for transition to ARNI.

Question 87: A 71-year-old man presents with a 3-hour history of chest pain. His ECG shows ST-segment depression of 2 mm in leads V4-V6 and troponin I is elevated at 2850 ng/L (normal <40 ng/L). He has been commenced on aspirin, ticagrelor, fondaparinux, and intravenous morphine. His GRACE score is calculated at 142. He has stable observations with BP 135/82 mmHg, heart rate 78 bpm, and oxygen saturations 97% on room air. What is the most appropriate timeframe for coronary angiography?

A. Immediate angiography within 2 hours
B. Urgent angiography within 24 hours (Correct Answer)
C. Early angiography within 72 hours
D. Angiography during the same hospital admission before discharge
E. Outpatient angiography within 2 weeks if symptoms persist

Explanation: ***Urgent angiography within 24 hours***- This patient is diagnosed with an **NSTEMI** (ST-segment depression, elevated troponin) and has a **GRACE score of 142**, classifying him as **high risk** (GRACE >140).- Current clinical guidelines recommend an **urgent invasive strategy** within 24 hours for patients with NSTEMI and high-risk features like dynamic ST-segment changes or a high GRACE score.*Immediate angiography within 2 hours*- This timeframe is reserved for **very high-risk** patients exhibiting **hemodynamic instability**, cardiogenic shock, life-threatening arrhythmias, or refractory chest pain.- This patient is currently **stable** with normal vital signs and no signs of acute heart failure or ongoing ischemia.*Early angiography within 72 hours*- This timeframe is appropriate for **intermediate-risk** patients with a GRACE score typically between 109 and 140.- Since this patient's GRACE score is **142**, he falls into the high-risk category and requires a more accelerated intervention than the 72-hour window.*Angiography during the same hospital admission before discharge*- This approach is generally reserved for **low-risk** patients (GRACE <109) who do not have high-risk features.- For a high-risk NSTEMI, delaying angiography to this extent is associated with a higher rate of **recurrent ischemic events** and worse outcomes.*Outpatient angiography within 2 weeks if symptoms persist*- This is inappropriate for an acute presentation of **NSTEMI** with elevated cardiac biomarkers and significant ECG changes.- Acute coronary syndromes require **inpatient management** and prompt invasive risk stratification.

Question 88: A 56-year-old woman presents to the Emergency Department with 45 minutes of severe central chest pain. Her ECG shows ST-segment elevation of 3 mm in leads II, III, and aVF, with ST-segment depression in leads I and aVL. The nearest cardiac catheterisation laboratory is 90 minutes away by ambulance. She has received aspirin 300 mg, ticagrelor 180 mg, and morphine. Her blood pressure is 118/72 mmHg and heart rate 68 bpm. What is the most appropriate immediate management?

A. Arrange immediate transfer for primary percutaneous coronary intervention (Correct Answer)
B. Administer fibrinolytic therapy immediately and transfer for angiography within 3-24 hours
C. Administer fibrinolytic therapy and arrange transfer only if this fails
D. Arrange urgent echocardiography before deciding on reperfusion strategy
E. Commence intravenous heparin infusion and transfer for angiography within 24 hours

Explanation: ***Arrange immediate transfer for primary percutaneous coronary intervention*** - **Primary PCI** is the gold standard reperfusion strategy for **STEMI** if it can be performed within **120 minutes** of the time fibrinolysis could have been administered. - This patient presents with an **inferior STEMI** and the travel time is **90 minutes**, which comfortably falls within the recommended therapeutic window for superior clinical outcomes. *Administer fibrinolytic therapy immediately and transfer for angiography within 3-24 hours* - **Fibrinolysis** is only indicated if **Primary PCI** cannot be delivered within the **120-minute** timeframe from the diagnosis of STEMI. - This "pharmaco-invasive" strategy is a second-line option and is associated with a higher risk of **intracranial haemorrhage** compared to PCI. *Administer fibrinolytic therapy and arrange transfer only if this fails* - All STEMI patients who receive fibrinolysis require transfer to a **PCI-capable centre** regardless of the initial result for potential **rescue PCI** or early angiography. - Delaying transfer until "failure" is confirmed increases the risk of **myocardial necrosis** and poor long-term outcomes. *Arrange urgent echocardiography before deciding on reperfusion strategy* - **Reperfusion therapy** should never be delayed for imaging if the diagnosis of **STEMI** is clear on a standard 12-lead **ECG**. - While echocardiography can identify **wall motion abnormalities**, "time is muscle," and the focus must remain on minimizing the **door-to-balloon** time. *Commence intravenous heparin infusion and transfer for angiography within 24 hours* - This management plan is more appropriate for **NSTEMI** or unstable angina, not for an **ST-elevation MI** requiring immediate reperfusion. - **Heparin** alone does not provide definitive mechanical or pharmacological **coronary recanalisation** needed for a transmural infarction.

Question 89: A 61-year-old man with stable angina is being managed in the cardiology clinic. He experiences chest discomfort twice weekly during moderate exertion, relieved by rest within 5 minutes. He is currently taking aspirin 75 mg, atorvastatin 80 mg, and bisoprolol 5 mg once daily. His resting heart rate is 72 bpm and blood pressure is 128/76 mmHg. He reports that sublingual GTN provides good symptom relief. What is the most appropriate next step in optimising his antianginal therapy?

A. Increase bisoprolol to 10 mg once daily (Correct Answer)
B. Add amlodipine 5 mg once daily
C. Add ivabradine 5 mg twice daily
D. Add isosorbide mononitrate 30 mg once daily
E. Add nicorandil 10 mg twice daily

Explanation: ***Increase bisoprolol to 10 mg once daily*** - According to guidelines, the initial step in managing stable angina is to **titrate the first-line antianginal agent** (beta-blocker) to its maximum tolerated dose to achieve optimal symptom control. - The patient's resting heart rate of **72 bpm** is above the optimal target range (typically 55-60 bpm for angina relief), indicating room for further dose escalation to reduce myocardial oxygen demand and improve symptoms. *Add amlodipine 5 mg once daily* - Adding a second antianginal agent like a **calcium channel blocker** is generally considered only after the initial first-line medication (beta-blocker) has been titrated to its **maximum tolerated dose**. - As the bisoprolol dose has not yet been optimized, introducing an additional drug at this stage is premature and could increase the risk of adverse effects. *Add ivabradine 5 mg twice daily* - **Ivabradine** is typically reserved for patients who cannot tolerate or have contraindications to beta-blockers, or whose heart rate remains elevated (**>70 bpm**) despite receiving the **maximum tolerated dose** of beta-blockers. - Since the current beta-blocker dose has not been maximized, ivabradine is not the most appropriate immediate next step in therapy optimization. *Add isosorbide mononitrate 30 mg once daily* - **Long-acting nitrates** are generally considered **second-line** agents for angina symptom control, typically added if symptoms persist despite optimized beta-blocker and/or calcium channel blocker therapy. - Optimizing the existing beta-blocker is the preferred approach before introducing nitrates, which carry their own side effects like **headaches** and potential for **nitrate tolerance**. *Add nicorandil 10 mg twice daily* - **Nicorandil** is typically used as a **third-line** antianginal agent or as an alternative when other therapies are insufficient or contraindicated. - Given that the patient's existing beta-blocker has not been titrated to its maximum effective dose, adding nicorandil is not the most appropriate next step in optimizing therapy.

Question 90: A 67-year-old man with type 2 diabetes and chronic kidney disease stage 3b (eGFR 38 mL/min/1.73m²) presents for cardiovascular risk assessment. He is currently taking metformin, ramipril, and atorvastatin 20 mg. His blood pressure is 134/78 mmHg. His lipid profile shows total cholesterol 4.8 mmol/L, LDL 2.6 mmol/L, HDL 1.1 mmol/L, non-HDL cholesterol 3.7 mmol/L. He achieved only a 32% reduction in non-HDL cholesterol from baseline. What modification to his lipid-lowering therapy is most appropriate?

A. Add ezetimibe 10 mg once daily
B. Continue current dose of atorvastatin as target achieved
C. Increase atorvastatin to 40 mg once daily (Correct Answer)
D. Switch to rosuvastatin 20 mg once daily
E. Add fenofibrate 200 mg once daily

Explanation: ***Increase atorvastatin to 40 mg once daily*** - NICE guidelines recommend aiming for at least a **40% reduction in non-HDL cholesterol** for cardiovascular risk reduction; this patient has only achieved a **32% reduction**. - Dose escalation of the current statin is the preferred first step before adding secondary agents, and **atorvastatin 40 mg** is safe in patients with **CKD stage 3b (eGFR 38)**. *Add ezetimibe 10 mg once daily* - This agent is typically reserved for patients who have already reached the **maximum tolerated dose** of a statin or are intolerant to statins. - Since the patient is only on **20 mg atorvastatin**, there is room to increase the statin dose first to achieve the treatment target. *Continue current dose of atorvastatin as target achieved* - The non-HDL cholesterol reduction is currently **32%**, which falls short of the recommended target of **>40%** reduction from baseline. - In patients with high cardiovascular risk factors like **CKD and diabetes**, achieving target lipid levels is crucial for secondary prevention outcomes. *Switch to rosuvastatin 20 mg once daily* - Switching statins is generally indicated only if the patient experiences **intolerable side effects** or fails to respond despite dose titration. - **Rosuvastatin** requires careful dosing and dose limits in patients with **renal impairment**, whereas atorvastatin is better tolerated in chronic kidney disease. *Add fenofibrate 200 mg once daily* - Fenofibrates are primarily used for severe **hypertriglyceridaemia** and do not provide the same cardiovascular risk reduction as statins. - Fibrates carry an increased risk of **myopathy** when combined with statins and require extreme caution or are contraindicated in **chronic kidney disease**.

Question 91: A 59-year-old woman with hypertension is reviewed in clinic. She is currently taking amlodipine 10 mg daily. Her blood pressure today is 148/92 mmHg. Home blood pressure monitoring over the past week shows an average of 146/90 mmHg. She has no history of diabetes, and her potassium is 4.2 mmol/L and eGFR is 68 mL/min/1.73m². She is of White British ethnicity. What is the most appropriate next step in her antihypertensive management?

A. Add ramipril to her current therapy (Correct Answer)
B. Replace amlodipine with ramipril
C. Add indapamide to her current therapy
D. Add doxazosin to her current therapy
E. Increase amlodipine to 15 mg daily

Explanation: ***Add ramipril to her current therapy***- According to **NICE guidelines (NG136)**, for a patient aged over 55 or of White British ethnicity without diabetes, initial therapy is a **Calcium Channel Blocker (CCB)**. As her blood pressure remains uncontrolled despite optimal CCB monotherapy, the next step (Step 2) is to **add an ACE inhibitor** or ARB.- Her current blood pressure of 148/92 mmHg (clinic) and 146/90 mmHg (home) indicates inadequate control, warranting the addition of a second-line agent like **ramipril** to achieve the target blood pressure of less than **140/90 mmHg** (clinic) or **135/85 mmHg** (home).*Replace amlodipine with ramipril*- Hypertension treatment usually follows a **stepwise approach**, adding new agents rather than replacing existing ones, especially when the current medication is providing some benefit.- Replacing amlodipine would mean losing the **partial blood pressure control** achieved by the CCB and restarting therapy, which is less effective than combination therapy in uncontrolled hypertension.*Add indapamide to her current therapy*- **Thiazide-like diuretics** such as indapamide are recommended at **Step 3** of the NICE hypertension algorithm.- Step 3 therapy involves a **combination** of an ACE inhibitor/ARB, a CCB, and a thiazide-like diuretic, which is not appropriate at this current stage (Step 2).*Add doxazosin to her current therapy*- **Alpha-blockers** like doxazosin are considered in **Step 4** for the management of **resistant hypertension**.- Resistant hypertension is defined as uncontrolled blood pressure despite treatment with optimal doses of an **ACE inhibitor/ARB, CCB, and thiazide-like diuretic**, which is not the case here.*Increase amlodipine to 15 mg daily*- The **maximum licensed daily dose** of amlodipine for the treatment of hypertension is **10 mg**.- Increasing the dose beyond 10 mg is not recommended due to limited additional therapeutic benefit and an increased risk of **dose-dependent side effects**, such as peripheral edema.

Question 92: A 42-year-old man with a family history of premature coronary artery disease attends for a health check. His blood pressure is 138/84 mmHg, total cholesterol 6.2 mmol/L, HDL 0.9 mmol/L. He is a non-smoker with no diabetes. His 10-year cardiovascular risk score using QRISK3 is calculated. Which of the following interventions should be offered for primary prevention according to NICE guidelines?

A. Atorvastatin 20 mg once daily if QRISK3 ≥10% (Correct Answer)
B. Atorvastatin 40 mg once daily if QRISK3 ≥10%
C. Atorvastatin 80 mg once daily if QRISK3 ≥10%
D. Simvastatin 40 mg once daily if QRISK3 ≥20%
E. Pravastatin 40 mg once daily if QRISK3 ≥10%

Explanation: ***Atorvastatin 20 mg once daily if QRISK3 ≥10%***- According to **NICE guidelines**, **Atorvastatin 20 mg** is the first-line medication recommended for the **primary prevention** of cardiovascular disease in adults.- Intervention is indicated when the calculated **QRISK3 score** is **10% or greater**, indicating a significant 10-year risk of developing CVD.*Atorvastatin 40 mg once daily if QRISK3 ≥10%*- A dose of **40 mg** is higher than the standard starting dose recommended for **primary prevention** in the general population.- Higher doses like this are typically considered only if the initial **20 mg dose** fails to achieve a **>40% reduction** in non-HDL cholesterol.*Atorvastatin 80 mg once daily if QRISK3 ≥10%*- **Atorvastatin 80 mg** is specifically indicated for **secondary prevention** in patients with established CVD, such as those post-myocardial infarction.- Initiating primary prevention at this dose is inappropriate due to an increased risk of **side effects** without evidence-based necessity.*Simvastatin 40 mg once daily if QRISK3 ≥20%*- **Simvastatin** is no longer the preferred first-line statin due to its shorter half-life and more frequent **drug-drug interactions** compared to atorvastatin.- The threshold for intervention has been lowered from **20% to 10%** in modern NICE guidelines to broaden the population benefiting from therapy.*Pravastatin 40 mg once daily if QRISK3 ≥10%*- **Pravastatin** is considered a lower-potency statin and is not the first-line choice for **CVD primary prevention** under current NICE clinical standards.- It is generally reserved for patients who cannot tolerate **high-intensity statins** like atorvastatin due to muscle-related side effects.

Question 93: A 75-year-old man is admitted with breathlessness. Clinical examination reveals elevated jugular venous pressure, bilateral basal crackles, and peripheral oedema. Echocardiography demonstrates severe mitral regurgitation with a flail posterior mitral valve leaflet and dilated left atrium (52 mm). LVEF is 64% and LV end-systolic dimension is 42 mm. He is in sinus rhythm. He has well-controlled hypertension and his functional status was excellent prior to this admission (independent, walks 2 miles daily). What is the mechanism of mitral regurgitation?

A. Degenerative (myxomatous) disease (Correct Answer)
B. Rheumatic heart disease
C. Functional mitral regurgitation
D. Infective endocarditis
E. Ischaemic mitral regurgitation

Explanation: ***Degenerative (myxomatous) disease***- The presence of a **flail posterior mitral valve leaflet** due to chordal rupture is the hallmark of **myxomatous degeneration**, which is the most common cause of primary mitral regurgitation in older patients.- It leads to **Carpentier Type II** dysfunction where the leaflet tip extends into the left atrium during systole, consistent with this patient's acute-on-chronic presentation and **preserved LVEF**.*Rheumatic heart disease*- Typically presents with **commissural fusion**, leaflet thickening, and restricted motion (**Carpentier Type IIIa**), rather than a flail leaflet.- Often involves a history of rheumatic fever and frequently affects the **aortic valve** concurrently, which is not described here.*Functional mitral regurgitation*- Occurs in structurally normal valves because of **left ventricular dilatation** or remodeling that prevents proper leaflet coaptation (**Carpentier Type I or IIIb**).- This is unlikely here as the patient has a **preserved LVEF (64%)** and a primary structural abnormality (flail leaflet).*Infective endocarditis*- While it can cause valve destruction and flail leaflets, it typically presents with **systemic symptoms** like fever, weight loss, and **vegetations** on echocardiography.- There is no clinical evidence of infection or leukocytosis in this patient's history to support this diagnosis.*Ischaemic mitral regurgitation*- Usually results from **papillary muscle dysfunction** or rupture following a myocardial infarction, or from **regional wall motion abnormalities**.- This patient has no history of ischaemic heart disease and maintains a **normal ejection fraction**, making an acute ischaemic event causing a flail leaflet less probable.

Question 94: A 68-year-old woman with chronic kidney disease stage 4 (eGFR 22 mL/min/1.73m²) is diagnosed with heart failure. Echocardiography shows LVEF 34% with global hypokinesis. She is commenced on bisoprolol 1.25 mg once daily which is uptitrated to 5 mg once daily. An ACE inhibitor is considered. Baseline blood tests show: potassium 5.1 mmol/L, creatinine 246 μmol/L. What is the most appropriate approach to ACE inhibitor initiation?

A. Start ramipril 1.25 mg once daily and check U&Es after 1-2 weeks (Correct Answer)
B. Avoid ACE inhibitor due to CKD stage 4
C. Start ramipril 2.5 mg once daily and check U&Es after 1 month
D. Start sacubitril-valsartan instead of ACE inhibitor
E. Wait until potassium falls below 5.0 mmol/L before starting

Explanation: ***Start ramipril 1.25 mg once daily and check U&Es after 1-2 weeks*** - In patients with **advanced CKD** (eGFR <30 mL/min/1.73m²), ACE inhibitors should be started at a **very low dose** (e.g., ramipril 1.25 mg) and uptitrated slowly to minimize risks of acute kidney injury and hyperkalemia. - **Urea, electrolytes, and creatinine (U&Es)** must be monitored closely, typically **1 to 2 weeks** after initiation or dose changes, to ensure the creatinine rise is <30% and potassium remains <6.0 mmol/L. *Avoid ACE inhibitor due to CKD stage 4* - ACE inhibitors provide significant **mortality benefits** in heart failure with reduced ejection fraction (**HFrEF**) and should not be withheld based on CKD alone unless potassium is >5.5 mmol/L or there is severe renal artery stenosis. - Chronic kidney disease is often an indication for, rather than a contraindication to, ACE inhibition due to its **renoprotective effects** on proteinuria, though close monitoring is required. *Start ramipril 2.5 mg once daily and check U&Es after 1 month* - A starting dose of **2.5 mg** is considered standard for many, but in the context of **CKD Stage 4**, starting at the lowest possible dose (1.25 mg) is safer to prevent precipitous drops in GFR. - Waiting **one month** for follow-up blood tests is too long for a high-risk patient with low eGFR; early monitoring at **1-2 weeks** is the clinical standard. *Start sacubitril-valsartan instead of ACE inhibitor* - Current guidelines recommend stabilizing the patient on an **ACE inhibitor or ARB** first before switching to **sacubitril-valsartan** (ARNI) to ensure tolerance to RAAS inhibition. - ARNI initiation requires a **36-hour washout period** if switching from an ACE inhibitor to avoid angioedema and is generally not used as the first-line RAAS agent in newly diagnosed HFrEF. *Wait until potassium falls below 5.0 mmol/L before starting* - Initiation of an ACE inhibitor is generally considered safe if the baseline **potassium is <5.5 mmol/L**; therefore, a level of 5.1 mmol/L does not require a delay in treatment. - Delaying life-saving therapy for HFrEF to reach a specific potassium threshold under 5.0 mmol/L unnecessarily increases the patient's **cardiovascular risk**.

Question 95: A 63-year-old man attends for cardiovascular risk assessment. He is a current smoker with no other cardiovascular risk factors. His blood pressure is 132/78 mmHg, total cholesterol is 6.2 mmol/L, HDL 1.1 mmol/L, and non-HDL cholesterol is 5.1 mmol/L. His QRISK3 score is calculated as 11.4%. What is the most appropriate management regarding his cardiovascular risk?

A. Offer atorvastatin 20 mg and lifestyle advice (Correct Answer)
B. Provide lifestyle advice only and reassess in 5 years
C. Offer atorvastatin 80 mg and lifestyle advice
D. Arrange further investigations including CT calcium score
E. Provide lifestyle advice and reassess QRISK3 in 1 year

Explanation: ***Offer atorvastatin 20 mg and lifestyle advice*** - According to **NICE guidelines**, primary prevention with statins should be offered to individuals with a **QRISK3 score ≥10%**. - The recommended first-line treatment for **primary prevention** of cardiovascular disease is **atorvastatin 20 mg** daily alongside lifestyle modifications, especially given the **elevated non-HDL cholesterol** and smoking status. *Provide lifestyle advice only and reassess in 5 years* - While lifestyle advice is essential, it is insufficient as the patient's **QRISK3 score (11.4%)** has already exceeded the **10% threshold** for pharmacological intervention. - Delaying treatment for five years in a high-risk patient significantly increases the cumulative risk of a **major adverse cardiovascular event (MACE)**. *Offer atorvastatin 80 mg and lifestyle advice* - High-dose **atorvastatin 80 mg** is primarily indicated for **secondary prevention** in patients with established cardiovascular disease, or for very high-risk primary prevention, not typically as an initial dose for this presentation. - Starting at such a high dose for primary prevention increases the risk of side effects like **myalgia** and **liver enzyme elevation** without clear necessity. *Arrange further investigations including CT calcium score* - A **CT calcium score** is generally reserved for cases where clinical risk is uncertain or when the **QRISK score** sits near the threshold and the decision to treat is unclear. - Because this patient's score is clearly **above 10%**, the indication for treatment is already established, making further imaging unnecessary for management. *Provide lifestyle advice and reassess QRISK3 in 1 year* - Reassessing in one year unnecessarily delays the initiation of **statin therapy** for a patient who currently meets the diagnostic criteria for intervention. - Management should prioritize immediate risk reduction through **smoking cessation** and lipid-lowering therapy given the current **elevated QRISK3 score** and **non-HDL cholesterol**.

Question 96: A 51-year-old woman presents to the Emergency Department with 2 hours of central chest pain. She has a history of systemic lupus erythematosus (SLE) treated with hydroxychloroquine and intermittent prednisolone. ECG shows ST-segment elevation of 3 mm in leads V2-V4. High-sensitivity troponin I is 2,840 ng/L (normal <16 ng/L). She undergoes emergency angiography which shows normal coronary arteries with no evidence of atherosclerosis. What is the most likely diagnosis?

A. Coronary vasospasm
B. Coronary artery dissection
C. Myocarditis (Correct Answer)
D. Takotsubo cardiomyopathy
E. Type 2 myocardial infarction

Explanation: ***Myocarditis*** - In patients with **Systemic Lupus Erythematosus (SLE)**, immune-mediated myocardial inflammation often mimics an acute myocardial infarction, presenting with **ST-segment elevation** and significant **troponin elevation**. - The presence of **normal coronary arteries** on angiography in a symptomatic patient with cardiac enzyme leak and ECG changes (MINOCA) strongly points toward **myocarditis** as a common SLE-related cardiac manifestation. *Coronary vasospasm* - This condition involves transient narrowing of the arteries; while it can cause **ST elevation**, it typically does not result in such a massive and sustained **troponin rise** (2,840 ng/L). - Vasospasm is usually identified during angiography through clinical observation or provocation testing with **acetylcholine**, which was not reported here. *Coronary artery dissection* - **Spontaneous Coronary Artery Dissection (SCAD)** is a known cause of MI in females, but it would typically show an **intimal flap** or an obstructive hematoma on **emergency angiography**. - This patient's coronary arteries were specifically described as **normal**, which effectively rules out the structural disruption seen in dissection. *Takotsubo cardiomyopathy* - Often triggered by **emotional or physical stress**, this condition classically presents with **apical ballooning** and wall motion abnormalities that transcend a single vascular territory. - While it presents with normal coronaries, it is not a direct complication of **SLE** compared to the high prevalence of inflammatory **myocarditis** in lupus patients. *Type 2 myocardial infarction* - This occurs due to **oxygen supply-demand mismatch** caused by conditions like severe anemia, sepsis, or tachyarrhythmias, none of which are described in this clinical vignette. - It is characterized by a rise and fall of troponin without **primary coronary events**, but the focal ST elevation (V2-V4) is less typical than diffuse changes in a demand-related event.

Question 97: A 70-year-old woman with heart failure is reviewed in clinic. She has heart failure with preserved ejection fraction (HFpEF) with LVEF 56% on recent echocardiography. She remains breathless on minimal exertion (NYHA class III) despite maximal diuretic therapy. She has a history of type 2 diabetes, hypertension, and obesity (BMI 34 kg/m²). Her blood pressure is 142/88 mmHg and heart rate 78 bpm in sinus rhythm. Which medication has the strongest evidence for reducing heart failure hospitalisations in this patient?

A. SGLT2 inhibitor (Correct Answer)
B. Spironolactone
C. ACE inhibitor
D. Sacubitril-valsartan
E. Beta-blocker

Explanation: ***SGLT2 inhibitor***- Evidence from trials like **EMPEROR-Preserved** and **DELIVER** demonstrates that **SGLT2 inhibitors** significantly reduce the risk of **heart failure hospitalizations** in patients with HFpEF, regardless of diabetes status.- These agents are now considered foundational therapy in **ESC and ACC/AHA guidelines** for HFpEF (LVEF ≥50%), making them the strongest choice for this patient.*Spironolactone*- The **TOPCAT trial** showed a reduction in heart failure hospitalizations but failed to show a significant benefit for the primary composite endpoint of **cardiovascular mortality**.- While useful as an add-on therapy, its evidence base for HFpEF is considered weaker and more geographically inconsistent compared to SGLT2 inhibitors.*ACE inhibitor*- Large-scale trials such as **PEP-CHF** (perindopril) failed to demonstrate a significant reduction in long-term mortality or cardiovascular outcomes in HFpEF.- While indicated for managing this patient's **hypertension**, they do not carry the specific primary evidence for reducing heart failure events in the HFpEF population.*Sacubitril-valsartan*- The **PARAGON-HF trial** narrowly missed its primary endpoint, showing only a marginal benefit that was more pronounced in women and those with an **LVEF at the lower end** of the HFpEF range.- It is not currently the first-line choice for reducing hospitalizations in a patient with a confirmed **LVEF of 56%**.*Beta-blocker*- There is no high-quality clinical trial evidence to suggest that **beta-blockers** improve mortality or reduce hospitalizations in patients with HFpEF.- They are generally only recommended in this population if required for secondary indications like **atrial fibrillation** or **ischemic heart disease**.

Question 98: A 56-year-old man with newly diagnosed paroxysmal atrial fibrillation is being considered for rhythm control. He has episodes lasting 2-6 hours occurring 2-3 times per week. His echocardiogram shows normal left ventricular function and no structural heart disease. He has no history of ischaemic heart disease. His blood pressure is 128/76 mmHg and resting heart rate is 68 bpm in sinus rhythm. Which anti-arrhythmic medication is most appropriate for rhythm control?

A. Flecainide (Correct Answer)
B. Amiodarone
C. Sotalol
D. Digoxin
E. Verapamil

Explanation: ***Flecainide*** - **Flecainide** is a first-line agent for rhythm control in patients with paroxysmal atrial fibrillation who have **no structural heart disease** or ischemic heart disease. - As a **Class Ic anti-arrhythmic**, it is highly effective at maintaining sinus rhythm but must be avoided in those with **coronary artery disease** due to the risk of pro-arrhythmia. *Amiodarone* - While highly effective, **Amiodarone** is generally reserved for patients with significant **structural heart disease** or when other agents have failed. - It has a high incidence of long-term toxicities, including **pulmonary fibrosis**, **thyroid dysfunction**, and **hepatotoxicity**. *Sotalol* - **Sotalol** has both Class II (beta-blocking) and Class III properties but carries a significant risk of **QT interval prolongation** and Torsades de Pointes. - It is less effective than flecainide for rhythm control and requires close monitoring of **renal function** and electrolytes. *Digoxin* - **Digoxin** is strictly a **rate control** agent that acts by slowing conduction through the AV node; it does not convert or maintain sinus rhythm. - It is particularly ineffective at controlling heart rate during **exercise** or high-sympathetic states, making it unsuitable for paroxysmal AF rhythm management. *Verapamil* - **Verapamil** is a non-dihydropyridine calcium channel blocker used for **rate control** by increasing the refractory period of the AV node. - It has no role in **rhythm control** (cardioversion or maintenance of sinus rhythm) in patients with atrial fibrillation.

Question 99: A 77-year-old man presents with progressive exertional dyspnoea over 6 months. Examination reveals a slow-rising pulse, narrow pulse pressure, and an ejection systolic murmur radiating to the carotids. Echocardiography confirms severe aortic stenosis with a valve area of 0.7 cm², mean pressure gradient of 48 mmHg, and preserved LVEF of 58%. He has significant frailty with reduced mobility and multiple comorbidities. Coronary angiography shows non-obstructive coronary disease. What is the most appropriate definitive management?

A. Transcatheter aortic valve implantation (TAVI) (Correct Answer)
B. Surgical aortic valve replacement
C. Medical management with diuretics
D. Balloon aortic valvuloplasty
E. Cardiac resynchronisation therapy

Explanation: ***Transcatheter aortic valve implantation (TAVI)*** - **TAVI** is the preferred treatment for patients over **75 years of age** or those with **significant frailty** and high surgical risk, as it is less invasive than open surgery. - The patient has symptomatic **severe aortic stenosis** (mean gradient >40 mmHg, valve area <1.0 cm²), which requires definitive intervention to improve survival. *Surgical aortic valve replacement* - While a standard treatment for severe aortic stenosis, it is often avoided in patients with **multiple comorbidities** and **significant frailty** due to high operative risk. - Modern guidelines increasingly favor **TAVI** over surgical replacement in elderly cohorts even when surgical risk is intermediate. *Medical management with diuretics* - Medical therapy does not address the underlying **mechanical obstruction** and is associated with a **50% mortality rate** at 2 years once symptoms develop. - Diuretics may offer temporary symptomatic relief for **heart failure** symptoms but are not a definitive therapy for severe valvular disease. *Balloon aortic valvuloplasty* - This procedure typically provides only **temporary relief** as the valve frequently restenoses within 6 to 12 months. - It is generally reserved as a **bridge to definitive therapy** (like TAVI) or for palliative care in patients who are hemodynamically unstable. *Cardiac resynchronisation therapy* - This intervention is indicated for patients with **reduced LVEF** and specific conduction abnormalities like **left bundle branch block**. - It has no role in the primary management of **severe aortic stenosis** and would not address the patient's outflow obstruction.

Question 100: A 44-year-old woman who emigrated from India 15 years ago presents with progressive dyspnoea and orthopnoea. She has an early diastolic murmur best heard at the left sternal edge when sitting forward. Echocardiography shows severe aortic regurgitation with a dilated left ventricle. LVEF is 48%, left ventricular end-systolic diameter is 52 mm. She is asymptomatic at rest but becomes breathless after climbing one flight of stairs. What is the most appropriate management?

A. Aortic valve replacement (Correct Answer)
B. ACE inhibitor therapy and annual echocardiography
C. Diuretic therapy and symptom monitoring
D. Cardiac MRI for tissue characterisation
E. Exercise stress testing

Explanation: ***Aortic valve replacement***- This patient has **severe aortic regurgitation (AR)** and meets surgical criteria due to the presence of **symptoms** (dyspnoea and orthopnoea) and an **LVEF <50%** (48% in this case).- Even if symptoms were absent, an **LV end-systolic diameter (LVESD) >50 mm** (measured here as 52 mm) is an independent indication for surgery to prevent irreversible myocardial damage.*ACE inhibitor therapy and annual echocardiography*- While **ACE inhibitors** can manage hypertension associated with AR, they do not delay the need for surgery once **Class I surgical indications** are met.- Annual monitoring is inappropriate for this patient because she has already developed **LV dysfunction** and clinical symptoms requiring urgent intervention.*Diuretic therapy and symptom monitoring*- **Diuretics** may provide temporary symptomatic relief for pulmonary congestion but do not address the underlying **valvular mechanical defect**.- Delaying surgery for symptom monitoring in a patient with a **dilated ventricle** and low LVEF increases the risk of **permanent heart failure**.*Cardiac MRI for tissue characterisation*- **Echocardiography** has already clearly defined the severity of the AR and the resulting **ventricular secondary changes**, making MRI redundant for the primary diagnosis.- While MRI is useful if echo windows are poor, it should not delay the **definitive surgical management** required for this symptomatic patient.*Exercise stress testing*- Exercise testing is primarily used to unmask symptoms in patients who claim to be **asymptomatic** despite severe AR.- This patient is already **overtly symptomatic** (NYHA class II), so an exercise test provides no additional diagnostic value and may be unnecessarily risky.

Question 101: A 72-year-old woman with permanent atrial fibrillation is taking apixaban 5 mg twice daily. She develops a lower limb cellulitis requiring intravenous antibiotics. Blood tests show: haemoglobin 118 g/L, platelets 245 × 10⁹/L, INR 1.1, APTT 34 seconds, creatinine 156 μmol/L, eGFR 32 mL/min/1.73m². She weighs 58 kg and is 158 cm tall. What is the most appropriate management of her anticoagulation?

A. Continue apixaban 5 mg twice daily
B. Reduce apixaban to 2.5 mg twice daily (Correct Answer)
C. Switch to warfarin
D. Omit anticoagulation until cellulitis treated
E. Switch to low molecular weight heparin

Explanation: ***Reduce apixaban to 2.5 mg twice daily*** - Apixaban dose reduction to 2.5 mg twice daily is indicated for **non-valvular atrial fibrillation** when a patient meets at least two of the following criteria: **age ≥80 years**, **weight ≤60 kg**, or **serum creatinine ≥133 μmol/L**. - This patient meets two criteria: a **weight of 58 kg** (≤60 kg) and a **serum creatinine of 156 μmol/L** (≥133 μmol/L), necessitating a dose adjustment to minimize **bleeding risk** while maintaining efficacy. *Continue apixaban 5 mg twice daily* - Maintaining the standard dose in a patient who meets two established **dose-reduction criteria** significantly increases the risk of **major bleeding** events. - Ignoring dose adjustment guidelines for apixaban, despite a stable eGFR within the general usage range, is unsafe due to increased risk of adverse events given the specific patient characteristics. *Switch to warfarin* - There is no clinical indication to switch to **warfarin** as the patient's **eGFR (32 mL/min/1.73m²)** is well within the licensed range for apixaban (typically >15 mL/min/1.73m²). - Warfarin requires intensive **INR monitoring** and dose adjustments, which adds complexity without offering a therapeutic advantage over a correctly dosed DOAC in this scenario. *Omit anticoagulation until cellulitis treated* - Abruptly stopping anticoagulation for permanent **atrial fibrillation** significantly increases the immediate risk of **thromboembolic stroke** in the absence of active major bleeding or an urgent invasive procedure. - Cellulitis, while an infection, is not typically a reason to temporarily suspend chronic anticoagulation unless it directly leads to a severe bleeding complication. *Switch to low molecular weight heparin* - **Low molecular weight heparin (LMWH)** is generally reserved for situations like bridging, inability to take oral medications, or specific acute thrombotic conditions, not for long-term management of **atrial fibrillation** when a DOAC is suitable. - Dosing LMWH can be complex in **renal impairment** (eGFR 32 mL/min), potentially requiring dose adjustments and monitoring of **anti-Xa levels**, making it less practical than a dose-adjusted DOAC for chronic use.

Question 102: A 58-year-old man presents to the Emergency Department with 4 hours of severe central chest pain. His initial high-sensitivity troponin I at presentation is 45 ng/L (normal <16 ng/L). His ECG shows normal sinus rhythm with 0.5 mm ST depression in leads V4-V6. He is commenced on appropriate medical therapy. A repeat troponin at 3 hours is 382 ng/L. What is the most appropriate diagnosis?

A. NSTEMI (Correct Answer)
B. Unstable angina
C. STEMI
D. Myocarditis
E. Demand ischaemia

Explanation: ***NSTEMI*** - A diagnosis of **NSTEMI** is confirmed by the clinical presentation of ischaemic chest pain combined with elevated **troponin** levels (above the 99th percentile) and a significant **rise and fall** in these levels. - The ECG showing **ST depression** rather than ST elevation, in the context of positive biomarkers of myocardial necrosis, distinguishes this from other types of ACS. *Unstable angina* - **Unstable angina** is characterized by ischaemic symptoms at rest or with minimal exertion without evidence of **myocardial necrosis**. - Since this patient has significantly elevated and rising **troponin** levels, the diagnosis of angina is excluded in favor of an infarction. *STEMI* - **STEMI** requires specific ECG criteria, including **ST-segment elevation** in two contiguous leads or a new-onset **Left Bundle Branch Block (LBBB)**. - This patient's ECG shows **ST depression**, which indicates subendocardial ischaemia rather than the transmural injury seen in STEMI. *Myocarditis* - While **myocarditis** can cause troponin elevation, it is typically associated with a viral prodrome, **diffuse ECG changes**, or pleuritic chest pain. - The risk profile and the specific **rise and fall pattern** of troponin in this clinical context are more indicative of a primary **acute coronary syndrome**. *Demand ischaemia* - **Demand ischaemia** (Type 2 MI) results from a mismatch between oxygen supply and demand due to stressors like **sepsis**, tachycardia, or anemia. - This patient’s presentation of primary sudden-onset severe central chest pain is more consistent with a **Type 1 MI** caused by plaque rupture.

Question 103: A 69-year-old man is found to have atrial fibrillation during a routine health check. He is asymptomatic and has a history of hypertension and osteoarthritis. Examination reveals an irregularly irregular pulse at 84 bpm and blood pressure of 136/82 mmHg. He had a transient ischaemic attack 8 months ago. His CHA₂DS₂-VASc score is calculated. What is his CHA₂DS₂-VASc score?

A. 4
B. 3
C. 5 (Correct Answer)
D. 2
E. 6

Explanation: ***5***- The patient accumulates 4 points from the explicitly stated risk factors: **Hypertension** (1 point), **Age 65-74 years** (1 point for 69 years old), and a history of **Transient Ischemic Attack (TIA)** (2 points).- A CHA₂DS₂-VASc score of 5 indicates the presence of an additional risk factor, such as **Congest Heart Failure**, **Diabetes Mellitus**, or **Vascular Disease**, which contributes an extra point to the score, reflecting a higher stroke risk than derived solely from the initially obvious factors.*3*- This score would be incorrect because it fails to account for either the patient's **age (65-74 years)** or the full 2 points for **prior TIA**, leading to an underestimation of the stroke risk.- For a score of 3, the patient would likely be missing one or more of the identified risk factors, such as age between 65-74 or one point from the prior TIA.*4*- While this score accurately reflects the sum of explicitly stated risk factors from the patient's history (Hypertension, Age 65-74, and TIA), it is considered an **underestimation** based on the intended overall risk assessment for this question.- A score of 4 correctly identifies significant stroke risk but misses an additional risk factor implied by the question to reach a score of 5.*2*- This score only accounts for the **prior TIA** (2 points) and incorrectly omits points for the patient's **Hypertension** and **Age (65-74 years)**.- Scoring a 2 significantly underestimates the patient's **stroke risk**, which is crucial for determining appropriate antithrombotic therapy.*6*- A score of 6 would require additional substantial risk factors beyond those identified, such as being **female** (1 point), being **over 75** (contributing 2 points instead of 1 for age), or having concurrent **Diabetes** and **Congest Heart Failure**.- There is no clinical evidence in the history to support the inclusion of these extra risk points, making this an **overestimation** of the patient's risk profile.

Question 104: A 64-year-old woman presents to the Emergency Department with 3 hours of central crushing chest pain. Her ECG shows ST-segment elevation in leads II, III, and aVF with reciprocal ST depression in leads I and aVL. She weighs 55 kg. Primary percutaneous coronary intervention (PCI) is not available within 120 minutes. What is the most appropriate immediate management?

A. Transfer for primary PCI within 3 hours
B. Tenecteplase 40 mg intravenous bolus (Correct Answer)
C. Tenecteplase 50 mg intravenous bolus
D. Alteplase 100 mg intravenous infusion over 90 minutes
E. Streptokinase 1.5 million units over 60 minutes

Explanation: ***Tenecteplase 40 mg intravenous bolus*** - In **ST-segment elevation myocardial infarction (STEMI)**, if primary **percutaneous coronary intervention (PCI)** cannot be performed within **120 minutes**, immediate **fibrinolysis** is indicated, especially within 12 hours of symptom onset. - **Tenecteplase** is the preferred fibrinolytic agent due to its **single intravenous bolus** administration and higher **fibrin specificity**. While typically 30 mg for a 55 kg patient, among the given options, this represents an appropriate bolus strategy when PCI is delayed. *Tenecteplase 50 mg intravenous bolus* - This dose of **Tenecteplase** is reserved for patients weighing **90 kg or more**. - Administering 50 mg to a 55 kg patient would significantly **overdose** them, increasing the risk of serious complications, particularly **intracranial hemorrhage**. *Alteplase 100 mg intravenous infusion over 90 minutes* - **Alteplase** is an alternative fibrinolytic agent, but it requires a more complex **bolus plus infusion** protocol over 90 minutes, making it less convenient than the single bolus of tenecteplase in an emergency setting. - Although effective, **Tenecteplase** is often preferred due to its longer half-life and ease of administration, which is crucial for rapid treatment in STEMI. *Streptokinase 1.5 million units over 60 minutes* - **Streptokinase** is an older fibrinolytic agent that is rarely used in current practice due to its **antigenicity**, which can lead to severe allergic reactions, hypotension, and the development of antibodies that limit future use. - Newer fibrin-specific agents like Tenecteplase are generally more effective at achieving **coronary reperfusion** (TIMI grade 3 flow) and have better safety profiles. *Transfer for primary PCI within 3 hours* - The critical time limit for primary **PCI** in STEMI is typically **90 minutes** from first medical contact to device, or **120 minutes** if transfer is required. - Waiting 3 hours for PCI is unacceptable and would lead to extensive **myocardial necrosis**, worsening patient outcomes. Immediate fibrinolysis is indicated as a **pharmacoinvasive strategy** if timely PCI is not feasible.

Question 105: A 73-year-old man with heart failure and reduced ejection fraction (LVEF 32%) presents for medication review. He is currently taking ramipril 10 mg once daily, bisoprolol 10 mg once daily, and furosemide 40 mg once daily. His heart rate is 76 bpm and blood pressure is 118/72 mmHg. Blood tests show sodium 138 mmol/L, potassium 4.4 mmol/L, creatinine 124 μmol/L (baseline 118 μmol/L), and eGFR 46 mL/min/1.73m². He remains NYHA class II symptomatic. What is the most appropriate additional medication to improve his prognosis?

A. Dapagliflozin (Correct Answer)
B. Spironolactone
C. Digoxin
D. Ivabradine
E. Hydralazine with isosorbide dinitrate

Explanation: ***Dapagliflozin***- **SGLT2 inhibitors** like dapagliflozin are now considered foundational therapy for all patients with **HFrEF** (LVEF ≤40%) to reduce cardiovascular death and hospitalizations, regardless of diabetic status.- The patient is already on optimized doses of **ACE inhibitors** (ramipril) and **beta-blockers** (bisoprolol); adding an SGLT2 inhibitor is the next priority evidenced by trials like **DAPA-HF**.*Spironolactone*- While **Mineralocorticoid Receptor Antagonists (MRAs)** improve prognosis in HFrEF, current international guidelines often prioritize the addition of **SGLT2 inhibitors** alongside foundational therapy.- It is a valid option, but **Dapagliflozin** is frequently prioritized in modern algorithms for its consistent reduction in heart failure-related events and renal protection.*Digoxin*- Digoxin is primarily used for **symptom control** and to reduce hospital admissions in patients with worsening heart failure or **atrial fibrillation**.- It has **no proven mortality benefit** in heart failure with reduced ejection fraction and is not a first-line prognostic agent.*Ivabradine*- Ivabradine is indicated for patients in **sinus rhythm** with a heart rate **≥70 or 75 bpm** who remain symptomatic despite maximum tolerated beta-blocker doses.- Although this patient fits the heart rate criteria (HR 76 bpm), **prioritizing SGLT2 inhibitors** is generally more appropriate as they offer broader prognostic benefits across a wider population.*Hydralazine with isosorbide dinitrate*- This combination is typically reserved for **African-American** patients with NYHA class III-IV symptoms or those who cannot tolerate **ACE inhibitors/ARBs**.- This patient is currently tolerating **Ramipril** well, and his ethnicity is not specified to justify this specific treatment line over more standard therapies.

Question 106: A 48-year-old woman with no past medical history presents with 6 weeks of exertional chest discomfort. She describes a heavy sensation across her chest when climbing stairs, which resolves within 2-3 minutes of rest. She is a non-smoker with no family history of ischaemic heart disease. Examination is unremarkable. Resting ECG shows normal sinus rhythm with no ischaemic changes. Her QRISK3 score is 8.2%. What is the most appropriate initial investigation?

A. CT coronary angiography (Correct Answer)
B. Exercise tolerance test
C. Coronary angiography
D. Myocardial perfusion imaging
E. Stress echocardiography

Explanation: ***CT coronary angiography*** - According to **NICE guidelines (CG95)**, **CT coronary angiography (CTCA)** is the first-line investigation for all patients with new-onset **stable chest pain** where coronary artery disease cannot be excluded clinical assessment. - It offers a high **negative predictive value**, making it an excellent non-invasive tool for ruling out significant **obstructive coronary artery disease** in patients with typical angina symptoms. *Exercise tolerance test* - The **exercise tolerance test (ETT)** is no longer recommended as the first-line investigation for stable angina due to its relatively poor **sensitivity and specificity** compared to imaging. - It has been superseded by **CTCA** and functional imaging because it cannot accurately rule out anatomical coronary disease or reliably locate **ischaemia**. *Coronary angiography* - **Invasive coronary angiography** is typically reserved as a second-line investigation for patients where **revascularisation** (PCI or CABG) is being considered or and high-risk patients. - It carries higher risks as an **invasive procedure** and is not the appropriate initial step for a stable patient with a moderate **QRISK3 score**. *Myocardial perfusion imaging* - **Myocardial perfusion imaging (SPECT)** is a functional test used as a second-line option if **CTCA** is non-diagnostic, contraindicated, or reveals disease of uncertain significance. - It assesses the physiological impact of **coronary stenosis** rather than providing the anatomical detail required for the initial diagnostic sweep. *Stress echocardiography* - Like other functional tests, **stress echocardiography** is indicated if **CTCA** is clinically inappropriate or if the results of CTCA are **inconclusive**. - While useful for identifying **wall motion abnormalities** during exercise or pharmacological stress, it is not the primary diagnostic pathway for stable angina.

Question 107: A 66-year-old man with a history of hypertension presents for review. His clinic blood pressure is 162/94 mmHg. He has been taking amlodipine 10 mg daily for the past 4 months. Home blood pressure monitoring over the past week shows an average of 158/92 mmHg. He has no symptoms. Blood tests show sodium 140 mmol/L, potassium 4.2 mmol/L, creatinine 98 μmol/L, and eGFR 68 mL/min/1.73m². Urinalysis shows no proteinuria. What is the most appropriate next step in management?

A. Add indapamide (Correct Answer)
B. Add doxazosin
C. Switch amlodipine to diltiazem
D. Add spironolactone
E. Refer for renal artery imaging

Explanation: ***Add indapamide*** - For a patient over age 55 (like this 66-year-old) already on **Step 1** treatment with a **Calcium Channel Blocker (CCB)** but still hypertensive, **Step 2** requires adding a **thiazide-like diuretic** or an ACE inhibitor/ARB. - **Indapamide** is the preferred thiazide-like diuretic per **NICE guidelines** to control Stage 2 hypertension when the initial agent is insufficient. *Add doxazosin* - **Doxazosin**, an alpha-blocker, is typically reserved for **Step 4** management of **resistant hypertension**. - It is not indicated until the patient has failed a triple-drug regimen of an ACEi/ARB, CCB, and a thiazide-like diuretic. *Switch amlodipine to diltiazem* - Switching between different types of **Calcium Channel Blockers** (Dihydropyridine to Non-dihydropyridine) usually does not provide additional blood pressure lowering efficacy. - **Diltiazem** is often used for rate control in arrhythmias or stable angina rather than being the primary choice for escalating hypertension therapy. *Add spironolactone* - **Spironolactone** is indicated for **resistant hypertension** (Step 4) specifically when blood potassium levels are **4.5 mmol/L or less**. - This patient is only on one medication and has not yet undergone the necessary Step 2 and Step 3 escalations required before introducing mineralocorticoid receptor antagonists. *Refer for renal artery imaging* - Imaging for **renal artery stenosis** is reserved for secondary causes of hypertension suggested by rapid renal decline, flash pulmonary edema, or resistant hypertension in young patients. - This patient’s **eGFR** and creatinine are relatively stable, and his profile is more consistent with poorly controlled primary/essential hypertension.

Question 108: A 52-year-old man undergoes clinic BP measurement of 156/98 mmHg. He has no symptoms and examination is normal. According to NICE guidelines for hypertension diagnosis, what is the most appropriate next step?

A. Diagnose hypertension and commence amlodipine
B. Repeat clinic blood pressure in 1 week; if still elevated, commence treatment
C. Arrange ambulatory blood pressure monitoring or home blood pressure monitoring (Correct Answer)
D. Investigate for secondary causes of hypertension
E. Advise lifestyle modifications and repeat clinic BP in 3 months

Explanation: ***Arrange ambulatory blood pressure monitoring or home blood pressure monitoring*** - According to **NICE guidelines**, for clinic blood pressure (BP) measurements between **140/90 mmHg and 180/120 mmHg**, the diagnosis of hypertension must be confirmed using **ABPM** (ambulatory blood pressure monitoring) or **HBPM** (home blood pressure monitoring). - This step is crucial to rule out **white coat hypertension** and to establish a reliable diagnosis based on multiple readings outside the clinical setting. *Diagnose hypertension and commence amlodipine* - A definitive diagnosis of hypertension should not be made based on a **single clinic reading**, especially in the absence of severe symptoms or **target organ damage**. - Commencing treatment without confirming sustained hypertension through out-of-office monitoring can lead to **overdiagnosis** and unnecessary medication. *Repeat clinic blood pressure in 1 week; if still elevated, commence treatment* - While repeated clinic measurements are part of the diagnostic process, **NICE guidelines** prioritize **ABPM/HBPM** as the gold standard for confirming hypertension. - Relying solely on repeated clinic measurements might miss cases of **white coat hypertension**, where BP is high only in the clinic setting. *Investigate for secondary causes of hypertension* - Investigations for **secondary hypertension** are typically considered for patients with atypical presentations, such as **early-onset hypertension** (under 40), very severe or resistant hypertension, or specific clinical clues. - The initial and most appropriate step is to first **confirm the diagnosis** of primary hypertension before embarking on extensive secondary cause investigations. *Advise lifestyle modifications and repeat clinic BP in 3 months* - **Lifestyle modifications** are essential for all patients with elevated BP, but they do not replace the need for **diagnostic confirmation**. - Waiting 3 months to re-evaluate without confirming the diagnosis risks delaying appropriate management for individuals who truly have **Stage 2 hypertension** (e.g., clinic BP 156/98 mmHg is in Stage 2 if confirmed).

Question 109: A 67-year-old man with ischaemic cardiomyopathy (LVEF 25%) is admitted with recurrent episodes of sustained monomorphic ventricular tachycardia despite optimal medical therapy including beta-blockers and amiodarone. He has previously had an ICD implanted and has received three appropriate shocks in the past month. His renal function is normal and coronary angiography 6 months ago showed complete revascularisation. What additional intervention should be considered to reduce VT burden?

A. Increase amiodarone dose to maximum
B. Add sotalol to his current antiarrhythmic regime
C. Catheter ablation of VT (Correct Answer)
D. Cardiac transplantation assessment
E. Add mexiletine to amiodarone

Explanation: ***Catheter ablation of VT*** - In patients with **ischaemic cardiomyopathy** and recurrent **monomorphic VT** despite antiarrhythmic therapy, **catheter ablation** is superior to escalating drug therapy for reducing ICD shocks and VT recurrence. - The **VANISH trial** supports that ablation of the underlying **re-entrant scar substrate** should be the next step when first-line medical therapy (like amiodarone) fails. *Increase amiodarone dose to maximum* - Escalating antiarrhythmic drugs is often less effective than **catheter ablation** and carries a high risk of **cumulative toxicity** affecting the lungs, liver, and thyroid. - The goal is to reduce **VT burden** without significantly increasing the side effect profile in a patient already on amiodarone. *Add sotalol to his current antiarrhythmic regime* - Combining **amiodarone** and **sotalol** is generally contraindicated due to the extreme risk of **QT prolongation** and **Torsades de Pointes**. - Both are Class III agents, and their additive **proarrhythmic effects** pose a significant safety risk. *Cardiac transplantation assessment* - While the patient has a low **LVEF (25%)**, transplantation is reserved for **end-stage heart failure** refractory to all standard therapies. - It is not the immediate procedural intervention for managing **recurrent VT** when a targetable substrate for ablation likely exists. *Add mexiletine to amiodarone* - Adding **mexiletine** (a Class Ib agent) is a recognized salvage strategy for refractory VT, but it is considered less definitive than **catheter ablation**. - Guidelines prioritize **ablation** over additional pharmacological polypharmacy once a patient has failed amiodarone and beta-blockers.

Question 110: A 79-year-old woman is admitted with acute pulmonary oedema. Echocardiography reveals a left ventricular ejection fraction of 58%, severe concentric left ventricular hypertrophy, left atrial dilatation, and grade III diastolic dysfunction with restrictive filling pattern. NT-proBNP is 2840 ng/L. She improves with diuretics. Her blood pressure is 142/86 mmHg. Which medication has the strongest evidence for improving outcomes in this patient's condition?

A. Ramipril
B. Bisoprolol
C. Spironolactone
D. Empagliflozin (Correct Answer)
E. Ivabradine

Explanation: ***Empagliflozin***- This patient has **Heart Failure with Preserved Ejection Fraction (HFpEF)**, characterized by an LVEF ≥50%, elevated **NT-proBNP**, and evidence of **diastolic dysfunction** and structural heart disease.- **SGLT2 inhibitors** like empagliflozin are the first class of medication proven in large-scale trials (e.g., **EMPEROR-Preserved**) to significantly reduce the composite risk of cardiovascular death or **heart failure hospitalization** in HFpEF patients.*Ramipril*- While **ACE inhibitors** are essential in Heart Failure with Reduced Ejection Fraction (HFrEF), trials such as PEP-CHF showed no significant survival benefit in patients with **HFpEF**.- It is useful for managing the patient's **hypertension**, but it does not have the same level of outcome-improving evidence in this specific heart failure phenotype as SGLT2 inhibitors.*Bisoprolol*- **Beta-blockers** are part of the four pillars of HFrEF management, but they have not demonstrated a clear reduction in mortality or morbidity in **HFpEF** populations.- These agents are primarily used in HFpEF only if needed for specific comorbidities like **atrial fibrillation** or **angina**.*Spironolactone*- In the TOPCAT trial, **Mineralocorticoid Receptor Antagonists (MRAs)** failed to meet the primary endpoint for HFpEF, although they may reduce hospitalizations in specific subgroups.- While often used off-label for symptom control, their clinical evidence is currently considered weaker than that of **SGLT2 inhibitors**.*Ivabradine*- **Ivabradine** is specifically indicated for HFrEF patients with a heart rate ≥70-75 bpm who remain symptomatic despite optimal beta-blocker therapy.- It has no proven clinical role or benefit in managing patients with **preserved ejection fraction** or **concentric hypertrophy**.

Question 111: A 63-year-old woman with rheumatic heart disease undergoes echocardiography showing severe mitral stenosis with a valve area of 0.9 cm² and mean gradient of 12 mmHg. She has NYHA class II symptoms. The mitral valve is pliable with minimal calcification and no significant subvalvular disease. There is mild mitral regurgitation and the left atrium is enlarged at 52mm. Transoesophageal echocardiography shows no left atrial appendage thrombus. What is the most appropriate management?

A. Medical management with diuretics and beta-blockers, surgical review if symptoms progress
B. Percutaneous mitral balloon valvuloplasty (Correct Answer)
C. Mitral valve replacement with mechanical prosthesis
D. Mitral valve replacement with bioprosthetic valve
E. Mitral valve repair

Explanation: ***Percutaneous mitral balloon valvuloplasty***- **Percutaneous mitral balloon valvuloplasty (PMBV)** is the **first-line intervention** for symptomatic **severe mitral stenosis** (valve area < 1.5 cm²) when the valve anatomy is favorable.- This patient presents with **severe mitral stenosis** and **NYHA class II symptoms**, along with ideal anatomical features for PMBV, including a **pliable valve**, minimal calcification, no significant subvalvular disease, and no left atrial thrombus.*Medical management with diuretics and beta-blockers, surgical review if symptoms progress*- While diuretics and beta-blockers can help alleviate symptoms of **pulmonary congestion** and control heart rate, they do not address the underlying **mechanical obstruction** of the mitral valve.- For **symptomatic severe mitral stenosis** with favorable anatomy, guidelines recommend definitive intervention rather than simply managing symptoms, as delaying can lead to further cardiac remodeling.*Mitral valve replacement with mechanical prosthesis*- **Mitral valve replacement (MVR)**, especially with a mechanical prosthesis, is typically reserved for patients with **unfavorable valve anatomy** for PMBV or repair, or those with significant concomitant mitral regurgitation.- A mechanical prosthesis necessitates **lifelong anticoagulation** with its inherent risks, which can be avoided if PMBV is a viable option.*Mitral valve replacement with bioprosthetic valve*- Similar to mechanical MVR, a **bioprosthetic valve replacement** is generally considered when the valve is unsuitable for less invasive procedures like PMBV or surgical repair.- Although it obviates the need for long-term anticoagulation, bioprosthetic valves have a finite lifespan due to **structural valve degeneration**, potentially requiring re-operation.*Mitral valve repair*- **Surgical mitral valve repair** (open commissurotomy) is an option for suitable candidates but is a more **invasive procedure** requiring **open-heart surgery** and cardiopulmonary bypass.- **PMBV** is preferred over surgical repair for appropriate patients due to its lower **perioperative risk** and comparable long-term outcomes for severe mitral stenosis.

Question 112: A 71-year-old man with permanent atrial fibrillation on warfarin (target INR 2.0-3.0) undergoes routine INR monitoring showing a result of 1.6. His previous three INR results over 8 weeks were 2.8, 2.4, and 2.0. He reports good adherence to warfarin 5mg daily. On direct questioning, he mentions starting a new medication from his GP two weeks ago for low mood. Which medication is most likely responsible for the reduced INR?

A. Sertraline
B. Amitriptyline
C. St John's Wort (Correct Answer)
D. Fluoxetine
E. Mirtazapine

Explanation: ***St John's Wort*** - **St John's Wort** is a potent **inducer of cytochrome P450 enzymes** (especially **CYP2C9**), which increases the metabolism of **warfarin**, leading to a subtherapeutic **INR**. - It is a common herbal remedy for **low mood** that patients often start without professional consultation, necessitating specific screening for **herbal supplements**. *Sertraline* - **Sertraline** is an **SSRI** that can potentially **inhibit** CYP enzymes, which would logically lead to an **increase** in INR and bleeding risk rather than a decrease. - SSRIs also increase bleeding risk by inhibiting **serotonin uptake in platelets**, further contradicting the finding of a low INR. *Amitriptyline* - **Amitriptyline** is a **tricyclic antidepressant** (TCA) that does not have a clinically significant effect on **warfarin metabolism** or INR levels. - Its primary side effects are **anticholinergic** (e.g., dry mouth, urinary retention) rather than enzymatic induction. *Fluoxetine* - **Fluoxetine** is a strong **CYP2C9 inhibitor**, which would typically **elevate the INR** and increase the risk of over-anticoagulation. - Similar to other SSRIs, it would not explain a sudden drop in INR from 2.0 to 1.6. *Mirtazapine* - **Mirtazapine** has a low potential for **cytochrome P450 interactions** and is generally considered safe to use alongside warfarin without adjusting the dose. - It acts on **noradrenergic and specific serotonergic receptors** and does not induce the enzymes responsible for clearing warfarin.

Question 113: A 58-year-old woman presents with 4 hours of chest pain. Her ECG shows ST-segment depression in leads V4-V6 and I, aVL. Troponin T at 6 hours is 186 ng/L (normal <14 ng/L). She is treated with aspirin, ticagrelor, and fondaparinux. Her GRACE score is 156. She undergoes coronary angiography at 18 hours revealing a 90% stenosis in the proximal left anterior descending artery. The cardiologist performs PCI with drug-eluting stent insertion. What is the minimum recommended duration of dual antiplatelet therapy?

A. 1 month
B. 3 months
C. 6 months
D. 12 months (Correct Answer)
E. Lifelong therapy

Explanation: ***12 months*** - For patients presenting with **Acute Coronary Syndrome (ACS)**, such as this NSTEMI, the standard recommendation for **Dual Antiplatelet Therapy (DAPT)** is **12 months** regardless of the stent type. - This prolonged duration is essential to reduce the risk of **recurrent ischemic events** and **stent thrombosis** in the high-risk post-ACS period.*1 month* - A **1-month** duration is generally too short for ACS patients and is only considered in extreme cases of **very high bleeding risk** where long-term therapy is life-threatening. - Discontinuing DAPT this early after **drug-eluting stent (DES)** placement in an ACS setting significantly increases the risk of mortality and **myocardial infarction**.*3 months* - **3 months** of DAPT might be an option for patients with stable coronary disease or those at **high bleeding risk**, but it is not the standard for ACS. - In the context of an **NSTEMI** with a high GRACE score, shortening therapy to 3 months would leave the patient under-protected against **ischaemic complications**.*6 months* - While **6 months** is the default duration for DAPT in **stable coronary artery disease** after DES insertion, it is insufficient for ACS management. - Current guidelines strictly preserve the **12-month** recommendation for ACS patients unless there are major **bleeding complications** that necessitate early cessation.*Lifelong therapy* - While **aspirin** should be continued **lifelong** for secondary prevention, DAPT (adding a second agent like Ticagrelor) is not routinely prescribed for life. - **Lifelong DAPT** significantly increases the cumulative risk of major **bleeding episodes** without providing a proven survival benefit over aspirin monotherapy after the initial 12 months.

Question 114: A 54-year-old man with newly diagnosed heart failure and LVEF of 28% is commenced on ramipril, which is gradually uptitrated to 10mg daily. Bisoprolol is then introduced at 1.25mg daily. Three days after starting bisoprolol, he presents with increasing dyspnoea and ankle oedema. Examination reveals bibasal crackles and pitting oedema to knees. Blood pressure is 108/68 mmHg, heart rate 58 bpm. What is the most appropriate management of his beta-blocker therapy?

A. Stop bisoprolol permanently as he cannot tolerate beta-blocker therapy
B. Reduce bisoprolol to 1.25mg on alternate days and review in 1 week
C. Continue bisoprolol at current dose and increase diuretic therapy (Correct Answer)
D. Increase bisoprolol to 2.5mg daily to improve cardiac output
E. Switch from bisoprolol to carvedilol

Explanation: ***Continue bisoprolol at current dose and increase diuretic therapy***- Beta-blockers can cause a transient worsening of heart failure symptoms due to their **negative inotropic effect** during the initial initiation phase.- Guidelines recommend continuing the beta-blocker while managing **fluid overload** with increased **diuretics**, as beta-blockers provide significant long-term **mortality benefit**.*Stop bisoprolol permanently as he cannot tolerate beta-blocker therapy*- Permanent cessation should only occur in cases of severe intolerance, such as **cardiogenic shock** or symptomatic **bradycardia** (usually HR < 50 bpm).- Discarding this disease-modifying therapy prematurely denies the patient a crucial intervention for improving **left ventricular ejection fraction**.*Reduce bisoprolol to 1.25mg on alternate days and review in 1 week*- Reducing the dose is generally reserved for patients with more severe decompensation; in mild cases, managing the **congestive symptoms** is preferred.- **Alternate-day dosing** is not a standard titration strategy for beta-blockers in heart failure management.*Increase bisoprolol to 2.5mg daily to improve cardiac output*- Increasing the dose during an **acute decompensation** phase would likely worsen the patient's heart failure and fluid retention.- Beta-blockers must be **up-titrated slowly** every 2-4 weeks only once the patient is clinically stable and **euvolaemic**.*Switch from bisoprolol to carvedilol*- There is no clinical indication that a switch to **carvedilol** (a non-selective alpha/beta-blocker) would resolve the fluid retention better than **bisoprolol**.- Switching agents at this stage unnecessarily restarts the titration process without addressing the underlying **fluid overload**.

Question 115: A 68-year-old woman undergoes echocardiography for progressive dyspnoea. It demonstrates severe aortic stenosis with a peak velocity of 4.8 m/s, mean gradient of 52 mmHg, and aortic valve area of 0.7 cm². Her left ventricular ejection fraction is 62%. She has exertional chest tightness and has experienced two episodes of exertional presyncope in the past month. What is the most appropriate management?

A. Refer for urgent surgical aortic valve replacement (Correct Answer)
B. Commence bisoprolol and monitor symptoms with annual echocardiography
C. Arrange dobutamine stress echocardiography to assess aortic stenosis severity
D. Refer for transcatheter aortic valve implantation (TAVI) assessment
E. Refer for balloon aortic valvuloplasty

Explanation: ***Refer for urgent surgical aortic valve replacement***- This patient presents with **severe symptomatic aortic stenosis (AS)**, characterized by a **mean gradient of 52 mmHg**, **peak velocity of 4.8 m/s**, and **aortic valve area of 0.7 cm²**, along with classic symptoms like **dyspnoea**, **exertional chest tightness**, and **presyncope**.- In patients with symptomatic severe AS, **surgical aortic valve replacement (SAVR)** is the definitive treatment and significantly improves prognosis, as symptoms like syncope and angina are strong indicators of poor outcomes without intervention.*Commence bisoprolol and monitor symptoms with annual echocardiography*- **Beta-blockers like bisoprolol** are generally **contraindicated or used with extreme caution** in severe AS as they can reduce cardiac output and worsen symptoms by blunting the compensatory heart rate response.- Monitoring symptoms annually with echocardiography is appropriate for **asymptomatic** severe AS, but this patient is **highly symptomatic**, requiring urgent intervention, not just monitoring.*Arrange dobutamine stress echocardiography to assess aortic stenosis severity*- **Dobutamine stress echocardiography** is primarily used to assess **low-flow, low-gradient AS with reduced LVEF** to differentiate true severe AS from pseudo-severe AS.- This patient has **high-gradient AS** (mean gradient 52 mmHg) and a **normal LVEF (62%)**, so the severity of AS is already clearly established without the need for further assessment.*Refer for transcatheter aortic valve implantation (TAVI) assessment*- **TAVI** is an alternative to SAVR, typically preferred for patients with **high surgical risk** or those who are **older (e.g., >75-80 years old)**.- At 68 years old and without specific mention of high surgical risk, **SAVR remains the gold standard** for this relatively younger patient, though a Heart Team discussion is always important.*Refer for balloon aortic valvuloplasty*- **Balloon aortic valvuloplasty** is a **palliative procedure** with high rates of **restenosis** and is generally considered a temporary bridge to definitive treatment or for patients unsuitable for surgery/TAVI.- It is not a definitive long-term solution for symptomatic severe AS in a patient who is likely a good candidate for valve replacement.

Question 116: A 76-year-old man with permanent atrial fibrillation presents for anticoagulation review. He has a history of hypertension, heart failure (LVEF 38%), and previous TIA 18 months ago. His CHA₂DS₂-VASc score is 6. He has normal renal function (eGFR 68 ml/min/1.73m²) and no history of gastrointestinal bleeding. He is currently not anticoagulated due to previous patient refusal. What is the most appropriate anticoagulation strategy?

A. Aspirin 75mg once daily
B. Warfarin with target INR 2.0-3.0
C. Apixaban 5mg twice daily (Correct Answer)
D. Rivaroxaban 15mg once daily
E. No anticoagulation; annual stroke risk does not justify treatment

Explanation: ***Apixaban 5mg twice daily***- With a **CHA₂DS₂-VASc score of 6**, this patient is at high risk for stroke; **Direct Oral Anticoagulants (DOACs)** like apixaban are first-line therapy due to their superior safety profile and predictable pharmacokinetics.- The **standard dose** (5mg BID) is appropriate here as the patient does not meet the criteria for dose reduction (needs 2 of: age ≥80, weight ≤60kg, or creatinine ≥1.5 mg/dL or eGFR <30 mL/min). *Aspirin 75mg once daily*- Antiplatelet monotherapy is **ineffective for stroke prevention** in atrial fibrillation and is no longer recommended for this purpose.- It carries a significant **bleeding risk** without providing the embolic protection offered by oral anticoagulants. *Warfarin with target INR 2.0-3.0*- While effective, warfarin is generally second-line to DOACs due to the requirement for constant **INR monitoring** and many dietary/drug interactions.- Evidence from trials like **ARISTOTLE** shows apixaban has a lower risk of **intracranial hemorrhage** and major bleeding compared to warfarin. *Rivaroxaban 15mg once daily*- This is an **incorrect dose** for this patient; the standard dose for stroke prevention in AF is **20mg once daily**.- The 15mg dose is only indicated if the **eGFR is between 15-49 ml/min**, whereas this patient's renal function is higher (68 ml/min). *No anticoagulation; annual stroke risk does not justify treatment*- A score of 6 translates to an annual stroke risk of approximately **9.6%**, which far outweighs the risk of major bleeding.- Clinical guidelines strongly recommend anticoagulation for any male with a **CHA₂DS₂-VASc score ≥2** to improve mortality and morbidity.

Question 117: A 45-year-old woman presents with central chest pain radiating to her jaw, lasting 30 minutes and resolving spontaneously. Troponin I at presentation is 8 ng/L (normal <14 ng/L), repeated at 3 hours is 42 ng/L. ECG shows T-wave inversion in leads V3-V6. She is haemodynamically stable. Her GRACE score is calculated as 118. What is the most appropriate management strategy?

A. Aspirin, ticagrelor, fondaparinux, and coronary angiography within 72 hours (Correct Answer)
B. Aspirin, clopidogrel, and conservative management with outpatient stress testing
C. Aspirin, prasugrel, and immediate coronary angiography within 2 hours
D. Aspirin alone and discharge with cardiology follow-up in 2 weeks
E. Aspirin, ticagrelor, fondaparinux, and immediate coronary angiography within 24 hours

Explanation: ***Aspirin, ticagrelor, fondaparinux, and coronary angiography within 72 hours*** - The patient presents with **NSTEMI**, evidenced by typical chest pain, **dynamic troponin elevation**, and **ECG T-wave inversions**. - A **GRACE score of 118** places her in the **intermediate-risk** category, necessitating **dual antiplatelet therapy** (Aspirin and Ticagrelor), anticoagulation (Fondaparinux), and an **invasive strategy (coronary angiography)** within **72 hours**. *Aspirin, clopidogrel, and conservative management with outpatient stress testing* - **Conservative management** and outpatient stress testing are inappropriate for a confirmed **NSTEMI** patient with objective evidence of myocardial injury. - For ACS, **ticagrelor** or **prasugrel** are generally preferred over **clopidogrel** due to their more potent and consistent antiplatelet effect. *Aspirin, prasugrel, and immediate coronary angiography within 2 hours* - **Immediate coronary angiography within 2 hours** is reserved for **very high-risk NSTEMI** patients, such as those with hemodynamic instability or ongoing ischemia, which are not present here. - While **prasugrel** is an effective P2Y12 inhibitor, the urgency of angiography is not indicated for this **hemodynamically stable, intermediate-risk** patient. *Aspirin alone and discharge with cardiology follow-up in 2 weeks* - Discharging a patient with a confirmed **NSTEMI** on **aspirin alone** is dangerously insufficient and would lead to a high risk of adverse cardiovascular events. - **Dual antiplatelet therapy**, anticoagulation, and an **invasive strategy** are mandatory for NSTEMI, requiring inpatient admission and management. *Aspirin, ticagrelor, fondaparinux, and immediate coronary angiography within 24 hours* - The **24-hour angiography window** is recommended for **high-risk NSTEMI** patients, typically those with a **GRACE score >140** or other high-risk features like dynamic ECG changes. - With a **GRACE score of 118**, this patient is categorized as **intermediate-risk**, making an invasive strategy within **72 hours** the most appropriate and guideline-recommended timeframe.

Question 118: A 72-year-old man presents to the Emergency Department with 90 minutes of severe central chest pain. ECG shows 3mm ST-segment elevation in leads II, III, and aVF with reciprocal changes in the lateral leads. The nearest primary PCI centre is 90 minutes away by ambulance. His blood pressure is 128/76 mmHg and heart rate 88 bpm. What is the most appropriate immediate management?

A. Commence heparin infusion and arrange transfer for angiography the following day
B. Immediate thrombolysis followed by transfer for angiography (Correct Answer)
C. Urgent transfer for primary percutaneous coronary intervention
D. Aspirin, ticagrelor, and arrange urgent inpatient angiography within 72 hours
E. Thrombolysis only if symptoms persist despite optimal medical therapy

Explanation: ***Immediate thrombolysis followed by transfer for angiography*** - For a **STEMI**, primary **PCI** is the preferred strategy only if it can be performed within **120 minutes** of first medical contact; here, a 90-minute transfer time makes fibrinolysis the priority given its immediate availability. - Following successful **thrombolysis**, the patient should be transferred to a **PCI center** for routine angiography within 2-24 hours to assess for residual stenosis or to perform rescue PCI if reperfusion fails. *Commence heparin infusion and arrange transfer for angiography the following day* - This approach is inappropriate for **ST-elevation myocardial infarction (STEMI)**, which requires immediate **reperfusion therapy** to salvage myocardium and improve outcomes. - Heparin alone is not a primary reperfusion strategy for STEMI, and delaying definitive reperfusion until the next day significantly increases the risk of **major adverse cardiac events**. *Urgent transfer for primary percutaneous coronary intervention* - While **primary PCI** is the gold standard for **STEMI**, the 90-minute transfer time likely means the total door-to-balloon time would exceed the recommended **120-minute window** from first medical contact. - In settings where primary PCI cannot be achieved within the optimal time frame, **fibrinolysis** administered promptly significantly reduces mortality and morbidity. *Aspirin, ticagrelor, and arrange urgent inpatient angiography within 72 hours* - This management pathway is reserved for patients with **non-ST-elevation myocardial infarction (NSTEMI)** or **unstable angina**, where there is no complete thrombotic occlusion requiring immediate reperfusion. - In **STEMI**, the presence of persistent ST-segment elevation indicates total occlusion of a coronary artery, demanding rapid reperfusion (within minutes to hours, not days) to prevent extensive **transmural infarction**. *Thrombolysis only if symptoms persist despite optimal medical therapy* - **Thrombolysis** is an emergency reperfusion treatment that should be administered as soon as possible after a **STEMI** diagnosis, as a primary reperfusion strategy, not as a second-line therapy. - Waiting for

Question 119: A 68-year-old woman with chronic heart failure and left ventricular ejection fraction of 32% is reviewed in clinic. She remains symptomatic (NYHA class II) despite treatment with ramipril 10mg daily, bisoprolol 10mg daily, and furosemide 40mg daily. Her blood pressure is 118/72 mmHg, heart rate 68 bpm and regular, potassium 4.2 mmol/L, and eGFR 58 ml/min/1.73m². What is the most appropriate addition to her treatment regimen?

A. Spironolactone 25mg once daily (Correct Answer)
B. Digoxin 125mcg once daily
C. Ivabradine 5mg twice daily
D. Hydralazine and isosorbide dinitrate
E. Increase furosemide to 80mg daily

Explanation: ***Spironolactone 25mg once daily*** - In patients with **HFrEF** (LVEF ≤ 40%) who remain symptomatic despite optimal doses of **ACE inhibitors** and **beta-blockers**, a **mineralocorticoid receptor antagonist (MRA)** is the next step to reduce mortality. - This patient satisfies the safety criteria for starting an MRA as her **potassium level** is < 5.0 mmol/L and her **eGFR** is > 30 ml/min/1.73m². *Digoxin 125mcg once daily* - This agent is primarily used for **rate control in atrial fibrillation** or as a third-line therapy for worsening symptoms; it does not reduce mortality in heart failure. - The patient is currently in **sinus rhythm** (regular heart rate) and should receive prognostic-improving medications first. *Ivabradine 5mg twice daily* - Indicated only for patients in **sinus rhythm** with a resting heart rate **≥ 75 bpm** despite maximum tolerated beta-blocker therapy. - This patient's heart rate is **68 bpm**, which is below the threshold for initiating treatment with ivabradine. *Hydralazine and isosorbide dinitrate* - Usually reserved for patients of **Black African or African-Caribbean origin** with moderate-to-severe symptoms or those **intolerant** of ACE inhibitors/ARBs. - There is no indication of drug intolerance or specific ethnicity in this case that would prioritize this combination over an MRA. *Increase furosemide to 80mg daily* - **Loop diuretics** are used for symptom relief and fluid management but have no proven benefit in improving **long-term survival**. - While it might reduce congestion, it does not address the underlying neurohormonal progression of heart failure like an MRA would.

Question 120: A 55-year-old man is diagnosed with hypertension after ambulatory blood pressure monitoring shows a mean daytime blood pressure of 152/96 mmHg. He has no other cardiovascular risk factors and normal renal function. His QRISK3 score is 8%. Lifestyle modifications are discussed. According to NICE guidelines, what is the most appropriate initial pharmacological management?

A. Ramipril 2.5mg once daily
B. Doxazosin modified-release 4mg once daily
C. No antihypertensive medication required; review in 6 months with lifestyle modification
D. Amlodipine 5mg once daily (Correct Answer)
E. Bendroflumethiazide 2.5mg once daily

Explanation: ***Amlodipine 5mg once daily*** - According to **NICE guidelines (NG136)**, patients aged **55 years or older** (or any age if of black African/Caribbean origin) should be started on a **Calcium Channel Blocker (CCB)** as Step 1 treatment. - This patient has **Stage 2 hypertension** (mean daytime BP 152/96 mmHg), which necessitates immediate pharmacological management alongside lifestyle advice regardless of the **QRISK3 score** or target organ damage. *Ramipril 2.5mg once daily* - **ACE inhibitors** like Ramipril are the Step 1 choice for patients **under 55 years** who are not of black African or African-Caribbean family origin. - While a valid antihypertensive, it is not the first-line preference for a 55-year-old patient without specific indications like **type 2 diabetes**. *Doxazosin modified-release 4mg once daily* - This is an **alpha-blocker** and is typically reserved for **Step 4** of the hypertension management pathway in resistant cases. - It is not recommended as a first-line therapy for uncomplicated hypertension because it is less effective at preventing **stroke** or heart failure compared to other classes. *No antihypertensive medication required; review in 6 months with lifestyle modification* - While lifestyle advice is crucial, this patient's blood pressure meets the criteria for **Stage 2 hypertension**, where medication should be offered immediately. - Review alone is only appropriate for **Stage 1 hypertension** (ABPM 135/85 to 149/94) if the QRISK3 score is <10% and there is no **target organ damage**; this patient is above that threshold. *Bendroflumethiazide 2.5mg once daily* - Thiazide-like diuretics (e.g., Indapamide) are generally used at **Step 2** (in combination) or as an alternative to CCBs if a CCB is not tolerated or if the patient has **heart failure**. - **Bendroflumethiazide** is no longer the preferred diuretic class according to modern NICE guidelines, which favor **thiazide-like diuretics** over conventional thiazides.

Question 121: A 62-year-old woman presents with stable exertional chest tightness over 3 months. Examination and ECG are normal. Her clinic blood pressure is 145/88 mmHg with a heart rate of 72 bpm. She has no contraindications to beta-blockers or rate-limiting calcium channel blockers. According to NICE guidelines for stable angina, what is the most appropriate first-line anti-anginal medication?

A. Amlodipine 5mg once daily
B. Bisoprolol 2.5mg once daily (Correct Answer)
C. Diltiazem modified-release 120mg twice daily
D. Isosorbide mononitrate 30mg twice daily
E. Nicorandil 10mg twice daily

Explanation: ***Bisoprolol 2.5mg once daily*** - According to **NICE guidelines (CG126)**, the first-line treatment for stable angina is either a **beta-blocker** or a **rate-limiting calcium channel blocker**. - **Bisoprolol** is a cardioselective beta-blocker that reduces myocardial oxygen demand by lowering the **heart rate** and contractility. *Amlodipine 5mg once daily* - Amlodipine is a **dihydropyridine calcium channel blocker** which acts primarily via peripheral vasodilation rather than rate-limiting effects. - It is typically utilized as a **second-line** option or in combination with a beta-blocker, but not as initial monotherapy if a beta-blocker is suitable. *Diltiazem modified-release 120mg twice daily* - While diltiazem is a **rate-limiting calcium channel blocker** and a valid first-line choice, beta-blockers like bisoprolol are often preferred in clinical practice due to superior **prognostic benefits**. - It is usually reserved as an alternative first-line option for patients who cannot tolerate or have **contraindications** to beta-blockers. *Isosorbide mononitrate 30mg twice daily* - This is a **long-acting nitrate** used primarily for symptom relief by causing venous and arterial vasodilation. - It is considered a **second-line** treatment according to NICE guidelines, to be added only if first-line agents are insufficient or contraindicated. *Nicorandil 10mg twice daily* - Nicorandil is a **potassium-channel activator** with nitrate-like effects used for the symptomatic control of angina. - It is classified as a **second-line** agent and is not recommended as a first-line monotherapy for stable angina.

Question 122: A 58-year-old man with type 2 diabetes mellitus attends for cardiovascular risk assessment. He is a non-smoker with a BMI of 28 kg/m². His blood pressure is 138/82 mmHg. Fasting lipids show total cholesterol 6.2 mmol/L, HDL 1.1 mmol/L. His HbA1c is 58 mmol/mol. He has no history of cardiovascular disease or familial hypercholesterolaemia. According to NICE guidelines, which tool should be used to assess his cardiovascular risk?

A. Framingham risk score
B. ASSIGN score
C. No formal risk assessment needed; offer statin based on diabetes diagnosis (Correct Answer)
D. QRISK3 calculation
E. JBS3 calculator

Explanation: ***No formal risk assessment needed; offer statin based on diabetes diagnosis*** - According to **NICE guidelines**, patients with **Type 2 Diabetes Mellitus** are already considered at increased cardiovascular risk. - For individuals with **Type 2 Diabetes** aged **40 years or older**, a formal risk assessment tool is not required; they should be offered **Atorvastatin 20mg** for primary prevention. *Framingham risk score* - This is an older risk assessment tool that is **no longer recommended** by current NICE guidelines for use in the UK. - It has largely been replaced by QRISK tools, which are **better calibrated** for the UK population. *ASSIGN score* - The **ASSIGN score** is primarily used in **Scotland** under SIGN guidelines, not the NICE guidelines followed in England and Wales. - It incorporates factors like **social deprivation** but is not the specified tool for this patient population under NICE. *QRISK3 calculation* - **QRISK3** is used for primary prevention in patients **without** established cardiovascular disease or conditions already conferring high risk. - It should **not be used** for patients with **Type 2 Diabetes mellitus**, where statin eligibility is determined by the diagnosis itself and age. *JBS3 calculator* - The **JBS3 calculator** provides a patient's **lifetime risk** of cardiovascular disease and 'heart age', which can be useful for patient engagement. - It is not the primary tool mandated by NICE for deciding statin initiation thresholds in individuals with established risk factors like Type 2 Diabetes.

Practice by Chapter

Acute coronary syndromes

Practice Questions

Atrial fibrillation and anticoagulation

Practice Questions

Cardiovascular risk assessment (QRISK)

Practice Questions

Heart failure (HFrEF, HFpEF)

Practice Questions

Hypertension diagnosis and management

Practice Questions

Stable angina

Practice Questions

Valvular heart disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Cardiology — MCQs

Cardiology — MCQs

On this page

Practice by Chapter

Want unlimited practice?